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Abstract 
Friedreich ataxia (FRDA) is an inherited autosomal recessive neurodegenerative 
disorder caused by a GAA trinucleotide repeat expansion mutation within the first intron of 
the FXN gene. Normal individuals have 5 to 30 GAA repeats, whereas affected individuals 
have from approximately 70 to more than 1,000 GAA triplets. In addition to progressive 
neurological disability, FRDA is associated with cardiomyopathy and an increased risk of 
diabetes mellitus. Currently there is no effective therapy for FRDA and this is perhaps due to 
the lack of an effective system to test potential drugs. Therefore, the main aim of this thesis 
is to develop a novel cell culture system, to aid in rapid drug screening for FRDA. 
 Firstly, I have demonstrated the establishment of novel cell culture systems, including 
primary fibroblasts, neural stem cells (NSC) and splenocytes, from FRDA YAC transgenic 
mouse models (YG8 and YG22). Then, I have shown the differentiation of NSCs into neurons, 
oligodendrocytes and astrocytes. The presence of these cells was confirmed by using cell 
specific immunofluorescence assays.  I have also shown that both YG8 and YG22 rescue mice 
have less tolerance to hydrogen peroxide induced oxidative stress than WT mice, as similarly 
seen in FRDA patient fibroblasts. 
 Recent findings indicate that FRDA is associated with heterochromatin-mediated 
silencing of the FXN gene accompanied by histone changes, flanking the GAA repeats. This 
suggested potential therapeutic use of compounds which can reduce the methylation and 
increase the acetylation of histone proteins. Therefore, using human and mouse primary 
fibroblast cell lines I have investigated the efficacy and tolerability of various DNA 
demethylating agents, GAA interacting compounds and class III histone deacetylase (HDAC) 
inhibitors. Although DNA demethylating agents showed increased FXN expression, no 
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correlation between the level of DNA methylation and FXN expression was identified. 
Nevertheless, the use of GAA interacting compounds, particularly DB221, and the HDAC 
inhibitor, nicotinamide, have shown encouraging results, provoking us to use such 
compounds in future long-term in vivo studies. 
In addition, I have also investigated the long-term efficacy of two benzamide-type 
HDAC inhibitors, RGFA 136 and RGFP 109, on the FRDA YAC transgenic mice. No overt 
toxicity was identified with either drug, indicating a safe administration of these compounds. 
Both compounds produced improved functional analysis together with significantly reduced 
DRG neurodegeneration. However, neither of these compounds was shown to significantly 
increase the FXN mRNA expression. Nevertheless, elevated levels of frataxin protein in the 
brain tissues were obtained with RGFP 109, suggesting that RGFP 109 is capable of crossing 
the blood-brain barrier. I have also found increased levels of global acetylated H3 and H4 
histone proteins in brain tissues, along with significant increase in aconitase enzyme activity, 
particularly with RGFP 109 treatments. Overall, these results support future clinical trial 
development with such compounds.   
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Friedreich ataxia (FRDA, OMIM #229300) is an autosomal recessive trinucleotide 
repeat neurodegenerative disorder for which there is currently no effective therapy. It is the 
commonest inherited ataxia, with an incidence of approximately 1 in 50,000 (reviewed 
inSchulz et al. 2009). However, the carrier frequency varies depending on the ethnic group 
from 1 in 60 to 1 in 120 (Cossee et al. 1999). FRDA is predominantly caused by homozygous 
expanded GAA repeats in the first intron of the FXN gene (Campuzano et al. 1996). Normal 
individuals have 5 to 30 GAA repeat sequences, whereas affected individuals have from 70 
to a maximum of 1600 repeats, but most commonly 600-900 repeats (Pandolfo 2002). The 
effect of the GAA expansion mutation is to reduce greatly the expression of frataxin 
(Campuzano et al. 1997), a mitochondrial protein involved in iron-sulphur cluster 
biosynthesis (Gerber et al. 2003). Frataxin insufficiency leads to oxidative stress, 
mitochondrial iron accumulation and resultant cell death, with the primary sites of 
pathology being the large sensory neurons of the dorsal root ganglia (DRG) and the dentate 
nucleus of the cerebellum (Koeppen et al. 2007; Koeppen et al. 2009).  
Generally the first symptoms appear at childhood but age of onset may vary from 
childhood to adult (Pandolfo 2002). The main symptoms include loss of coordination (known 
as ataxia), muscle weakness, scoliosis, and sensory loss. There is also some pathological 
involvement of non-neuronal tissues, with cardiomyopathy as a common secondary effect 
and risk of diabetes also found in 10% of FRDA patients (Schulz et al. 2009). Within 20 years 
after the first appearance of symptoms, affected individuals are confined to a wheelchair 
and most commonly die in early adulthood from the associated heart disease (Delatycki et 
al. 2000). Therefore, there is a high unmet clinical need to develop a therapy for this 
devastating disorder.  
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1.1 -  Frataxin gene: structure, function and expression 
 The gene, which is responsible for the production of frataxin protein and plays a 
crucial role in FRDA, is the ‘FXN’ gene, previously known as X25. The FXN gene was mapped 
to chromosome 9 in 1988 (Chamberlain et al. 1988) and is localized in the proximal long arm 
at position 9q13 (Figure 1.1). 
  
 
Figure 1.1 - Schematic representation of human chromosome 9.  The red mark indicates 
the location of frataxin gene (Ensembl 2006). 
 
 The FXN gene structure was resolved by obtaining intronic sequences flanking the 
identified exons, by inverse polymerase chain reaction (PCR) and by the direct sequencing of 
cosmids (Campuzano et al. 1996).  The FXN gene spans 95 kb of genomic DNA and contains 
seven exons, 1-5a, 5b and 6 (Figure 1.2) (Campuzano et al. 1996). Generally the first five 
exons, 1 to 5a, transcribe and produce the major transcript encoding a 210 amino acid 
mitochondrial protein called frataxin (Campuzano et al. 1996). Rarely, by alternative splicing, 
exon 5b can be transcribed and here a predicted 171 amino acid protein arises. Exon 6 is 
non-coding (Campuzano et al. 1996). 
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Figure 1.2 - Schematic representation of exons and splicing pattern of the FXN gene. The 
GAA repeat in intron 1 is indicated (▼). This diagram was adapted from (Cossee et al. 
1997b). 
 
Since there is no in vivo evidence for an effect on RNA processing in FRDA, it is 
believed that the disease results directly from reduced FXN mRNA levels followed by 
reduced amounts of frataxin protein (Cossee et al. 1997a; Bidichandani et al. 1998; Ohshima 
et al. 1998). However, it has been recently reported that the GAA repeats affect the pre-
mRNA splicing in a position-dependent and repeat length-dependent manner in a hybrid 
minigene construct inserted with 15 or 100 GAA repeats (Baralle et al. 2008). In contrast, 
Punga and Buhler (2010) demonstrated that FXN mRNA levels were inversely correlated with 
repeat length in FRDA lymphoblastoid cell lines showing more consistent reduction of FXN 
mRNA in cell lines with larger GAA repeats. Importantly, the authors also reported that no 
alternatively spliced FXN transcripts were observed in any FRDA cell lines, suggesting that 
long GAA repeat tracts at the FXN gene locus are unlikely to affect pre-mRNA splicing but 
perhaps affect either mRNA half-life or transcription of the FXN gene (Punga and Buhler 
2010). 
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The FXN gene is expressed in all cells, but at varying levels in different tissues and 
during development (Campuzano et al. 1996; Koutnikova et al. 1997). FXN mRNA is 
expressed predominantly in tissues with a high metabolic rate, including kidney, liver, heart 
and brown fat. However, highest levels of FXN were identified in the spinal cord and 
somewhat lower levels in cerebellum. Frataxin expression is generally higher in 
mitochondria-rich cells, such as cardiomyocytes and neurons (Koutnikova et al. 1997). The 
FXN mRNA levels in FRDA patients vary in between 13% and 30% compared to unaffected 
individuals (Campuzano et al. 1996; Pianese et al. 2004). Along with FRDA, other diseases 
have also been reported to be caused by the expansion of various trinucleotide repeats in 
the non-coding region of the gene(s) (Table 1.1). 
 
Table 1.1 - Diseases caused by expansion of non-coding trinucleotide repeats (adopted from 
Cummings and Zoghbi 2000). 
Disease Gene/Locus Protein Location 
Fragile X-syndrome FRAXA/Xq27.3 FMRP 5'-UTR 
Fragile XE-syndrome FRAXE/Xq28 FMR-2 protein Promoter 
Myotonic Dystrophy DMPK /19q13 DMPK 3'-UTR 
Spinocerebellar ataxia type 8 SCA8 /13q21 None 3'-terminal exon 
Spinocerebellar ataxia type 12 SCA12/5q31-33 PP2A-PR55β 5'-UTR 
 
As mentioned earlier, the common mutation that causes FRDA is the hyperexpansion 
of the GAA repeats in the first intron of the FXN gene.  Ninety six percent of FRDA patients 
are homozygous for GAA expansions (Campuzano et al. 1996), and the remaining 4% are 
compound heterozygous for an expanded allele and a point mutation within the coding 
sequence of the gene (Christodoulou et al. 2001). So far, no patients have been identified 
that carry point mutations in both copies of the frataxin gene. 
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Normal individuals contain less than 30 GAA repeats, whereas disease-causing 
expanded GAA repeats (>1000 triplets) arise from hyperexpansion of a premutation (30-65 
triplets) (Cossee et al. 1997b; Montermini et al. 1997b). Late onset patients of FRDA can be 
divided into three sub groups; firstly, late onset FRDA (LOFA), posses fewer than 500 GAA 
repeats (Durr et al. 1996; Filla et al. 1996). Secondly, very late onset FRDA, which contains 
fewer than 300 GAA repeats and have at least one expanded allele (Bidichandani et al. 2000; 
Berciano et al. 2002), and thirdly, acadians, who are different from the other types of FRDA 
and show a late onset with a mean age of 27 years, accompanied by wheelchair confinement 
(Montermini et al. 1997a). 
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1.1.1 - Origin of the GAA repeat expansion 
 There is no clear explanation of how the GAA repeats are expanding in the FRDA 
patients.  To obtain clues about the origin of the GAA repeat expansions, Pandolfo et al. 
(1998) investigated the GAA repeats in normal chromosomes and they found that GAA 
repeats were distributed in two ways; small normal (83%, 6-10 triplets), and large normal 
(17%, 12-36 triplets) groups.  This finding suggested that polymerase ‘stuttering’ may take 
place that leads to size heterogeneity within small normal and large normal groups.  
Furthermore, the authors also speculated that the jump from the small normal to the large 
normal group was probably a rare or singular event, as also suggested by linkage 
disequilibrium results revealing the association of different marker haplotypes to small 
normal and large normal alleles (Cossee et al. 1997b; Montermini et al. 1997a). Eventually, 
in consistency with myotonic dystrophy (Imbert et al. 1993), large number alleles containing 
uninterrupted triplet of more than 34 GAA repeats, so called risk alleles, have indeed been 
observed to undergo hyperexpansion to hundreds of GAA triplets in one generation, and this 
leads to FRDA pathology with expanded GAA repeats (Cossee et al. 1997b; Montermini et al. 
1997a; Pandolfo 1998).  
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1.1.2 - GAA repeat instability 
The FRDA-associated expanded alleles show both intergenerational and somatic 
(mitotic) instability.  
Intergenerational instability 
Like other trinucleotide repeat disorders, the GAA repeat that underlies FRDA is 
unstable when it is transmitted from parent to offspring, showing both expansions and 
contractions (Campuzano et al. 1996; Durr et al. 1996; Montermini et al. 1997b). However, 
the intergenerational GAA instability showed a sex bias as both expansions and contractions 
were found during maternal transmission, while predominantly contractions were identified 
during paternal transmission (Monros et al. 1997; Pianese et al. 1997). 
 
 
Figure 1.3 - Analysis of Intergenerational repeat length variation in parental gender. 
Contraction/expansion ratio differed according parental gender (p<0.004) (Pianese et al. 
1997) 
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Somatic instability 
Small pool PCR (SP-PCR) analysis of DNA from tissues of an 18-week foetus, 
homozygous for the expanded allele, has revealed that there are remarkably low levels of 
somatic instability (4.2%) in all tissues tested compared to tissues from a 24 year old adult 
(30.6%) (Figure 1.4) (De Biase et al. 2007b). These findings indicate that somatic instability in 
FRDA is age-dependent and maybe perhaps DNA replication has a potential role.  
 
Figure 1.4 - Small pool PCR analysis of somatic instability in foetus and adult tissues. 
Southern blot showing limited somatic instability in representative tissues of A) foetus, 
and B) adult, each of whom is homozygous for expanded alleles. C) Cumulative average 
mutation load of fetal and adult tissues. Error bars depict ±2 SEM (De Biase et al. 2007b). 
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 Subsequently, the mutation load was also investigated in blood samples from multiple 
patients and carriers and showed significantly (p=0.0001) increased mutation load with age, 
ranging from 7.5% at 18-weeks gestation to 78.7% at 49 years of age.  It has been 
hypothesized that in FRDA somatic instability occurs after early embryonic development (De 
Biase et al. 2007b). 
 Recently, SP-PCR analysis on multiple tissues obtained from six autopsies of FRDA 
patients revealed that somatic instability was exhibited in a tissue specific manner (Figure 
1.5A) (De Biase et al. 2007a). In addition, a significantly greater frequency of expansions was 
detected in DRG in an age-dependent manner showing small expansions in early age and 
large expansions at a later stage (Figure 1.5B) (De Biase et al. 2007a). The increased levels of 
somatic instability in post-mitotic tissues indicate that erroneous DNA replication alone is 
unlikely to be the mechanism and the other factors must be at play. 
 
 
Figure 1.5 - High prevalence of large expansions in DRG as identified by SP-PCR in foetus 
and adult tissues. A) Frequency distribution (plotted on the y-axis) of expansion seen in 
various tissues derived from a FRDA patient, and B) increasing levels of large expansions in 
DRG samples derived from the patients aged 17, 24, and 47 years. Each lane contains 
“small pools” of 10-15 individual FXN molecules (De Biase et al. 2007a). 
 
A B 
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1.1.3 - Pathological GAA repeat expansions and abnormal structures 
It has been suggested that development of FRDA is caused by an expanded GAA 
repeat in intron 1 of the FXN gene.  Severely reduced levels of FXN mRNA and protein have 
been demonstrated in FRDA patients’ tissue samples and cultured cells (Campuzano et al. 
1997). Inhibition of the FXN gene is characterized at the transcriptional level and not at the 
post transcriptional RNA processing level (Delatycki et al. 2000). The expanded GAA·TTC 
repeat sequence associated with FRDA adopts non-B DNA structures, such as triplex and 
sticky DNA structures (Mariappan et al. 1999; Sakamoto et al. 1999; Sakamoto et al. 2001). 
A DNA triplex is formed upon binding of a pyrimidine (Y) or a purine (R) single-
stranded DNA to the major groove of a double helix, forming Hoogsten or reverse-Hoogsten 
hydrogen bonds between the purine strand and the duplex (Jain et al. 2002). Triplexes in 
general may take the form R·R·Y or Y·R·Y, depending on whether the third strand is purine-
rich or pyrimidine-rich (Figure 1.6a) (Grabczyk and Usdin 2000). Eventually, these structures 
can be formed as intermolecular structures or as folded intramolecular structures (Frank-
Kamenetskii and Mirkin 1995; Grabczyk and Usdin 2000; Mirkin 2007). However, the exact 
molecular mechanism by which the GAA·TTC expansion reduces the FXN mRNA levels is still 
unknown. Furthermore, models based on several different triplex variants have been 
suggested to explain the effects of GAA·TTC tract expansion as a possible block to 
transcription elongation in FXN (Sakamoto et al. 1999; Jain et al. 2002; Krasilnikova and 
Mirkin 2004). 
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Sticky DNA structures are the expanded state of triplex DNA and are more stable than 
triplex structures. Son et al. (2006) have described that sticky DNA structures were formed 
by the association of two long GAA·TTC repeat sequences and this was a novel and 
unprecedented feature of the repeat (Figure 1.6b) (Son et al. 2006). 
 
 
 
Figure 1.6 - Model of intramolecular DNA triplex and sticky DNA structures. A) Diagram 
showing DNA triplex structure formed by the expansion of GAA·TTC triplet repeats (Wells 
2008), B) Model diagram showing the sticky DNA in a closed circular plasmid. The green 
and yellow strands represent one GAA•TTC duplex and the red and blue strands represent 
the other duplex (Son et al. 2006). 
 
 
 
 
 
 
 
A B 
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1.1.4 - Epigenetic changes in FRDA 
In contrast to the earlier mentioned abnormal structure hypothesis, Saveliev et al. 
(2003) showed that when expanded GAA repeats were introduced into the mouse genome, 
position-effect variegation (PEV) of an adjacent reporter gene was induced. PEV is the 
hallmark of heterochromatin-mediated gene silencing and is thought to be caused by 
variable spreading of heterochromatin, which renders the gene inaccessible to the 
transcriptional machinery (Dillon and Festenstein 2002). Therefore, one can speculate that in 
FRDA where FXN deficiency is associated with expanded GAA repeats, there may be 
abnormal chromatin organization. PEV occurs when a gene is located abnormally close to 
regions of heterochromatin, and silent heterochromatin is characterized by the presence of 
certain types of histone modifications. These are indicated by the absence of acetylated 
histones and the presence of methylated histones, histone deacetylases (HDACs), DNA 
methyltransferases, chromodomain proteins and polycomb group proteins (Elgin and Grewal 
2003).   
It has been shown that when heterochromatin protein 1 (HP1), a key constituent of 
heterochromatin (Eissenberg et al. 1992; Elgin 1996), is over expressed, it acts as a powerful 
modifier of mammalian PEV, leading to increased GAA repeat-associated reporter gene 
silencing in transgenic mice (Festenstein et al. 1999; Saveliev et al. 2003). Furthermore, 
recent studies have indicated that FRDA may be caused by heterochromatin formation 
Inhibiting FXN transcription factors, thereby leading to gene silencing (Figure 1.7) (Saveliev et 
al. 2003; Festenstein 2006). This hypothesis was further strengthened by the finding of a 
differential DNA methylation profile accompanied by histone acetylation and methylation 
changes in FRDA (Herman et al. 2006; Greene et al. 2007; Al-Mahdawi et al. 2008).  
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Figure 1.7 - Putative heterochromatin-mediated silencing pathway in FRDA. The chromatin 
organization of an active FXN gene is shown on the far left. Protruding from the 
nucleosomes are acetylated histone tails (Ac, acetyl). The presence of GAA repeats might 
nucleate heterochromatin formation, pushing the pathway to the right through several 
stages. An early step in this process may be the deacetylation of the lysines on histones, 
which would provide a substrate for histone methyltransferases (HMTases). Methylation 
of the histone H3 tail (on Lys9) would provide a binding site for HP1, consistent with a 
histone code for silencing. If the nucleosomes were sufficiently close (possibly because of 
the repetitive nature of the DNA), then HP1 dimers might stabilize a condensed higher-
order heterochromatin structure that prohibits access of the transcriptional machinery to 
the FXN locus (Festenstein 2006). 
 
For the consideration of future FRDA therapy, it is first essential to understand the 
mechanism of GAA-induced inhibition of FXN gene transcription. Therefore, Al-Mahdawi and 
colleagues (2008) have investigated the DNA methylation changes of FXN flanking GAA 
regions in FRDA patients’ brain, heart and cerebellum tissues. This investigation revealed a 
shift in the FRDA DNA methylation profile, with upstream CpG sites comparatively 
hypermethylated and downstream CpG sites becoming consistently hypomethylated. In 
addition, differential DNA methylation at three specific CpG sites within the FXN promoter 
and one CpG site within exon 1 were also identified (Al-Mahdawi et al. 2008). 
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In FRDA patients, comparable histone modifications were also observed such as 
reduced H3 and H4 acetylation, and increased H3K9 trimethylation at the upstream and 
downstream regions of the expanded GAA repeat tract compared to normal individuals 
(Herman et al. 2006; Al-Mahdawi et al. 2008).  
 Although several epigenetic changes have been identified in FRDA (Table 1.2), it is still 
unclear of which histone modification is directly involved in FXN silencing. However, it has 
been shown that the promoter region of FRDA patients is associated with reduced levels of 
acetylated H3K5, H3K14, H4K5 and H4K16 (Herman et al. 2006; Al-Mahdawi et al. 2008; 
Kumari and Usdin 2010) indicating a less permissive region for transcription. In particular, 
acetylated H4K16 is thought to play an important role in maintaining an open chromatin 
configuration (Shogren-Knaak et al. 2006). In addition, lymphoblasts derived from FRDA 
patients have shown reduced levels of H3K4me3 and H4K36me3, two important histone 
modifications associated with transcription initiation and elongation respectively, compared 
with normal lymphoblasts (Kumari and Usdin 2010). These findings have suggested that FXN 
silencing in FRDA alleles may be as a consequence of transcription initiation and elongation 
problems due to abnormal histone modifications. Therefore, considering these histone 
changes in future studies may perhaps give rise to more potential FRDA therapies. 
 
 
  
Chromatin Change Location Patients/Cell type/animal model Reference(s) 
DNA methylation ↑ 
FXN promoter 
Lymphoblasts, FRDA patients, FRDA YAC transgenic mice, 
primary fibroblasts 
(Herman et al. 2006; Greene et al. 2007; Al-Mahdawi et al. 2008) 
GAA upstream FRDA patients and FRDA YAC transgenic mice (Al-Mahdawi et al. 2008) 
H3K9me2/3↑ 
FXN promoter 
FRDA patients, FRDA YAC transgenic mice, Primary 
fibroblasts 
(Al-Mahdawi et al. 2008; De Biase et al. 2009) 
GAA upstream 
Lymphoblasts, FRDA YAC transgenic mice, KIKI mice 
(H3K9me3) 
(Herman et al. 2006; Al-Mahdawi et al. 2008; Rai et al. 2008; Punga 
and Buhler 2010) 
GAA downstream FRDA patients, FRDA YAC transgenic mice, Lymphoblasts (Al-Mahdawi et al. 2008; Punga and Buhler 2010) 
H3K4me2↓ 
FXN promoter, GAA up and 
downstream  
Lymphoblasts (Kumari et al. 2010) 
H3K4me3↓ 
FXN exon 1, GAA up and 
downstream 
Lymphoblasts (Kumari et al. 2010) 
H3K27me3 and HP1α/δ↑ FXN 5'UTR Primary fibroblasts (De Biase et al. 2009) 
H3K36me3↓ GAA downstream, FXN exon 2 Lymphoblasts (Kumari et al. 2010) 
H3K9ac↓ 
FXN promoter FRDA patient brain tissue, Lymphoblasts (Al-Mahdawi et al. 2008; Kumari et al. 2010) 
GAA upstream 
FRDA patients, FRDA YAC transgenic mice, Lymphoblasts 
cells, KIKI mice 
Al-Mahdawi, 2008 #2911}(Herman et al. 2006; Rai et al. 2008; 
Kumari et al. 2010) 
GAA downstream FRDA patients, FRDA YAC transgenic mice, Lymphoblasts (Herman et al. 2006; Al-Mahdawi et al. 2008; Kumari et al. 2010) 
H3K14ac↓ 
FXN promoter FRDA patients (Al-Mahdawi et al. 2008) 
GAA upstream KIKI mice, Lymphoblasts (Herman et al. 2006; Kumari et al. 2010) 
GAA downstream FRDA YAC transgenic mice, Lymphoblasts (Kumari et al. 2010) 
H4K5ac↓ 
FXN promoter Lymphoblasts (Kumari et al. 2010) 
GAA upstream Lymphoblasts, KIKI mice (Herman et al. 2006; Rai et al. 2008; Kumari et al. 2010) 
GAA downstream FRDA patients, FRDA YAC transgenic mice, Lymphocytes (Herman et al. 2006; Al-Mahdawi et al. 2008; Kumari et al. 2010) 
H4K8ac↓ 
GAA upstream Lymphoblasts, FRDA patients, KIKI mice 
(Herman et al. 2006; Al-Mahdawi et al. 2008; Rai et al. 2008; 
Kumari et al. 2010) 
GAA downstream Lymphoblasts, FRDA patients (Herman et al. 2006; Kumari et al. 2010) 
H4K12ac↓ 
FXN promoter Lymphoblasts (Herman et al. 2006) 
GAA up and downstream Lymphoblasts, FRDA patients, FRDA YAC transgenic mice (Herman et al. 2006; Al-Mahdawi et al. 2008) 
H4K16ac↓ 
FXN promoter Lymphoblasts (Rai et al. 2008; Kumari et al. 2010) 
GAA up and downstream 
Lymphoblasts, FRDA patients, FRDA YAC transgenic mice, 
KIKI mice 
(Herman et al. 2006; Al-Mahdawi et al. 2008; Rai et al. 2008; 
Kumari et al. 2010) 
Abbreviations/symbols: ↓- reduced, ↑-increased, H-histone, K-lysine, me2-dimethylation, me3-trimethylation, ac-acetylation, HP-heterochromatin protein
Table 1.2 - Epigenetic changes as seen in FRDA patients, cell lines or mouse models. 
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1.2 -  Frataxin protein: structure 
 To date, crystal structures of yeast, human and bacterial (CyaY) frataxin orthlogues 
have been reported and they were shown to be structurally similar (Cho et al. 2000; Dhe-
Paganon et al. 2000; Musco et al. 2000; Nair et al. 2004). Frataxin does not resemble any 
other protein of known function. Mature frataxin is a compact, globular protein containing 
an N-terminal α-helix; seven β strands and a C-terminal end (Figure 1.8) (Dhe-Paganon et al. 
2000; Musco et al. 2000). Strands β1– β5 form a flat anti-parallel β sheet that interacts with 
the two helices, α1 and α2. The axes of the two helices are nearly parallel to each other, and 
both are parallel to the plane of the large β sheet. The C terminus of β5 and strands β6 and 
β7 forms a second, smaller β sheet. This smaller sheet projects from the N terminus of α2 
along its long axis. The connections between all elements of secondary structures are short 
and well ordered, which contributes to the compact appearance of frataxin (Dhe-Paganon et 
al. 2000).  
 
Figure 1.8 - Structure of frataxin protein. Ribbon diagram showing the fold of frataxin, a 
compact   αβ sandwich, with helices coloured turquoise and β strands in green. (Dhe-
Paganon et al. 2000). 
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1.2.1 - Localization and maturation of frataxin protein 
Frataxin is a conserved protein found ubiquitously in prokaryotes and eukaryotes and 
it is required for the cellular regulation of iron homeostasis. Frataxin homologues are 
expressed in the cytoplasm as larger precursors, which are proteolytically removed by the 
mitochondrial processing peptidase (MPP) enzyme upon entry into the mitochondria to yield 
mature frataxin protein (Koutnikova et al. 1998; Gordon et al. 1999).  Selective deletion of 
yeast frataxin homologue, Yfh1p, has shown reduced mitochondrial respiration (Wilson and 
Roof 1997), loss of mtDNA (Koutnikova et al. 1997) and accumulation of iron in the 
mitochondria (Babcock et al. 1997). Frataxin is predominantly localized to the mitochondrial 
cristae and is a free soluble protein within the mitochondrial matrix (Campuzano et al. 1997). 
However, recently extramitochondria localization of frataxin has also been demonstrated in 
Caco-2 cells (Acquaviva et al. 2005), lymphocytes, HeLa and HEK293 cells (Condo et al. 2006; 
Condo et al. 2010) 
The mature form of frataxin was initially reported to be 56-210 amino acids (m56-
FXN). However, two independent reports have challenged these studies describing two 
different forms encoded by amino acids 78-210 (m78-FXN) (Condo et al. 2007; Yoon et al. 
2007) and 81-210 (m81-FXN) (Figure 1.9) (Schmucker et al. 2008). Boehm et al. (2010) have 
recently shown that frataxin protein levels vary up to three fold between normal individuals 
(<26 GAA repeats). Interestingly, the protein levels in these individuals are independent of 
age and GAA repeat size.  
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Figure 1.9 - Schematic representation of different forms of frataxin protein. The precursor 
of frataxin (encoded by amino acids 1–210) is targeted to the mitochondria and undergoes 
a two-step maturation process. The intermediate (i-FXN) and the three described mature 
forms beginning at the amino acids 56 (m56-FXN), 78 (m78-FXN) or 81 (m81-FXN) are 
represented. This picture was adopted from Schmucker et al.(2008). 
 
 
 
 
 
 
 
 
 
 
 
                         
                             Chapter 1 - Friedreich ataxia: Introduction 
   
      20 
1.2.2 - Molecular functions of frataxin 
Although the exact function of FXN is still unknown, complete deficiency of FXN in 
mice leads to early embryonic lethality (Cossee et al. 2000), indicating that FXN is essential 
for early development. In eukaryotes, frataxin is necessary for normal mitochondrial 
function (Koutnikova et al. 1997; Pianese et al. 1997). Studies in human, yeast and mouse 
models of FRDA have provided further insights into FRDA pathogenesis. These studies have 
suggested that frataxin may be involved in mitochondrial iron homeostasis (Bradley et al. 
2000; Lodi et al. 2001b), synthesis of Fe-S cluster proteins (Koutnikova et al. 1997; Cavadini 
et al. 2000; Puccio et al. 2001) and protection from oxidative stress (Schulz et al. 2000; 
Wilson 2003). 
 
Frataxin and iron homeostasis 
The investigation of the yeast frataxin homologue gene 1 (Yfh1) demonstrated that 
the frataxin protein was involved in iron efflux from mitochondria (Radisky et al. 1999). 
Furthermore, accumulation of iron was consistently observed in autopsy of heart muscle 
(Bradley et al. 2000) and the dentate nucleus (Waldvogel et al. 1999; Koeppen et al. 2007) of 
FRDA patients. In addition, small but significant intra-mitochondrial iron accumulation has 
also been reported in FRDA patients (Schapira et al. 1990). However, total mitochondrial 
iron levels were not increased (Puccio and Koenig 2000; Wong et al. 2000). In addition, 
mitochondrial iron accumulation and changes in Fe-S dependent enzyme activity, in a 
conditional mouse model of FRDA occur considerably later than the onset of pathology 
(Puccio et al. 2001), indicating that this cannot be the causative pathological mechanism. 
 
                         
                             Chapter 1 - Friedreich ataxia: Introduction 
   
      21 
 
In contrast, by using the bacterial frataxin orthologue (CyaY), Adinolfi et al. (2009) 
proposed that frataxin is not merely an iron chaperon, but it works as a molecular regulator 
able to inhibit, depending on the extent to which it is iron saturated, the formation of 2Fe-2S 
clusters (Figure 1.10). However, more investigation is needed to confirm the details of the 
molecular mechanism underlying the Fe-S cluster biosynthesis inhibition exerted by CyaY.  
 
Figure 1.10 - Schematic representation of the molecular mechanism of frataxin in the cell 
during a) normal iron concentrations, b) excess of iron concentrations, and c) 
absent/insufficient of frataxin conditions (Adinolfi et al. 2009). 
 
                         
                             Chapter 1 - Friedreich ataxia: Introduction 
   
      22 
Frataxin and oxidative stress 
 Regardless of the mechanism of mitochondrial iron accumulation, which is probably a 
secondary consequence in FRDA, it is likely that it contributes to the production of reactive 
oxygen species (ROS) leaking from the respiratory chain, leading to the formation of free 
radicals through Fenton chemistry (Lenaz et al. 2002; Lodi et al. 2002; Voncken et al. 2004). 
In support to this hypothesis, evidence of increased oxidative stress and damage in FRDA 
patients includes raised 8 hydroxy 2’ deoxyguanosine (8OH2’dG) levels in urine (Schulz et al. 
2000) and raised plasma malondialdehyde (MDA) levels (Emond et al. 2000; Bradley et al. 
2004). In addition, reduced aconitase activity and mitochondrial electron transport 
complexes I-III were also demonstrated in endomyocardial biopsies of FRDA patients (Rotig 
et al. 1997). Recent evidence has revealed an impaired response of antioxidant enzymes in 
cell lines and model organisms (Wong et al. 1999; Chantrel-Groussard et al. 2001; Seznec et 
al. 2005; Calmels et al. 2009).  
Interestingly, a recent study has demonstrated increased levels of nuclear and 
mitochondrial DNA damage in peripheral blood samples from FRDA patients (Haugen et al. 
2010). However, whether the increase in DNA damage is a consequence of an impaired 
antioxidant defence or directly linked to an ISC deficit remains to be determined, as several 
damaged proteins are ISC proteins (reviwed in Schmucker and Puccio 2010).   
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1.3 -  Therapeutic approaches 
Since the identification of the disease gene causing FRDA in 1996, important progress 
in the comprehension of frataxin function has been made. To date several agents have been 
found to increase frataxin expression in cellular and mouse models of FRDA and some of 
these compounds are already in different stages of clinical trial (Figure 1.11). However, the 
mode of action for most of these compounds in up-regulating FXN expression is still unclear.  
 
1.3.1 - Iron chelators 
Recent discoveries on the potential function of frataxin suggested that intracellular 
iron imbalance resulting in oxidative stress is involved in pathogenesis of FRDA. Therefore, it 
has been considered that iron chelation therapy may be able to ameliorate disease by 
protecting mitochondria from the adverse effects of iron over load. In a first instance iron 
chelator, desferrioxamine (DFO) which is already in the clinical trial for rheumatoid arthritis 
(Voest et al. 1994), was used as a potential therapy for FRDA. Wong et al. (1999), 
demonstrated that DFO significantly rescues human fibroblast cells from induced oxidative 
stress by hydrogen peroxide. However, due to the lack of ability to target mitochondrial iron 
pools (Richardson 2003), DFO may cause severe generalized iron deficiency. Furthermore, 
reduced frataxin mRNA and protein levels were identified in fibroblasts from individuals with 
FRDA and normal individuals treated with DFO (Li et al. 2008). Therefore, care should be 
taken when using iron chelators as therapeutic agents since they could displace rather than 
protect against iron mediated toxicity.  
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In the next approach, a mitochondrial-specific iron chelator, 2-pyridylcarboxaldehyde 
isonicotinoyl hydrazone (PCIH), was used in an in vivo study and produced more promising 
results (Richardson et al. 2001; Richardson 2003). However, due to the lack of efficacy, this 
clinical trial was terminated. More recently, a small phase I/II clinical trial of individuals 
affected with FRDA has been carried out using the orally-available iron chelator, deferiprone 
(Boddaert et al. 2007). Encouraging results have now prompted the use of deferiprone in 
larger phase II clinical trial, which is ongoing. However, recently it has been reported that 
treatment of FRDA patients’ fibroblasts with deferiprone showed reduced aconitase enzyme 
activity (Goncalves et al. 2008), indicating that iron-chelation is beneficial only at some 
particular step of the disease.  
 
1.3.2 - Antioxidant therapy 
Coenzyme Q10 and vitamin E  
The involvement of mitochondrial respiratory chain dysfunction and oxidative stress in 
the pathogenesis of FRDA suggests that the course of the disease may be modified by 
treatment with antioxidant agents. Initial clinical trials utilizing a combination of coenzyme 
Q10 and vitamin E over a period of three months resulted in  improved ATP production in 
heart and skeletal muscle of individuals with FRDA (Lodi et al. 2001a). Another long-term 
follow-up study over a period of 47 months with 10 FRDA patients showed sustained 
improvement in bioenergetics and improved cardiac function (Hart et al. 2005). However, 
due to the absence of a placebo group in this clinical trial these results must be interpreted 
with caution and/or the results will be evaluated with additional controlled trials. Recently, it 
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has been reported that FRDA patients showed decreased serum CoQ10 and vitamin E levels 
(Cooper et al. 2008), which may contribute to the clinical progression of the disease. 
 
Idebenone 
Idebenone, a short-chain benzoquinone structurally related to coenzyme Q10, has been 
investigated in patients with FRDA. Early clinical trials with idebenone treatment at doses of 
5mg/kg/day showed a reduction of the left ventricular mass and wall thickness (Rustin et al. 
1999; Hausse et al. 2002; Mariotti et al. 2003; Hart et al. 2005). However, no neurological 
effect was determined with idebenone (Rustin et al. 1999). In addition, Ribai et al. (2007) 
investigated the efficacy of idebenone in a large cohort of 61 patients and found a marked 
reduction of left-ventricular mass, which was accomplished by worsening, rather than 
improvement, of ejection fraction. Furthermore, idebenone treatment has also resulted in 
decreased levels of urinary 8-hydroxy-2'-deoxyguanosine, which is a peripheral marker of 
oxidative DNA damage (Schulz et al. 2000). However, it has been confirmed that high doses 
(45mg/kg/day) of idebenone were generally well tolerated and associated with slight 
improvement in neurological function and activities of daily living (ADL) in individuals with 
FRDA (Di Prospero et al. 2007a; Di Prospero et al. 2007b). This finding indicating that a 
higher dose of idebenone may be necessary to have a beneficial neurological function.   
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Mito Q and Mito Vit E  
Recent evidence has revealed that the limited effectiveness of idebenone and vitamin 
E as antioxidant therapies for FRDA is due to the distribution of these compounds through 
extracellular and intracellular compartments, with only a small proportion accumulating in 
mitochondria (Jauslin et al. 2003). Thus, targeting these molecules to mitochondria may 
improve their effectiveness. Therefore, in an effort to improve the efficiency and delivery of 
idebenone and vitamin E, two mitochondria-targeted antioxidants, Mito Q and Mito Vit E, 
were developed by covalently coupling with lipophilic cations (Murphy 1997; Smith et al. 
1999; Murphy and Smith 2000; Kelso et al. 2001). Jauslin et al. (2003), showed that Mito Q 
successfully protected the cells 800 times more than idebenone, from endogenous oxidative 
stress. However, Mito Vit E failed to protect the cells more than Mito Q, but was still 20 
times more effective than idebenone. Interestingly, an in vivo study demonstrated the 
accumulation of Mito Q in the heart and brain of mice, indicating its capacity to cross the 
blood brain barrier (Smith et al. 2003). In conclusion, these data suggested that 
mitochondria-targeted antioxidants may be therapeutically more effective than untargeted 
antioxidants, particularly as they are rapidly taken up by the brain.  
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1.3.3 - Gene based approaches 
The current therapeutic strategies for FRDA mainly act to slow down the 
consequences of frataxin deficiency. Drugs that are able to increase the amount of frataxin 
would represent excellent candidates for a rational approach.  Recently, several drugs have 
been assessed for their ability to increase the amount of cellular frataxin, including; histone 
deacetylase (HDAC) inhibitors, peroxisome proliferator-activated receptor (PPAR)-agonists 
and recombinant human erythropoietin (rhu-EPO). 
 
HDAC inhibitors 
Recent studies indicated that expanded GAA repeats have been shown to induce 
heterochromatin mediated silencing of FXN gene in a manner reminiscent to PEV gene 
silencing (Saveliev et al. 2003). Since acetylation and deacetylation of histone proteins are 
involved in transcriptional regulation, it has been suggested that HDAC inhibitors may revert 
silent heterochromatin to an active chromatin and restore the normal function of genes that 
are silenced in these diseases (Langley et al. 2005). The use of HDAC inhibitors as an 
effective therapy for FRDA has been very well explored in recent years. Treatment of HDAC 
inhibitors produced significant increase of frataxin mRNA and protein expression, and 
elevated levels of histone acetylation in in vitro (Herman et al. 2006) and in vivo (Rai et al. 
2008; Rai et al. 2010) model systems. However, HDAC inhibitor therapeutic approaches still 
require long term in vivo studies. Therefore, we have investigated for the first time the long 
term efficacy of HDAC inhibitors in FRDA therapy and this will be discussed in more detail in 
chapter 5. 
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Peroxisome proliferator-activated receptor (PPAR)-agonists 
The peroxisome proliferator-activated receptors (PPAR α, β/δ and γ) are members of 
nuclear receptor family, and recently emerged as transcription factors that regulate diverse 
aspects of metabolism (Theocharis et al. 2004). PPAR-γ agonists, such as rosiglitazone and 
piogliotazone have already shown their potential use in diabetes mellitus (Richter et al. 
2007), other neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis, and amylotrophic lateral sclerosis (ALS) (Heneka and Landreth 2007). In 
FRDA, Marmolino et al. (2009) showed that the commercially available PPAR-γ agonist, 
azelaoyl PAF (APAF), produced statistically significant increases in frataxin mRNA and protein 
levels in fibroblasts and SKNBE cells from FRDA patients up to 2-fold. The first clinical trial is 
currently underway with pioglitazone.  
 
Recombinant human erythropoietin (rhu-EPO) 
 Recently, erythropoietin (EPO) has received considerable attention because of the 
unexpected finding that it also has broad neuroprotective and cardioprotective capabilities 
(Bogoyevitch 2004; Li et al. 2004). Additionally, considerable increase in FXN mRNA 
expression was achieved in FRDA lymphocytes, cardiomyocytes and neuronal cells following 
treatment with rhu-EPO (Sturm et al. 2005). Subsequently, rhu-EPO also showed significant 
increase in FXN expression levels in FRDA patients in a 2-month “proof-of-concept” study 
(Boesch et al. 2007). Furthermore, a first clinical trial with rhu-EPO over a period of 6 months 
showed stable and significant increase of frataxin expression (Boesch et al. 2008), suggesting 
that rhu-EPO is a good candidate for FRDA therapy. However, in a recent study Acquaviva et 
al. (2008) reported that rhu-EPO was able to increase the frataxin protein without increasing 
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mRNA at any of the times and doses tested, suggesting that the regulatory effects of rhu-
EPO on the frataxin protein are at the post-translational level. 
 
Gene therapy 
Although some of the above treatments improved the course of FRDA, they did not 
affect frataxin expression, so more specific and effective therapies are still needed. 
Therefore, the development of gene therapy would appear a valuable alternative to treat 
the neurological disorders in addressing the cause rather than the consequences of FRDA.  
As a first attempt, Fleming et al. (2005) reported the functional recovery of frataxin by 
delivering human frataxin cDNA by adeno-associated viral (AAV) and lentiviral (LV) vectors in 
human primary fibroblasts. In another experiment, selective deletion of frataxin in the brain 
stem of loxP(frda) mice resulted in deficit in the rotarod assay which was recovered by 
delivering human frataxin cDNA using HSV-1 amplicon vector (Lim et al. 2007). Recently, 
Gomez-Sebastian et al. (2007) demonstrated the successful construction and delivery of high 
capacity herpes simplex virus type 1 (HSV-1) amplicon vectors expressing the entire 80 kb 
FRDA genomic locus. Following vector transduction, increased frataxin expression and 
reduced oxidative stress was identified in FRDA fibroblasts (Gomez-Sebastian et al. 2007). 
However, a significant amount of research is still required before gene therapy may be 
practicable for clinical trials.   
 
                         
                             Chapter 1 - Friedreich ataxia: Introduction 
   
      31 
1.4 -  Development of model systems for FRDA 
Model systems of human cells and/or non-human organisms can provide insights into 
FRDA disease pathology. The high evolutionary conservation of frataxin across the species 
has enabled the development of disease models in various organisms, from the unicellular 
eukaryote Saccharomyces cerevisiae to the multicellular mouse model. Depending on the 
frataxin expression levels, various models of FRDA have shown that different, and even 
opposite, phenotypes can be observed. Therefore, enhanced studies will be needed for the 
better understanding of the pathophysiological functions of frataxin (reviewed in Puccio 
2009).  
 
1.4.1 - Human cell models 
 In order to generate a cellular model of a neural lineage, human neuronal precursor 
NT2 (N-tera2) cells were transfected with frataxin-specific interfering RNA (RNAi). The 
resultant cell line showed approximately 70% reduction in FXN mRNA and corresponding 
reduced levels of frataxin protein were found compared with a scrambled RNAi treated cell 
line (Tan et al. 2003). Sarsero and colleagues (2003) have generated another cell model with 
a BAC genomic reporter construct consisting of an in-frame fusion between the human FXN 
gene and EGFP under the control of FXN promoter (Sarsero et al. 2003). However, due to the 
absence of expanded GAA repeats (the construct has 6 GAA repeats) this model only allows 
the identification of molecules which act on the WT promoter but not on GAA repeats. Grant 
et al. (2006) have generated an additional GFP reporter cell line by combining part of the 
first intron of FXN, containing either 15 or 148 GAA•TTC repeats, to the coding sequence of 
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EGFP (Grant et al. 2006). Subsequent analysis of GFP expression levels by fluorescence assay 
and western blotting demonstrated reduced levels of GFP expression in the *GAA•TTC]148 
cell line compared with the *GAA•TTC]15 cell line (Grant et al. 2006), suggesting that these 
cell lines are appropriate models to study the GAA•TTC-mediated silencing effect of FXN 
gene. 
Later, Calmels et al (2009) have reported the establishment of first cellular models 
based on the frataxin missense mutation. These new cell models have shown all the 
biochemical phenotypes associated with FRDA. In addition, it has been recently reported the 
establishment of induced pluripotent stem (iPS) cells from FRDA patient fibroblasts (Ku et al. 
2010) and found MSH2 dependent expansion of GAA repeats. Therefore, one can speculate 
that such model systems are more accessible resource to study repeat instability mechanism 
as well as for differentiation of iPS into other cell types affected in this disease.  
 
1.4.2 - Drosophila model 
 A Drosophila model of FRDA was generated by selective suppression of Drosophila 
frataxin homologue (dfh) by a UAS-GAL4 transgene based RNA-interference (RNAi) 
technique (Anderson et al. 2005). Following suppression of dfh gene, distinct phenotypes 
were observed, such as giant long-lived larvae and conditional short-lived adults. 
Additionally, deficiency of DFH protein results in diminished activities of numerous haem 
and Fe-S containing enzymes, loss of iron homeostasis and increased susceptibility to iron 
toxicity (Anderson et al. 2005).  In a next attempt, to assess both the role of frataxin and 
oxidative stress in FRDA, Llorens and colleagues (2007) generated another Drosophila line by 
reducing the dfh levels by 30% compared to the controls thus overcoming the pre-adult 
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lethality observed in the previous model. This model has shown remarkably shortened life 
span and reduced climbing ability in adulthood. However, no differences in the activity of 
SDH and aconitase activity between control and dfh-RNAi flies were observed (Llorens et al. 
2007). Recently, this model also showed an increase in fatty acids catalyzing enhancement of 
lipid peroxidation levels in glial cells, elevating the intracellular toxic potential (Navarro et al. 
2010), suggesting a strong involvement of glial cells and lipid peroxidation in the generation 
of FRDA like symptoms. 
 
1.4.3 - Caenorhabditis elegans (C. elegans) model 
To date several C. elegans models with knockdown of the C. elegans FXN homolog frh-
1 have been published, but with conflicting findings. Intriguingly, the inactivation of several 
mitochondrial genes by RNAi prolonged the life span of C. elegans (Feng et al. 2001; Dillin et 
al. 2002; Lee et al. 2003; Rea and Johnson 2003). Similar effects were identified by Ventura 
et al. (2005), where knockdown of  the frh-1 gene extends the life span of C. elegans despite 
small body size, reduced fertility and altered oxidative response.  In contrast, Vazquez-
Manrique and colleagues (2006) reported that selective suppression of frh-1 gene by RNAi 
technology resulted in a consistent pleiotropic phenotype (slow growth, lethargic behaviour, 
egg laying defects, reduced brood size and altered defecation) associated with sensitivity to 
oxidative stress. However, it has been confirmed that the extended lifespan in C. elegans 
following suppression of frh-1 gene was due to the partial knockdown of the gene, and 
increased (not complete) inhibition of frh-1 gene has been shown to reduce lifespan (Rea et 
al. 2007).  
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1.4.4 - Saccharomyces cerevisiae (yeast) model 
Many studies in frataxin function arise from experiments performed with yeast, as 
frataxin and the yeast homologue YFH1 are orthologues. Yeast cells lacking Yfh1 have shown 
decreased cellular respiration, alterations in iron homeostasis and that leads to 
accumulation of iron (Babcock et al. 1997; Foury and Cazzalini 1997). It has been reported 
that mitochondrial DNA was lost when the ΔYfh1 cells were grown in iron rich media (Foury 
1999). In contrast, accumulation of zinc protoporophyrin (instead of haem) was accumulated 
in the ΔYfh1 mutant strains during the development. Microarray analysis of gene expression 
in ΔYfh1 mutant strains have shown enhanced expression of genes that are under the 
control of the iron-sensing transcription factors AFT1/AFT2, including genes involved in iron 
uptake (Foury and Talibi 2001). Depending on the strain background, the severity of these 
phenotypes differs quite substantially, thus rendering conclusions on the function of frataxin 
rather difficult (Muhlenhoff et al. 2002). 
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1.4.5 - Mouse models 
Mouse models of FRDA will provide valuable insights into the cascade of events 
associated with frataxin function, particularly in the early disease states, which can rarely be 
studied in the humans.   
 
1.4.5.1 - Knockout mouse models 
In order to investigate the function of frataxin and the mechanism of the disease, a 
mouse model was generated by homologous inactivation of Fxn gene (Cossee et al. 2000). 
However, this led to embryonic lethality, demonstrating an important function for frataxin 
during mouse development.  Therefore, in parallel, through a conditional gene targeting 
approach, two lines of conditional knockout mouse models were generated (Puccio et al. 
2001). These two lines were produced by using a loxP-flanked allele and Cre-lines that are 
driven by the neuron-specific enolase (NSE) and muscle creatine kinase (MCK) promoters, 
which exhibited heart and striated muscle, and neuron-restricted deletion of frataxin, 
respectively (Puccio et al. 2001). These mice displayed cardiac hypertrophy, large sensory 
neuron dysfunction, respiratory chain dysfunction, and time dependent intramitochondrial 
iron accumulation. However, the dorsal columns of the spinal cord, the primary sites of FRDA 
pathology, were not affected in these mice.  
To obtain specific and progressive neurological models for FRDA, Simon and 
colleagues (2004) have generated inducible knockout mouse models using two transgenic 
lines expressing the tamoxifen-dependent recombinase (Cre-ERT) under the mouse Prion 
protein (Prp) promoter. These mouse models have developed prominent features 
resembling FRDA such as neurodegeneration in DRG, slowly progressive mixed cerebellar 
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and sensory ataxia associated with posterior columns of the spinal cord and absence of 
motor involvement.  
 Subsequently, the involvement of frataxin in diabetes was also investigated in the 
knockout mice (Ristow et al. 2003), where selective suppression of frataxin in pancreatic β 
cells led to a reduction of insulin-secretory capacity, resulting in overt diabetes mellitus in 
older animals.  
 
1.4.5.2 - Knockin mouse models 
Although conditional knockout mouse models are excellent tools for studying disease 
pathophysiology and for evaluating some therapeutic approaches, they do not precisely 
mimic the human disease. Therefore, a new approach, the knockin strategy, was developed 
and resulted in producing knockin mouse models.  
 In a first attempt to produce the knockin mouse model for FRDA, Miranda et al. (2002) 
introduced 230 GAA repeats into the mouse frataxin gene by homologous recombination.  
Knockin mice were crossed with Frda knockout mice to obtain double heterozygous mice 
(GAA-/230GAA) expressing 25-36% of WT frataxin levels. In humans, these levels were typically 
associated with mild pathology of FRDA. In contrast, although a clear microarray gene 
expression was determined (Coppola et al. 2006), the knockin mice failed to develop FRDA 
associated pathology such as motor deficits, iron overload or meiotic/mitotic instability of 
GAA repeats (Miranda et al. 2002). Therefore, one can suggest that longer repeats might be 
essential to produce a good model of FRDA mouse model.  
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1.4.5.3 - FRDA YAC transgenic mouse models 
The FRDA YAC transgenic mouse model, perhaps the best model for FRDA, has been 
established by the generation of transgenic mice containing the human FRDA gene on a 370 
kb YAC clone (Pook et al. 2001).  
 
Generation of FRDA YAC transgenic mice 
In an effort to overcome the embryonic lethality of homozygous Fxn knockout mice 
and to study the behaviour of human frataxin in a mouse cellular environment, a human wild 
type FRDA YAC (Figure 1.12) transgenic mouse line was generated (Pook et al. 2001) and 
crossbred with heterozygous Fxn exon 4 deletion knockout mice (Fxn+/-) (Cossee et al. 2000). 
The resultant homozygous Frda knockout FXN transgenic mice (FXN+, Fxn-/-) were 
phenotypically normal, with lethality rescued by expression of functional YAC-derived 
human frataxin (Pook et al. 2001).  These results demonstrated that the re-introduction of 
human frataxin onto a mouse null background was an effective method that paved the way 
for further FRDA mouse models and frataxin functional studies.  
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Figure 1.12 - The position of YAC 37FA12 with respect to the FRDA  locus at 9q13. The 
position of YAC 37FA12 with respect to the FRDA locus at 9q13. Genes are represented as 
solid arrows, which indicate the direction of transcription, and the broken lines represent 
incomplete gene sequence. Individual exons are numbered and are shown below the 
relevant gene. STS markers used in the analysis are shown as downward pointing arrows 
(Pook et al. 2001). 
 
 
Generation of GAA containing FRDA YAC transgenic mice 
Subsequently, by using a yeast pop-in/pop-out homologous recombination strategy 
(Cemal et al. 1999), two lines of human FRDA YAC transgenic mice, YG8 and YG22,  
containing GAA repeat expansions derived from FRDA patient DNA were generated (Figure 
1.13) (Al-Mahdawi et al. 2004). Additionally, both lines were shown to contain transgene 
sequences spanning the whole 370 kb human YAC clone. The two founder mice, YG8 and 
YG22, differed in their GAA content as YG8 contained two copies of GAA repeats with 190 
and 90 repeats (GAA190+90), whereas YG22 was shown to have only one copy of 190 GAA 
repeats (GAA190) (Table 1.3) (Al-Mahdawi et al. 2004). Interestingly, both mice have shown 
intergenerational and age dependant somatic instability as seen in FRDA patients.  
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Figure 1.13 - GAA repeat modification of YAC 37FA12. The position and orientation of the 
normal FRDA gene (9 GAA repeats) within the human YAC clone 37FA12 are indicated by 
the arrow. L and R indicate left and right arms of the YAC. A 700-GAA PCR product was 
amplified from FRDA patient DNA using primers S2F and S3R. The PCR product was first 
cloned into pCR2.1 and then into YEp24, which contains a selectable URA3 gene, with 
resultant contraction to 230 GAA repeats. Pop-in/pop-out homologous recombination 
between Yep24 and YAC 37FA12 FRDA sequences produced the 190-GAA repeat YAC clone 
1(38), which was subsequently used to generate transgenic mice (Al-Mahdawi et al. 2004). 
 
 
Table 1.3 - Analysis of FRDA YAC transgenic mouse lines 
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Intergenerational instability in FRDA YAC transgenic mice 
Intergenerational instability of the GAA repeat expansions was assessed in both YG8 
and YG22 FRDA YAC transgenic mouse lines during transmission from transgenic parents to 
offspring. The results demonstrated that both lines have intergenerational contractions and 
expansions (Figure 1.14) (Al-Mahdawi et al. 2004). However, a trend towards a significant 
(p<0.05) excess of expansions upon paternal transmission was observed in the YG8 line. In 
contrast, no significant overall bias in the YG22 line was seen, but a bias toward contractions 
was seen upon maternal transmission (p<0.001) (Al-Mahdawi et al. 2004). However, large 
GAA expansions similar to those described in FRDA patients (Montermini et al. 1997a; 
Delatycki et al. 1998) have not yet been detected in this mouse model. 
 
 
Figure 1.14 - Intergenerational instability in FRDA YAC transgenic mice.(A) Ethidium 
bromide-stained agarose gel and (B) Southern blot autoradiograph of GAA PCR products 
from representative YG22 (190 repeats) and YG8 (90 + 190 repeats) transgenic mice 
showing expansions (↑)and contractions (↓) down to fewer than 9 repeats (both lines). 
An example of a discrete PCR product potentially corresponding to 340 repeats that failed 
to hybridize with a GAA probe is indicated by an asterisk (Al-Mahdawi et al. 2004). 
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Somatic instability in FRDA YAC transgenic mice 
To date, little is known about the somatic instability displayed by the expanded GAA 
trinucleotide repeat sequence in FRDA.  Therefore, a variety of tissues from YG8 mice and 
YG22 mice (2-12 months of age) were assessed for possible somatic instability (Al-Mahdawi 
et al. 2004) as seen in FRDA patients (De Biase et al. 2007b). Interestingly, no somatic 
instability was detected at the early age of the mice, but remarkable changes in somatic 
instability were detected in tissues from older mice of both lines (Figure 1.15) (Al-Mahdawi 
et al. 2004), suggesting that somatic instability is age dependent as observed in FRDA 
patients (De Biase et al. 2007b).  
 
Figure 1.15 - Somatic instability in FRDA YAC transgenic mice. Autoradiographs of 
Southern-blotted GAA PCR products from somatic tissues of representative transgenic 
mice. (A) 2-month F4 YG22, (B) 5-month F8 YG22, (C) 9-month F7 YG22, (D) 12-month F6 
YG22, (E) 2-month F4 YG8, and (F) 3-month F4 YG8. B, whole brain; Ch, cerebral 
hemisphere; Bs, brain stem; C, cerebellum; S, spinal cord; H, heart; L, liver; K, kidney; Sp, 
spleen; P, pancreas; Sk, skeletal muscle; T, testis; Ta, tail (Al-Mahdawi et al. 2004). 
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In contrast to the situation with intergenerational instability, noticeable similarities 
were observed between the FRDA patients and FRDA YAC transgenic mice when it comes to 
somatic instability of the GAA repeat as both YG8 and YG22 showed prominent GAA 
expansion changes in CNS tissues, particularly in the cerebellum (Al-Mahdawi et al. 2004). 
Recently, by using small-pool PCR (SP-PCR), a sensitive assay that utilizes low levels of 
genomic DNA (typically 6-600pg), somatic instability of the (GAA)190 tract was analysed in 
multiple tissues from 12-month old mice derived from both transgenic lines (Clark et al. 
2007). Although, both expansions and contractions were observed in most tissues, the 
(GAA)190 sequence was most unstable in the cerebellum and DRG suggesting that somatic 
instability is tissue specific. 
 
 
Figure 1.16 - Small-pool PCR analysis showing somatic instability of the GAA triplet-repeat 
sequence in multiple tissues from YG8 (a) and YG22 (b) transgenic mice. The locations of 
the constitutional (GAA)190 and (GAA)82 alleles, as determined by conventional PCR, are 
indicated by arrowheads (Clark et al. 2007). 
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In summary, both YG8 and YG22 lines show progressive and tissue specific GAA repeat 
instability specifically in regions of the nervous system that show a primary pathology in 
FRDA patients, when neither was observed with the 230-GAA repeat knockin mouse model 
(Miranda et al. 2002). Therefore, such a mouse model serves as a useful resource to 
delineate the mechanism(s) of somatic instability seen in FRDA patients, and to test 
potential interventional strategies.  
 
Human GAA expansion-containing FRDA YAC transgene rescue FRDA knockout mice 
To determine the viability of each GAA FXN transgene, both YG22 or YG8 mice (FXN+, 
Fxn+/+) were crossbred with heterozygous Fxn knockout mice (Al-Mahdawi et al. 2006). The 
FXN+, Fxn+/- offsprings from these crosses were further bred with Fxn+/- mice to generate 
FXN+, Fxn-/- “rescues”. Correct Mendelian ratios of rescue mice to overall offspring number 
were obtained from both YG22 and YG8 crosses, indicating that functional frataxin were 
obtained from both GAA repeat-containing transgenes (Al-Mahdawi et al. 2006).  
 
Decreased levels of frataxin mRNA and protein  
It has been confirmed that the YG8 and YG22 rescue mice show reduced levels of 
human FXN mRNA in all tissues and decreased levels of human frataxin protein in some 
tissues, compared to Y47, a normal-sized GAA containing FRDA YAC transgenic mice (Al-
Mahdawi et al. 2006; Al-Mahdawi et al. 2008). However, when compared with mouse 
endogenous frataxin (WT) all transgenic mice have produced more pronounced increases in 
FXN mRNA levels. Currently, there is no explanation for this phenomenon; however, it could 
be possibly due to several factors. Firstly, it could be over-expression of the human FXN gene 
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in a mouse background. Although YG8 mice have displayed increased levels of FXN mRNA 
compared with WT control mice, this may not fully translate into functional frataxin protein 
(Figure 1.17), hence an FRDA like phenotype is observed in such mice.  
 
Figure 1.17 - Relative expression of frataxin mRNA and protein. Comparison of frataxin 
mRNA and protein levels in brain tissues isolated from WT, Y47R (9 GAA), YG22R (190 
GAA) and YG8R (190+90 GAA). Data are normalized to the mean FXN mRNA and protein 
level found in the WT control samples taken as 100%.  
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Oxidative stress in FRDA YAC transgenic mice 
 To detect the potential oxidative stress in both transgenic mice lines (YG8 and YG22), 
the levels of oxidized proteins and malondialdehyde (MDA; a marker of lipoperoxides) were 
quantified in cerebrum, cerebellum, heart, and skeletal muscle tissues, compared with WT 
controls. Interestingly, oxidized proteins were increased in all tissues, most prominently in 
cerebrum and cerebellum, from both YG8 and YG22 rescue mice (Figure 1.18) (Al-Mahdawi 
et al. 2006).   
 
Figure 1.18 - Oxidative stress in FRDA YAC transgenic mice  (A) Oxyblot analysis detects 
protein oxidation in cerebrum, cerebellum, heart, and skeletal muscle tissues of 6- to 9-
month old YG22 and YG8 rescue mice, compared with WT controls. Error bars indicate 
SEM. *p<0.05, **p<0.01. (B) TBARS analysis shows levels of MDA (nmol/mg of protein) as 
a marker of lipoperoxidation in YG22 cerebrum and heart tissue compared with WT 
controls (n=6). Error bars indicate SEM. *p<0.05 (Al-Mahdawi et al. 2006). 
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Neurobehavioral deficits in FRDA YAC transgenic mice 
Subsequently, the neurobehavioral deficits were investigated in YG8 and YG22 mice 
and the coordination ability of these two mice were impaired from the age of 3 months as 
determined by reduced performance on an accelerating rotarod treadmill apparatus 
compared with WT littermate controls (p<0.01) (Al-Mahdawi et al. 2006).  Muscle strength, 
assessed by forelimb grip strength test, was decreased in YG22 rescues from 9 months of 
age (p<0.01), but no significant changes were detected in YG8 rescue mice. Locomotor 
activity, assessed by examining the unrestricted movement of mice in an open field, was 
decreased in both lines. The YG22 rescues showed a decreased trend in locomotor activity 
from 6 months of age, but no statistically significant difference was seen until one year of 
age p<0.05). On the other hand, YG8 rescue mice showed a significant decrease in locomotor 
activity from 6 months of age (p<0.05) (Al-Mahdawi et al. 2006).  
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Histological pathology in FRDA YAC transgenic mice 
Sections of brain, spinal cord and DRG of YG8 and YG22 mice were analysed to detect 
possible neuronal histopathology. Although, no histological abnormalities were identified in 
the brain and spinal cord, giant vacuoles were identified in the large sensory neuronal cell 
bodies of the DRG in both YG8 and YG22 rescue mice, but not in WT controls (Figure 1.19A) 
(Al-Mahdawi et al. 2006). In addition, Perl’s staining identified iron deposition within the 
heart, but only from the oldest (14-18 months) YG22 rescue mice studied (Figure 1.19B) (Al-
Mahdawi et al. 2006), confirming the later onset aspect of this pathology as previously 
described for cardiac frataxin conditional knockout mouse models (Puccio et al. 2001).  
Furthermore, electron microscopy of DRG from FRDA YAC GAA mice identified deposition of 
lipofuscin, chromatolysis, swelling of neuronal bodies and demyelination of axons (Al-
Mahdawi et al. 2006). 
 
Figure 1.19 - Neuronal and cardiac histopathology.  (A) H&E-stained section of lumbar DRG 
from a representative YG22 rescue mouse over 1 year of age, showing two neurons 
containing large vacuoles. Original magnification 400×. (B) Perl's staining of a heart section 
from a representative YG22 rescue mouse over 1 year of age, showing characteristic blue 
staining indicating iron deposition. Original magnification 600× (Al-Mahdawi et al. 2006). 
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Epigenetic changes in FRDA YAC transgenic mice 
Having determined the epigenetic profile around the human FXN gene (Herman et al. 
2006; Al-Mahdawi et al. 2008), epigenetic changes in FRDA YAC transgene mice have been 
investigated in the brain and heart tissues isolated from YG8 and YG22 mice  compared to 
Y47 mice (Al-Mahdawi et al. 2008). Epigenetic changes, such as differential DNA methylation 
and histone modifications, have been identified in both the FRDA YAC transgenic mice (Al-
Mahdawi et al. 2008), similar to those observed in FRDA patients.  
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DNA methylation profile in FRDA YAC transgenic mice 
Investigation of the DNA methylation profile in FRDA YAC transgenic mice has revealed 
a shift in DNA methylation, as the upstream GAA region is consistently hypermethylated and 
downstream GAA region is consistently hypomethylated (Figure 1.20) (Al-Mahdawi et al. 
2008).  
 
Figure 1.20 - DNA methylation analysis of the FRDA YAC transgenic promoter (A and B), 
upstream GAA (C and D) and downstream GAA (E and F) regions of Y47 (black columns), 
YG8 (light grey columns) and YG22 (dark grey columns) transgenic mouse brain and heart 
tissues (Al-Mahdawi et al. 2008). 
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Histone modification in FRDA YAC transgenic mice 
Subsequently, histone modifications were also investigated in FRDA YAC transgenic 
mice at exactly the same three regions of the FXN gene that had previously been analysed in 
human tissue (Al-Mahdawi et al. 2008). This analysis showed overall GAA repeat-induced 
decreases in histone H3K9 acetylation and increases in H3K9 methylation for both YG8 and 
YG22 transgenic mice (Figure 1.21) (Al-Mahdawi et al. 2008) as previously identified in 
human FRDA tissue. However, the level of deacetylation in the transgenic mouse brain tissue 
was not as great as that seen in the human brain tissue, possibly as a consequence of the 
smaller transgenic GAA repeat expansion sizes compared with FRDA patients.  
 
Figure 1.21 - Analysis of histone modifications in transgenic mouse brain tissue.ChIP 
quantitative PCR results for the transgenic FXN promoter/exon1 (Pro), upstream GAA (Up) 
and downstream GAA (Down) amplified regions are represented as the relative amount of 
immunoprecipitated DNA compared with input DNA, having taken negligible -Ab control 
values into account. FXN values were normalized with mouse GAPDH and all values have 
been adjusted so that all of the upstream GAA values from the non-GAA transgenic mouse 
tissues (Y47) are 100%. In each case two individual ChIP samples were analysed in 
triplicate from each of two mice per group. The means and SEMs of these values are 
shown (Al-Mahdawi et al. 2008). 
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1.4.5.4 - FXN BAC transgenic mouse model 
Recently, similar to the FRDA YAC transgenic mouse model strategy, Sarsero et al. 
(2004) have generated a FXN bacterial artificial chromosome (BAC) transgenic mouse model 
by inserting a 188 kb BAC clone (pBAC265) containing exon 1-5b of the normal human FRDA 
locus.  The human FRDA orthologue successfully rescued the embryonic lethality of the Fxn 
knockout mice (Sarsero et al. 2004). This FXN BAC transgene displays extensive tissue-
specific differential expression in relation to the endogenous locus, implying the existence of 
tissue-specific transcriptional mechanisms regulating FXN expression (Sarsero et al. 2004). 
Subsequently, a FXN BAC transgenic mouse model has also been generated by inserting large 
GAA expansion mutation (>500 GAA repeats), but this mouse, which retains a marker gene 
sequence, failed to exhibit any FRDA-like phenotype (Sarsero personal communication).   
In conclusion, there are many types of FRDA mouse models: knock-outs, knock-ins and 
YAC or BAC transgenics. In principle, the knock-ins, YAC transgenics and BAC transgenics are 
all suitable models to investigate epigenetics in FRDA. However, the currently available 
knock-ins and BAC transgenics retain disruptive marker gene sequences, whereas the YAC 
transgenics do not contain any such artificial sequences. Therefore, the YAC transgenics, 
which have shown comparable epigenetic changes and GAA instability as seen in FRDA 
patients, are regarded as the best model to study epigenetics in FRDA. This mouse model is 
considered a valuable resource in the study of FRDA pathology and/or therapeutic strategies 
aimed at interacting and modifying the GAA repeat expansion itself. 
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1.5 -  Aims of the study 
FRDA is a progressive neurodegenerative disorder and currently there is no effective 
therapy available that can stop the progression of this disease. To understand the 
pathological consequences and to find a potential therapy for FRDA, in vitro and/or in vivo 
model systems are considered to be essential. Therefore, the main aim of this research 
project was to establish a model cell culture system that would help drug screening for 
FRDA. Chapter 3 of this thesis describes the establishment of novel cell culture systems, 
including FRDA mouse primary fibroblasts and neural stem cells for in vitro therapeutic 
testing of FRDA.  
Recently, it has also been reported that FRDA is associated with increased DNA 
methylation and decreased acetylation of histones flanking the GAA repeat (Herman et al. 
2006; Greene et al. 2007; Al-Mahdawi et al. 2008). Therefore, in efforts to reduce the DNA 
methylation and increase the histone acetylation, I have investigated the use of DNA 
demethylating agents and HDAC inhibitors in the cell culture systems, as described in 
chapter 4. In addition, I also studied the efficacy of some GAA interacting compounds as 
potential therapeutics. 
Finally, recently described HDAC inhibitors, RGFA 136 and RGFP 109, have been 
reported to show increased frataxin mRNA and protein, along with increased levels of 
acetylated histone H3 and H4 levels, in a short-term preliminary study (Rai et al. 2010). 
Therefore, in chapter 5 I describe the efficacy and tolerability of such compounds in long-
term studies using the YG8 FRDA YAC transgenic mouse model. 
 
 
    
    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 - Materials and methods 
    
                                     Chapter 2 - Materials and methods                                                                                                        
   
      54 
2.1 -  Solutions/reagents 
 DMEM medium 
- 1x DMEM medium, 10% FCS, 2% pen-strep (5000U/ml penicillin and 5000mg/ml of 
streptomycin, Fisher Scientific). 
 
NSC medium (complete medium) 
- 1x NSC basal medium, 10% NSC proliferation supplements, 20ng/ml recombinant 
human epidermal growth factor (rhEGF), 10ng/ml recombinant fibroblast growth 
factor-basic (rhFGF-b), 2µg/ml heparin and 1% pen-strep (all from Stem Cell 
Technologies). 
 
NSC differentiation medium  
- 1x NSC basal medium, 10% NSC differentiation supplements (Stem Cell Technologies) 
and 1% pen-strep 
 
DMEM/F12 medium 
- 1x DMEM and F12 in 1:1 ratio, 10% FCS and 2% pen-strep (GIBCO) 
 
Neurobasal/B27 medium 
- 1x Neurobasal medium, 2% B27 supplements and 1% pen-step  
 
RPMI 1640 
- 1x RPMI 1640 medium, 2mM glutamine, 15% FCS  and 2% pen-step  
 
ACK lysis buffer 
- NH4Cl - 8.29 g/L; KHCO3 - 1g/L; disodium EDTA•2H2O - 0.0372 g/L in Cell Culture Grade 
Water 
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 Immunoflourescence assay 
- 4% paraformaldehyde saline (pH 7.4): 4% w/v paraformaldehyde, 30mM NaOH in 
PBS  (or) 50% acetone + 50% methanol 
- Permeabilization buffer: 0.5% Triton X-100 in 1x PBS 
- Blocking buffer: 0.2% skimmed dry milk, 0.1% Triton X-100 in 1x PBS 
- Washing buffer: 0.1% Triton X-100 in 1x PBS  
 
 Histological analysis  
- Heparinised saline: 2u/ml heparin in PBS  
- 4% paraformaldehyde saline (pH 7.4): 4% w/v paraformaldehyde, 30mM NaOH in 
PBS  
- Hillman & Lee’s EDTA: 150mM EDTA, 10% formalin  
- Acid alcohol: 1% HCl in 70% IMS  
 
 General solutions 
- Tail digestion buffer: 100mM Tris-HCl (pH 8), 5mM EDTA, 200mM NaCl, 0.2% SDS 
- TE buffer: 10mM Tris-HCl (pH 7.5), 1mM EDTA 
- Orange G loading dye (6x): 0.35% Orange G dye, 30% sucrose 
- 1x TBE: 90mM Tris, 90mM Boric acid, 2mM EDTA  
- 1x TAE: 40mM Tris, 20mM Acetic acid, 1mM EDTA 
- Tris/glycerol homogenization buffer: 100mM Tris-HCl (pH 9.0), 15% glycerol filter 
sterilized via 0.2μm pore 
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Western blot analysis  
- Running buffer: 25mM Tris, 190mM glycine, 3.5mM SDS 
- Sample buffer: 80mM Tris-HCl (pH 6.8), 12.5% glycerol, 10% SDS, 0.5% BPB, 1% BME 
- Transfer buffer: 25mM Tris, 190mM glycine, 10% methanol 
- PBS/T: 0.2% Tween-20 in PBS  
- 5% milk PBS/T: 5% w/v milk, 0.2% Tween-20 in PBS  
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2.2 -  Primers for genotyping and quantification of FXN 
Various primers were used for genotyping the FRDA YAC transgenic mouse model and 
for the quantification of the FXN gene (Table 2.1 and Table 2.2). Primer sequences were 
obtained either from previous studies (as indicated) or newly designed by using primer 3 
software (Rozen and Skaletsky 2000) and all primers were purchased from Sigma-Aldrich. 
 
Table 2.1 - Primers used for genotyping FRDA YAC transgenic mice 
Primer Name Sequence (5' - 3') Product length 
GAA repeat (Campuzano et al. 1996) 
GAA - F GGGATTGGTTGCCAGTGCTTAAAAGTTAG 
457 bp + (GAA)n GAA - R GATCTAAGGACCATCATGGCCACACTTGCC 
   FXN knockout (Cossee et al. 2000) 
WJ5 CTGTTTACCATGGCTGAGATCTC 
 WN39 (WT specific) CCAAGGATATAACAGACACCATT 520 bp 
WC76 (KO specific) CGCCTCCCCTACCCGGTAGAATTC 245 bp 
   Msh2 knockout (Toft et al. 1999) 
Msh2-P1 CGGCCTTGAGCTAAGTCTATTATAAGG 
 Msh2-P2 (KO specific) GGTGGGATTAGATAATGCCTGCTCT 194 bp 
Msh2-P3 (WT specific) CCAAGATGACTGGTCGTACATAAG 164 bp 
   Msh3 Knockout (de Wind et al. 1995) 
Msh3-P1 (WT specific) CAGGAAGAGGTCACTGGGAAATGG 130 bp 
Msh3-P2 (KO specific) GGTGGGATTAGATAATGCCTGCTCT 250 bp 
Msh3-P3 GCTGAGAATACTTAGTCTCTGGCA 
 
   Msh6 knockout (de Wind et al. 1995) 
Msh6-P1 (WT specific) CAAGTCCTAGGATTAGAGGTCTGG 220 bp 
Msh6-P2 (KO specific) CCGGTGGATGTGGAATGTGTGCG 253 bp 
Msh6-P3 CCATGCAAATCAGACTCGATACAA 
 
   Pms2 knockout (designed by Mark Pook) 
Pms2-P1 ACAGTTACATTCGGTGACAG 
 Pms2-P2 (KO specific) TTTACGGAGCCCTGGCGC 189 bp 
Pms2-P3 (WT specific) ACTAATTCCCCTACGGTTTAG 385 bp 
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Atm knockout (Liao et al. 1999) 
Atm - F GACTTCTGTCAGATGTTGCTGCC 
 Atm - B (WT specific) CGAATTTGCAGAAGTTGCTGAG 162 bp 
Atm - Neo (KO specific) GGGTGGGATTAGATAAATGCCTG 441 bp 
      
 
 
 
 
Table 2.2 - List of primers used for quantification of FXN expression 
Primer name Sequence (5' - 3') Product length 
FXN expression (Human Specific) (Al-Mahdawi et al. 2008) 
FXNRT-F CAGAGGAAACGCTGGACTCT 
172 bp 
FXNRT-R AGCCAGATTTGCTTGTTTGGC 
   FXN expression (Human and Mouse) 
 FRT I-F TTGAAGACCTTGCAGACAAG 
121 bp 
RRT II-R AGCCAGATTTGCTTGTTTGG 
   Gapdh (Human) (Al-Mahdawi et al. 2008) 
Gapdh-h-F GAAGGTGAAGGTCGGAGT 
 226 bp 
Gapdh-h-R GAAGATGGTGATGGGATTTC 
   Gapdh (Mouse) (Al-Mahdawi et al. 2008) 
Gapdh-m-F ACCCAGAAGACTGTGGATGG 81 bp 
 Gapdh-m-R GGATGCAGGGATGATGTTCT 
   RER1 (Mouse) 
RER1-F CCACCTAAACCTTTTCATTGCG 159 bp 
RER1-R TTTGTAGCTGCGTGCCAAAAT  
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2.3 -  General techniques 
Dilutions or stock solutions were prepared in deionised water (18.2 MΩ) unless 
otherwise specified.  The only exceptions were RNA experiments where RNAse-free DEPC-
treated sterile water was used. Centrifugation of samples was performed in different 
equipment according to sample size and temperature requirements. Centrifugation of small 
samples (≤ 1.5ml) at room temperature was performed using a standard bench top micro-
centrifuge (16K, BioRad) and at 4°C using a refrigerated micro-centrifuge (5415R, 
Eppendorf). The larger volumes (≤ 50ml) were centrifuged in a Centaur 2 centrifuge 
(Sanyo/MSE) and 96 well plates were centrifuged at room temperature using a Legend T 
centrifuge (Sorvall).  
Incubations at lower temperatures (37-60°C) were performed in water baths (Grant); 
while for higher temperatures a heating block (DB-2A, Techne) was used. The pH of solutions 
was determined using a pH meter (Delta 340, Mettler) and pH adjustments were made by 
adding either concentrated HCl or NaOH. DNA containing solutions were stored at 4°C for 
short time in the fridge and in the cold room for long term. RNA samples were snap frozen 
and stored at -80°C. All mouse tissues were stored at -80°C. Antibodies were stored either at 
4°C or -20°C according to the manufacturer’s recommendations, if necessary in the dark.   
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2.3.1 -  Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate the DNA fragments according to 
their size. Agarose gels were prepared in a range of 1% to 3% with agarose (UltraPure 
electrophoresis grade, Invitrogen) for the separation, in 1x TBE/TAE. The agarose was first 
boiled in a standard microwave and allowed to cool. Then, ethidium bromide was added to 
the gel in a final concentration of 0.5µg/ml and the gel was poured in to a casting tray with 
the required well comb. The small gels (50ml) were run in mini gel tanks (Flowgen 
Biosciences), while midi gels were used for the large volumes (>150ml). After adding 6X 
Orange G loading dye to a final concentration of 1x, the products were loaded into the gels 
and were run for a period of 30min at 60V. The gels were visualized and documented by a 
UV transilluminator imaging system (Alpha Innotech). 
 
2.3.2 -  DNA extraction - ethanol method 
This method was used to extract the genomic DNA quickly (where there was no need 
of great quality) for routine genotyping of mice or cell culture. Tail samples/cell pellet were 
collected in Eppendorf tubes and 400µl of tail digestion buffer and 10µl of proteinase K 
(50mg/ml) was added followed by a brief vortex and incubated at 55°C overnight. After the 
incubation, samples were vortexed and centrifuged at 14K rpm for 15min and the 
supernatant was carefully transferred into a new eppendorf tube by avoiding transferring 
any cell/hair/bone debris. Then 1ml of absolute alcohol was added and the samples were 
mixed by inverting the tube several times. Samples were incubated at -80°C for 10min 
followed by centrifugation at 14K rpm for 30min at 4°C.  The ethanol was drained off and the 
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pellet washed with 1ml of 70% ethanol. The samples were again centrifuged at 14K rpm for 
20min at 4°C and then ethanol was carefully drained off and the DNA pellet was air dried by 
inverting the Eppendorf tube on paper towels for a period of ~10min. The DNA pellet was 
resuspended in 50-100µl of TE buffer and stored at 4°C.  
 
2.3.3 -  DNA extraction – Phenol/Chloroform method 
Genomic DNA extraction by the phenol/chloroform method was used for samples 
where greater quality was necessary. Digestion of samples by proteinase K was performed as 
described in section 2.3.2. After digestion, samples were vortexed and 400µl of phenol 
(equilibrated with Tris-HCl pH 8.0) was added. Samples were mixed well by vortexing twice 
for 15 sec and centrifuged at 14K rpm for 5min at 4°C. Then, 380µl of the supernatant was 
removed to a fresh Eppendorf and 380µl of chloroform/isoamyl alcohol (24:1, v/v) was 
added. Samples were vortexed briefly and centrifuged again at 14K rpm for 5min at 4°C. 
Afterwards, 350µl of the resulting supernatant was removed to a fresh Eppendorf and 35µl 
of 3M Na-acetate (pH 5.2) was added. 700µl of absolute ethanol was then added and 
ethanol precipitation carried out as previously described (section 2.3.2).  
 
 
 
 
    
                                     Chapter 2 - Materials and methods                                                                                                        
   
      62 
2.3.4 -  Extraction of total RNA - Trizol® method (Invitrogen) 
Total RNA was extracted from the drug-treated cells and mouse tissues using the 
Trizol® method following supplier guidelines. About 106 cells or 30-40mg tissue were used to 
extract the RNA.  The cell pellet was first washed once with PBS and collected by 
centrifugation at 1.5K rpm for 5min. The cell pellet was loosened by flicking the tube gently 
and resuspended in 1ml of Trizol®. Mouse tissues were similarly homogenized in 1ml of 
Trizol® by Eppendorf homogenizing rod. Samples were then incubated for 10min at room 
temperature. 0.2ml of chloroform per 1ml of Trizol® was added followed by vigorous shaking 
of samples for 15sec and incubated for further 15min at room temperature. Samples were 
phase separated by centrifugation at 14k rpm for 15min at 4°C. The upper aqueous phase 
(~0.5ml) was then transferred to a fresh labelled eppendorf tube and RNA was precipitated 
by adding 0.5ml of isopropyl alcohol. Samples were incubated for 10min at room 
temperature and centrifuged at 14k for 15min at 4°C. The supernatant was carefully 
removed and the RNA pellet was washed once with 1ml of 75% ethanol (made with DEPC-
water) and centrifuged again at 7.5k rpm for 5min at 4°C. The supernatant was removed 
carefully and the RNA pellet was briefly dried for a period of 5-10min and resuspended in 10-
20µl of DEPC-water. RNA samples were stored at -80°C, until required to use.  
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2.3.5 -  Complementary DNA (cDNA) synthesis 
Complementary DNA (cDNA) was synthesized by using cloned AMV first-strand cDNA 
synthesis kit (Invitrogen). On ice, 2µl of RNA was added to 10µl of primer component 
mastermix (7µl of DEPC-water, 2µl of 10mM dNTP mix and 1µl of Oligo (dT)20 primer). RNA 
and primer were denatured by keeping the samples at 65°C for 5min and immediately 
placing the samples on ice. Then the following reagents were added in order: 4µl of 5X cDNA 
synthesis buffer, 1µl of DEPC-water, 1µl of 0.1M DTT, 1µl of RNase OUT™ (40U/µl) and 1µl of 
cloned AMV RT (15 units/µl). The 20µl reaction mixture was gently mixed by flicking the tube 
and briefly centrifuged to bring all the contents to the bottom. The reaction mixture was 
incubated at 55°C for 60min. The reverse transcriptase reaction was terminated by keeping 
the samples at 85°C for 5min. The cDNA samples were used immediately or stored at -20°C. 
 
2.3.6 -  Determination of RNA/DNA quantity and purity 
RNA/DNA concentration and purity was determined by using NanoDrop™ 2000c 
spectrophotometer (NanoDrop, Thermo Scientific). The absorption (A) of ultra violet light 
(UV-light) was measured at 260nm and the quality was determined by using A260/280 ratio. 
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2.3.7 -  Poly-D-lysine coating of plates/coverslips 
 Poly-D-lysine coated plates/coverslips were used for the immunofluorescence assay 
for neural stem cells to improve the cell attachment capacity to the surface. A stock solution 
of poly-D-lysine (50µg/ml, Sigma) was prepared with tissue culture grade distilled water. 
Enough poly-D-lysine was added to the culture flask to cover the surface and the flask was 
incubated at room temperature overnight. Coverslips were coated by soaking in poly-D-
lysine. After incubation, the solution was aspirated and culture plates/coverslips were 
washed once with sterile tissue culture grade distilled water. Plates were allowed to air dry 
for 2-3 hours and stored at 4:C.  
 
2.4 -  Genotyping and breeding pattern of mice 
The animal husbandry was maintained in controlled temperature and light/dark 
cycles. New born mice were weaned approximately 3 weeks of age and were processed for 
genotyping. The ears were clipped for identification and the tip of the tail (<5mm) was 
collected by local anaesthesia with ethyl chloride BP (Cryogesic, Acorus Therapeutics Ltd) for 
DNA isolation and genotyping. The DNA from newborn mice was used for different types of 
genotyping, including estimation of GAA repeat size and knockout genotypes for Fxn, Msh2, 
Msh3, Msh6, Pms2 and Atm.  
All PCRs were performed in 1x Taq mastermix (Qiagen) with primers (Table 2.1), 
primer concentrations (Table 2.3) and conditions specified (Table 2.4) in a final volume of 
25µl,  using appropriate volumes of forward and reverse primers and 1µl of sample DNA. For 
each PCR experiment a control with known genotype was used as a reference. In addition, a 
sample containing dH20 in place of DNA was also prepared as a contamination control. 
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Table 2.3 - Concentrations of primers used in genotyping PCRs 
Primer 
Concentration 
per reaction  
Primer 
Concentration 
per reaction 
     
GAA PCR (repeat estimation) 
 
Msh2/Msh3/Msh6/Atm 
knockout 
GAA - F 12.5pmol 
 
Primer 1 12.5pmol 
GAA - R 12.5pmol 
 
Primer 2 12.5pmol 
   
Primer 3 12.5pmol 
Fxn Knockout 
    
WJ5 20pmol 
 
Pms2 knockout 
WN39 20pmol 
 
Primer 1 30pmol 
WC76 3.5pmol 
 
Primer 2 20pmol 
    
 
Primer 3 10pmol 
 
 
Table 2.4 - Cycling conditions for various genotyping PCRs 
GAA   Fxn   Msh2/3/6   Pms2   Atm 
              
 
94:C 2min 
  
94:C 2min 
  
94:C 1min 
  
94:C 1min 
  
94:C 1min 
 
  
  
  
  
  
  
  
     94:C 10s 
 
  94:C 20s 
 
  94:C 30s 
 
  94:C 20s 
 
  94:C 30s 
10x 60:C 30s 
 
40x 54:C 20s 
 
30x 60:C 30s 
 
30x 49:C 20s 
 
30x 60:C 30s 
  68:C 45s 
 
  72:C 20s 
 
  72:C 1min 
 
  72:C 20s 
 
  72:C 1min 
 
  
  
  
  
  
  
  
     94:C 10s 
  
72:C 6min 
  
72:C 10min 
  
72:C 10min 
  
72:C 10min 
20x 58:C 30s 
  
  
  
  
  
  
     68:C 1min* 
  
  
  
  
  
  
   
 
  
  
  
  
  
  
  
   
 
68:C 6min 
  
  
  
  
  
  
                     
* - time increased 20s per cycle 
 PCR reactions were performed in 0.25ml tubes (Fisher Scientific) using a thermo cycler 
(PTC-225, MJ Research) and the results were obtained by separating the products in 1-2% 
agarose mini gels with 1% TBE buffer along with a 1kb+ DNA ladder (Invitrogen).  For the 
estimation of GAA repeat size, samples which proved positively for the presence of the FRDA 
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YAC transgene were run in a 20cm long gels with 1.5% agarose and 1x TBE gels overnight 
along with 100bp and 1kb+ DNA ladders.  
 The breeding pattern of mice for drug treatment was designed to produce litters with 
a maximum number of FRDA rescue or WT mice.  Rescue mice were achieved by a cross 
between homozygous FXN rescue (FXN+/+, Fxn-/-) with a frataxin heterozygous mouse (Fxn+/-) 
and the WT mice were generated by a cross between two C57BL6/J WT mice. Resultant 
newborn mice were genotyped as previously described and grouped by gender and age with 
a maximum of 5 mice per cage.  
 
Expand long range PCR  
Long range PCR is used to efficiently amplify large genomic DNA fragments from 5kb 
to 25kb in length and this was done by using Expand Long Range PCR System kit from Roche 
Applied Science (USA, cat no 4829034001). The PCR mastermix was prepared in a final 
volume of 49µl using appropriate volumes of forward and reverse primers and 1µl of sample 
DNA (Table 2.5). For each PCR experiment a positive control was used as a reference. In 
addition, a sample containing dH20 in place of DNA was also prepared as a contamination 
control. 
 
Table 2.5 - Expand long range PCR mastermix concentrations 
Components Final concentration 
5x buffer (12.5mM MgCl2) 1x 
dNTPs  500µM 
DMSO 10% 
Expand Taq polymerase 3.5U 
Forward primer 0.5µM 
Reverse primer 0.5µM 
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2.5 -  Functional studies during drug treatment 
Weight and functional measurements were taken at the start and repeated every 
month during drug treatment. Three different types of functional data were collected in 
each drug trail: locomotor activity, rotarod analysis and open-field activity. 
 
Locomotor activity analysis 
Locomotor activity was assessed by placing the mice in a 3X5 gridded (33cm X 55cm) 
perspex box. The number of gridded squares entered by each mouse over a period of 30 
seconds was recorded, and the experiment was repeated four times for each mouse. A 
minimum of 200 seconds rest time was given in between each run. 
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Rotarod analysis  
Rotarod analysis of mice was performed using a Ugo-Basille 7650 accelerating rotarod 
treadmill apparatus (Figure 2.1) and used to assess motor co-ordination and balance. The 
rotarod apparatus consists of a rotating drum with a grooved surface for gripping with the 
speed of the rotation gradually increasing from 4 to 40 rpm. The mice were placed on the 
rotating rod and up to 5 mice were assessed per run. The time taken for each mouse to fall 
from the rod was recorded over a maximum period of 400 seconds. Four runs were 
performed and a minimum of 200 seconds rest time was given in between each run.  
 
 
Figure 2.1 – Rotarod apparatus with mice 
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Open field activity monitor (Beam breaker) 
Open field activity was monitored by using a MED-OFA-510 activity chamber (MED 
Associates Inc) with SOF-811 software. This windows application was specifically written and 
it allows flexible configuration of experiments and repeated data analysis. Each chamber 
measures 27.3cm X 27.3cm with three 16-beam I/R arrays (Figure 2.1) and two chambers 
were connected to the computer. Each chamber takes only one mouse per run, which was 
measured over a period of 2 min. Four runs were performed for each mouse and an average 
of four runs was taken for the calculations. The software counts the standard measures 
including ambulatory counts, distance, time and episodes; stereotypic counts and time; 
vertical counts and time; resting time; jump counts and time; average velocity. The data was 
directly exported to an excel spread sheet for statistical analysis.  
 
 
Figure 2.2 – Open field activity monitor chambers 
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2.6 -  Sample collection of mice post drug treatment 
At the completion of each drug treatment the mice were appropriately culled and all 
the tissues were collected according to the type of analysis desired.  
 
Preparation of mouse tissue for expression and biochemical analysis 
 The samples with intended use for frataxin expression and/or biochemical studies 
were collected by culling the mice by cervical dislocation and dissecting immediately. The 
collected tissues were snap-frozen in liquid nitrogen and stored at -80°C. The following 
samples were collected: brain (B); brain stem (Bs); cerebellum (C); spinal cord (Sc); heart (H); 
lung (Lu); liver (L); pancreas (P); kidney (K); spleen (Sp); skeletal muscle (Sk); blood (Bl); tail 
(Ta); lumbar vertebral column (VI); thoracic vertebral column (Vt); cervical vertebral column 
(Vc); testis (T) and sperm (S) from males; and ovaries (O) from females. 
 
Preparation of mouse tissues for histological analysis 
 For histological analysis, mice were terminally anaesthetized by intraperitoneal 
injection with 5µl/g pentobarbitone sodium (Pentoject, Ph.Eur. Animal Care Ltd), followed by 
a preliminary intracardial perfusion with approximately 50ml of heparinised saline.  Then, 
tissue fixation was performed by intracardial perfusion with approximately 100ml of 4% 
paraformaldehyde in PBS. The fixed mice were dissected immediately and the whole brain, 
spinal cord, lung, pancreas, liver and heart were collected carefully. The fixed tissues were 
left in 4% paraformaldehyde for first three days followed by a brief wash with dH20 and 
immersion in 70% (v/v) ethanol at 4°C for long term storage.  
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2.7 -  Establishment of primary fibroblasts 
Primary fibroblasts cells were derived from selected WT and FRDA mice and were 
maintained in DMEM culture medium.   
2.7.1 -  Culture medium of fibroblasts 
Preparation 
Aliquots of FCS and pen-strep were thawed at 37°C for 2 hours or 4°C overnight. Inside 
the hood, FCS and pen-strep were added to 500ml of 1x DMEM and mixed well by shaking 
the bottle gently. The contents were filter sterilized with a 0.22µM pour size filter unit 
(Nalgene) and stored at 4°C until required to use. 
 
2.7.2 -  Culture procedure of fibroblasts 
This method was based on Gomes-Pereira and Monckton (2004) and it is 
recommended for the establishment of cell cultures from large mouse organs like lung, liver, 
kidney and heart.  
 
Culture requirements 
DMEM medium, 1x sterile PBS (Invitrogen), 0.25% trypsin/EDTA (Thermo Scientific), 
sterile scalpel blades, scissors, forceps, Petri dish, culture flasks, 18G needles, syringe and 
centrifuge tubes. 
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Procedure 
The DMEM medium and trypsin solutions were prewarmed to 37°C in a water bath. 
The mouse was dissected on a clean bench and the kidney was collected aseptically in 50ml 
sterile ice-cold PBS.  The kidney was transferred to a laminar-flow hood to avoid 
contamination and placed on a 10-cm tissue culture dish with 10ml of ice-cold sterile PBS 
and washed briefly to remove blood cells and fat tissues. The tissue was minced into approx  
1-mm3 cubes and transferred into a sterile 15ml conical tube containing 10ml sterile ice-cold 
PBS. These tissue pieces were allowed to settle down over a period of 2min and aspirated 
PBS, washed twice with 10ml sterile PBS. Then 5ml of Trypsin/EDTA solution was added and 
the culture dish was incubated in a humidified 5% CO2 incubator at 37
oC for 30min by gently 
inverting the tube after every 5 min. 
The plunger was removed from a 5ml syringe and the pieces of tissue and enzymatic 
solution were transferred into the syringe. The plunger was placed back in syringe and the 
contents of the syringe were squirted into a 25-cm2 tissue culture flask, through a sterile 18-
gauge needle. The tissue culture flask was placed in the incubator for an extra 15min. The 
contents of the flask were transferred into a 15ml conical tube, the pieces of cellular debris 
were allowed to settle down over a period of 2min and then the supernatant was 
transferred into a fresh 15ml conical tube for centrifugation at 1.5K rpm for 5 min. The 
supernatant was removed and the cell pellet was resuspended in 4ml of complete culture 
medium and plated into one well of a 6-well plate. The primary cultures were incubated at 
37oC in a 5% CO2 humidified incubator. 5ml of Trypsin/EDTA solution was added to the 
remaining undigested tissue. This step was repeated until the entire tissue sample was fully 
    
                                     Chapter 2 - Materials and methods                                                                                                        
   
      73 
digested or six primary cultures had been independently plated on a 6-well tissue culture 
plate. The primary fibroblasts were ready in 5-7 days in culture. 
 
2.7.3 -  Passage of fibroblasts 
Once cells attach to the substratum and spread, they begin to divide, and the cell 
number increases. Cells progress from sparse to sub-confluent to confluent. Subculture 
provides the cell with fresh nutrients and space for continuous growth. The simplest way to 
remove the cells is to digest the attachment molecules, leaving the cells intact and free to 
float in suspension. The continuous subculture of mouse cell cultures results in spontaneous 
immortalization and generation of cell lines exhibiting unlimited proliferative capacity. 
Culture medium, PBS and Trypsin/EDTA solutions were prewarmed to 37oC in a water 
bath. The medium was removed by vacuum suction and cells were washed gently with 
sterile PBS. Adherent fibroblasts were digested with trypsin/EDTA for 5min at 37oC in the 
CO2 incubator to bring them into suspension. The trypsin/EDTA solution was neutralized by 
adding 10ml of DMEM culture medium. Cells were collected by centrifugation at 1.5K rpm 
for 5min and subcultured in 10ml DMEM culture medium at a 1:5 or 1:10 ratio. The cells 
were incubated at 37oC, 5% CO2 with 95% humidity and at every passage, the number of 
population doublings was determined based on the cell number. 
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2.7.4 -  Cell quantification and viability (Trypan blue exclusion assay) 
It is important to know the number of cells in the culture at given stages and whether 
these cells are viable. The use of haemocytometer and a dye, such as trypan blue, gives a 
quantitative standard for the viability of the cells. Cells that exclude trypan blue are 
considered viable, whereas cells that take up the dye are irreversibly dead. To perform this, 
cells were first digested with trypsin/EDTA and a cell suspension was made with DMEM 
medium. 100-200µL of cell suspension was taken into a fresh Eppendorf and an equal 
volume of 0.4% (w/v) trypan blue (Sigma) was added, mixed well by pipetting up and down. 
Cells were counted by using a haemocytometer and their viability was determined by the 
following formula: 
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2.7.5 -  Mycoplasma PCR testing 
Mycoplasma PCR was carried out using Mycosensor™ PCR Assay Kit (Stratagene). In 
brief, 100-μl of supernatant was taken carefully from a culture flask into a sterile 1.5ml 
Eppendorf tube and incubated for 5min at 95oC in a water bath. 10μl of strataclean was 
added to the tube and mixed well by flicking the tube followed by the centrifugation. Then, 
20-50μl of sample was taken from the supernatant (this acted as a template) and placed on 
ice. Mycoplasma PCR mastermix was prepared by adding the following reagents in order; 
33µl dH20, 5µl 10x PCR buffer (Qiagen), 1µl Q buffer (Qiagen), 2.5µl 10mM dNTP mix, 1µl 
primer mix, 2µl Taq DNA polymerase, 5µl internal control and 5µl test sample.  
PCR amplification was performed in 0.25ml tubes using a thermal cycler (PTC-225, MJ 
Research) and the cycling conditions were as described for “PCR using Taq DNA polymerase” 
in Table 2.6. To visualize the results, 10-15μl of PCR products were separated in 1-2% 
agarose TBE mini-gels along with a 1kb+ DNA ladder (Invitrogen) at 75V for ~30min. 
 
Table 2.6 - Mycoplasma PCR cycling parameters (Adopted from www.stratagene.com)  
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2.7.6 -  Cryopreservation and regeneration of fibroblasts 
Cells were digested with Trypsin/EDTA and their viability was determined by the 
trypan blue exclusion test. Cells were pelleted by centrifugation at 1.5K rpm for 5 min. and 
cells were resuspended in 1ml of DMEM culture medium supplemented with 10% (v/v) 
DMSO, at the desired density. A good standard to freeze is (0.5-1.0) x 106 cells/ml. Cells were 
frozen slowly using a cooling container containing isopropanol to avoid ice crystal formation, 
which may damage the cells.  
In contrast to the slow rate of cooling required to freeze cells, cells should be thawed 
as rapidly as possible to minimize the risk of cell damaging during ice crystal formation. The 
vial of cells was removed from the liquid nitrogen tank, quickly thawed by immersing the 
entire vial in a water bath at 37oC and transferring the cells into a 15-ml conical tube. Then, 
10ml of prewarmed culture medium was added to the cells, which were mixed gently by 
pipetting up and down. Then cells were collected by centrifugation at 1.5K rpm for 5 min.  
Afterwards, the old freezing medium was discarded and a new DMEM culture medium was 
added to the flask. Cells were incubated in a CO2 incubator at 37
oC and 90-95% humidity. 
 
2.7.7 -  Drug evaluation in primary fibroblasts 
Stock solutions of drug compounds were prepared in various solutions and aliquots of 
the drugs were stored at -80°C until required to use. When the confluence of the cells 
reached to 60 - 70%, old medium was removed and cells were washed once with PBS. 
Required concentrations of drug were freshly dissolved in complete culture medium from 
the stock solution and added to the cells. The cells were incubated for the specified time 
according to the type of the drug and concentrations used. After the incubation, cells were 
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washed once with PBS and cells were collected by centrifugation for RNA, DNA and protein 
extraction. 
 
 
2.8 -  Isolation of primary mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) were isolated from both WT and FRDA transgenic 
mice. The pregnant female mouse at day 13 p.c (post coitum) was sacrificed by cervical 
dislocation. The uterine horns were dissected out carefully, rinsed in 70% (v/v) ethanol and 
placed in ice cold PBS. Each embryo was separated from its placenta and surrounding 
membranes. The brain region, dark red organs and as much blood as possible was removed 
from the embryos, which were washed twice with ice cold PBS. Embryos were then finely 
minced in minimal amount of PBS with sterile razor blades and transferred to a fresh 15ml 
centrifuge tube. The minced tissues were allowed to settle down over a period of 2min. The 
supernatant was removed and 5ml of trypsin/EDTA was added to each embryo followed by 
incubation with gentle shaking at 37°C for 15min.  
After the incubation, the cell suspension was transferred to a 50ml falcon tube and 2 
volumes of fresh DMEM medium were added. To remove the undigested pieces of tissues, 
the cell suspension was allowed to settle down over few minutes and the supernatant was 
collected in another fresh 50ml falcon tube, followed by centrifugation at 1.5k rpm for 5min. 
The cell pellet was resuspended in 5ml of prewarmed DMEM medium and plated into one 
well of a 6-well plate. This step was repeated until the entire tissue sample was fully 
digested or six primary cultures had been independently plated on a 6-well tissue culture 
plate.  Subculture, cryopreservation and maintenance of MEFs were carried out as normal 
for fibroblasts (sections 2.7.3-2.7.6). 
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2.9 -  Establishment of neural stem cells (NSCs/neurospheres) 
Neural stem cells (NSCs), often referred as neurospheres, were established from the 
WT and both strains of FRDA mouse model (YG8 and YG22). This method was made available 
by Satyan Chintawar, Laboratory of Experimental Neurology, Erasme Hospital, Brussels. 
 
2.9.1 -   Culture medium of neurospheres 
Neurospheres were grown in a selective medium called, Neurocult® NSC proliferation 
medium and it consists of NSC basal medium, NSC proliferation supplements, recombinant 
human epidermal growth factor (rhEGF), recombinant human fibroblast growth factor-basic 
(rhFGF-b), heparin and pen-strep. 
 
1) Stock solutions of growth factors 
a) Recombinant human epidermal growth factor (rhEGF) 
A stock solution (10μg/ml) of rhEGF (Stem cell technologies) was prepared by adding 
0.1mL of sterile 10mM acetic acid containing at least 0.1% bovine serum albumin to initially 
dissolve the rhEGF powder and then added 19.9ml of NSC basal medium containing NSC 
proliferation supplements. The stock solution was stored as 1ml aliquots at -20°C until 
required for use. 2µl of 10μg/ml rhEGF was needed for to every 1ml of NSC medium, to give 
a final concentration of 20ng/ml of rhEGF. 
 
b) Recombinant human fibroblast growth factor-basic (rhFGF-b) 
A stock solution (10μg/ml) of rhFGF-b (Stem cell technologies) was prepared in 1x PBS 
and 0.1% BSA and stored as 0.5 ml aliquots at -20°C until required for use. 1µl of 10μg/ml 
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rhEGF was needed for to every 1ml of NSC medium, to give a final concentration of 10ng/ml 
of rhEGF. 
 
2) Stock solution of heparin 
0.2% heparin in PBS was purchased from Stem cell technologies and aliquoted into 0.5ml.  
The stock solution was stored at 4°C until required for use. 1µl of 0.2% heparin was added to 
every 1ml of NSC medium, to get a final concentration of 0.0002% (2µg/ml). 
 
3) Stock solution of Pen-strep 
A stock solution of pen-strep (5000U/ml penicillin and 5000µg/ml streptomycin) was 
prepared and stored at -20°C as an aliquot of 5ml in dark until required to use.  
 
2.9.2 -  NSC medium preparation 
Aliquots of growth factors, heparin, pen-strep and 50ml NSC proliferation 
supplements were thawed by keeping at 37°C for 2 hours or at 4°C overnight.  All the 
contents were mixed well in 450ml of NSC basal medium. Then, the medium was filter 
sterilized through 0.22µM pour size filter unit (Thermo Fisher) and aliquoted into 50ml 
universal tubes and stored at 4°C until required to use. 
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2.9.3 -  Culture of neurospheres 
Requirements 
Papain solution, Pg Solution, EBSS and NSC medium 
 
1. Papain solution (10ml) 
NSCs were prepared from the sub-ventricular zone (SVZ) of the brain, and each brain 
requires at least 10ml of freshly prepared papain solution. Papain solution consists of papain 
enzyme (Worthington), EDTA (Sigma), cysteine (Sigma) and EBSS (Invitrogen). 
 
Preparation 
10mg of papain enzyme was accurately weighed in an Eppendorf and transferred to a 
15ml centrifuge tube. The papain enzyme was dissolved in 5ml of EBSS by vortex. In another 
Eppendorf tube, 2mg of EDTA and 2mg of cysteine was accurately weighed and transferred 
to a 15ml centrifuge tube. The contents were dissolved in 5ml of EBSS by vortex. Inside the 
hood (laminar air flow), two solutions of EBSS were mixed well and filter sterilized through a 
0.22µM pour size filter attached to a 10ml syringe.  
 
2. Pen-strep and glucose solution (Pg solution) 
Each brain requires about 200-250ml of Pg solution for transferring the brain and 
washing and it consists of 1x PBS, 30% glucose and pen-strep. 
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Preparation 
5ml of pen-strep and 10ml of 30% glucose was added to 485ml of 1x PBS and mixed 
well by shaking the bottle gently. The solution was filter sterilized by a 0.22µM pour size 
filter and stored in dark at 4°C until required to use.   
 
Culture procedure 
Neurospheres were established individually from WT and FRDA (YG8 and YG22) mice. 
All mice were sacrificed and the brains were collected carefully in Pg solution. The brains 
were washed once in Pg solution and the SVZ was carefully isolated. The tissues were 
minced into small pieces with scalpel blades and transferred into a Petri dish containing 
10ml of papain solution, followed by incubation at 37°C for 60min on a rocking platform. At 
the end of the incubation, cells were collected by centrifugation at 1K rpm for 10 min and 
almost all the supernatant was removed overlaying the cell pellet carefully without using 
suction. The cell pellet was dissociated by triturating up and down with p1000 Gilson tips 
several times. Cells were resuspended in 7ml of EBSS followed by centrifugation at 1K rpm 
for 10min.  
After the centrifugation, the supernatant was discarded and the cell pellet was 
dissociated with p200 Gilson tips by pipetting up and down about 20-30 times.  Cells were 
resuspended in 8ml of EBSS and centrifuged at 500rpm for 15min. The supernatant was 
discarded cell pellet was gently dissociated with a p200 Gilson tip. Finally, the cell pellet was 
resuspended in 1ml of complete NSC medium and transferred to a flask containing 7ml of 
NSC medium. Cells were incubated at 5% CO2, 95% humidity and 37°C. A schematic 
representation of the entire procedure is shown in Figure 2.3. 
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Figure 2.3 - Establishment and maintenance of neural stem cells in culture at different 
stages (Reynolds and Rietze 2005). 
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2.9.4 -  Passage of Neurospheres 
Over time, cells proliferate and form spheroids, called neurospheres, which in general 
detach from the tissue culture flask and float in suspension. The neurospheres are ready for 
subculture 6-8 days after plating. If the neurospheres are attached to the culture substrate, 
tapping the culture flask against the bench top helps to detach the neurospheres. Subculture 
of neurospheres was accomplished by two different methods:  
 
i. Mechanical dissociation 
The medium with suspended neurospheres was removed and placed in an appropriately 
sized sterile culture tube. Any cells that remained attached to the flask were detached by 
shooting a stream of medium across the attached cells. The neurospheres were pelleted by 
centrifugation at 500rpm for 10 minutes. The supernatant was carefully removed leaving 
behind about 200-300µl. The pellet was dissociated gently by pipetting up and down 20-25 
times with a Gilson p200 tip or fire polished Pasteur pipette until a single cell suspension was 
achieved.  
 
ii. Chemical dissociation 
To obtain a higher percentage of viability and total cell expansion, the chemical 
dissociation method (Figure 2.4) was recommended. The chemical dissociation kit (Stem Cell 
Technologies) contains solution A, B and C. 
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Procedure 
  The cells were collected by centrifugation at 1K rpm as mentioned above. As much 
supernatant as possible was removed by leaving a minimal volume (less than 50μl) of 
supernatant above the cell pellet. 0.5ml of solution A was added to the pellet and 
resuspended by Gilson p1000 tip set at approximately 450μl by pipetting gently up and 
down 10-15 times. At this point the lab timer was set for 8 minutes and 125μl of solution B 
was added to the cell suspension. The tube was gently tapped to mix the solution with cell 
suspension and the lab timer immediately started. At the 3-minute time point, the cell 
suspension was gently mixed by pipetting up and down 8 times with a Gilson p200 tip 
volume set at 180μl. This process was repeated at 7- and 8-minute time points. At the 8- 
minute time point, 40μl of solution C and 350μl of NSC proliferation medium was added to 
bring the final total volume up to approximately 1ml. The cell suspension was mixed by 
pipetting up and down and at this point the cell suspension contained only single cells and 
no aggregates. 
The precise volume of the cell suspension was measured and the cell number was 
counted with a haemocytometer by using a dilution (1/5 or 1/10 dilution) in trypan blue to 
assess cell density and viability.  If a larger volume of cells (>100μl) was needed for the next 
subculture, a wash step was then necessary to remove the chemical reagents. This was 
performed by adding 10ml of NSC culture medium to the cell suspension and centrifuging for 
5min at 800rpm. The cell pellet was gently resuspended in 1ml of NSC proliferation medium 
and a further cell count was performed if required. Cells were incubated in a CO2 incubator 
for the next passage in NSC proliferation medium. 
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Figure 2.4 - Schematic representation different stages in chemical dissociation method 
(Stem Cell Technologies 2006). 
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2.9.5 -  Differentiation of NSCs 
This method was based on Jana et al. (2007) and used for the isolation of purified 
neurons, oligodendrocytes, astrocytes and microglia from the same mouse brain tissue and 
neural stem cells (Figure 2.5). It is important to note that microglial cells are only obtained 
from brain tissues and not from the NSCs. 
 
I. Isolation of primary neurons 
Neurospheres were pelleted by centrifugation at 500rpm for 10min and dissociated 
with p200 Gilson tips. The cell pellet was washed once with PBS and once with neurobasal 
medium. In the first step, neurons were enriched by allowing the cells to adhere to poly-D-
lysine coated flasks for 5min. Non-adherent cells containing astrocytes and oligodendrocytes 
were removed and used for the isolation of other cells. Adherent cells, mostly neurons, were 
incubated with DMEM/B27 medium including 10µM of cytosine arabinoside (AraC) for 10 
days to prevent proliferation of dividing cells (Jana et al. 2007).  
 
II. Isolation of primary microglia (only from brain) 
The remaining non-adherent suspensions enriched with mixed glial cells were collected 
by centrifugation for 10min at 1.5k rpm and then resuspended in DMEM supplemented with 
10% heat inactivated FBS. Cells were seeded on poly-D-lysine coated flasks followed by 
incubation at 37:C with 5% CO2.  The culture medium was replaced in regular intervals of 3 
days. On ninth day these mixed glial cultures were placed on a rotary shaker at 240rpm at 
37:C for 2 hours to separate the mixed glial cells based on selective cell adhesion properties. 
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The cell suspension was placed on uncoated culture plates for 30min followed by removal of 
non-adherent cells by washing (Jana et al. 2007). 
 
III. Isolation of primary oligodendrocytes 
 The oligodendrocytes were obtained after shaking the remaining cell culture for 18 h 
at 190rpm on eleventh day. To purify oligodendrocytes from astrocytes, the detached cell 
suspension was plated in non-coated tissue culture dishes for 60 min at 37°C. This step was 
repeated twice to minimize the contamination. The non-adherent cells were seeded into 
poly-D-lysine-coated culture plates in NSC medium at 37°C with 5% CO2 in air (Jana et al. 
2007).  
 
IV. Isolation of primary astrocytes 
 The attached cells remaining after removal of oligodendrocytes were primarily 
astrocytes. These cells were trypsinized and subcultured in complete media at 37°C with 5% 
CO2 in air to yield more viable and healthy cells (Jana et al. 2007). 
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Figure 2.5 - Differentiation of NSCs. Flow chart representing the entire process of isolation 
method (Jana et al. 2007). 
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2.9.6 - Cryopreservation and regeneration of neurospheres 
Neurospheres were stored in serum free cell freezing medium (Sigma). All the 
neurospheres were pooled together by centrifugation at 500rpm for 10min and almost all 
the supernatant was removed by vacuum suction (leaving not more than 50µl). The cell 
pellet was gently dissociated by tapping the tube and cells were resuspended in 1.5ml of 
serum free freezing medium. The cell suspension was transferred to a new polypropylene 
cryovial (Nunc), which was then placed in a cooling container at -800C for 3 hours, followed 
by transfer to liquid nitrogen. To re-establish the neurospheres, the vial containing 
neurospheres from the liquid nitrogen was carefully collected and quickly thawed at 37°C. 
The cells were added to a 15ml centrifuge tube containing 8ml of NSC medium and 
centrifuged at 500rpm for 10min. The supernatant was removed and cell pellet was gently 
dissociated with a Gilson p200 tip. The cells were incubated with 10ml NSC medium at 37°C, 
95% humidity and 5% CO2.  
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2.10 -  Isolation of murine fetal neural stem cells 
Mouse fetal neural stem cells were derived from selected WT and FRDA mice and 
were maintained in NSC culture medium.  
The pregnant female mouse at day 13.5 p.c (post coitum) was sacrificed by cervical 
dislocation. The uterine horns were dissected out carefully, rinsed in 70% (v/v) ethanol and 
placed in ice cold PBS. Each embryo was separated from its placenta and surrounding 
membranes. The brain region of the embryo was collected carefully and placed in 1ml of 
NSC medium. The tissue was homogenized with Gilson p1000 tips (set at 500µl) by pipetting 
up and down about 10-15 times, followed by adding 9ml NSC medium. Homogenized tissue 
was centrifuged at 1k rpm for 10min at room temperature and almost all the supernatant 
was removed overlaying the cell pellet carefully without using suction. The cell pellet was 
dissociated by triturating up and down with Gilson p200 tips and resuspended in 7ml of 
EBSS, followed by a centrifugation at 1k rpm for 10min.  
After the centrifugation, the supernatant was discarded and again the cell pellet was 
dissociated with Gilson p200 tip. Cells were resuspended in 8ml of EBSS and centrifuged at 
500rpm for 15min. The supernatant was discarded and the cell pellet was gently dissociated 
with Gilson p200 tip. Finally, the cell pellet was resuspended in 8ml of NSC medium and 
transferred to T25 flask, followed by incubation at 5% CO2, 95% humidity and 37°C. 
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2.11 -  Isolation of murine splenocytes 
Splenocytes are white blood cells established from the spleens of WT and FRDA mice 
for their similarity to human lymphocytes.  
To isolate splenocytes, the selected mouse was culled appropriately and wiped with 
70% ethanol. The spleen was collected aseptically and placed on ice-cold PBS. Immediately, 
the spleen was mashed through a 70µM cell strainer using the plunger end of the syringe 
into a Petri dish containing 5ml of RPMI 1640 medium. The cell strainer was washed with an 
additional 5ml of medium and then discarded. The suspended cells were transferred to a 
15ml centrifuge tube and centrifuged at 1.5k rpm for 5min. The supernatant was discarded 
and the cell pellet was resuspended with 1ml of ACK lysis buffer (to remove RBC) followed by 
an incubation of 10min at room temperature. Afterwards, 9ml of RPMI 1640 medium was 
added and the cells were centrifuged as before. Again, the supernatant was discarded and 
the cell pellet was resuspended in 3ml of RPMI 1640 medium, followed by removing of any 
dead cells mass. Cell count and viability was measured by the trypan blue exclusion assay as 
described before (section 2.7.4). Cells were resuspended at a concentration of 1x107/ ml and 
incubated at 37°C with 5% CO2. 
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2.12 -  Western blot analysis 
Protein lysates were obtained from frozen brain tissues, and frataxin western blot 
analysis was carried out as previously described (Pook et al. 2001), using an anti-frataxin 
rabbit polyclonal antibody (Santa Cruz). Histone H3 and H4 acetylation levels were 
determined by western blot analysis using anti-acetyl-histone H3 (Upstate) and anti-acetyl-
histone H4 (Upstate) antibodies, respectively. In all cases, normalization was carried out 
using an anti-tubulin rabbit polyclonal antibody (Sigma). Densitometry was carried out using 
UN-SCAN-IT software (Silk Scientific Corporation). 
 
2.13 -  Aconitase assay 
Aconitase is a Fe-S cluster protein that catalyzes the conversion of citrate to isocitrate. 
The assay used for this study was based on a combined protocol provided by Cayman 
Chemical Company (USA, Cat. No. 705502) and Dr. Mark Cooper (Royal Free Hospital, 
London).  It involves coupled enzymatic reactions that convert citrate to isocitrate, which is 
then converted to -ketoglutarate in a reaction catalysed by isocitric dehydrogenase (IDH).  
An increase in the absorbance at 340 nm is measured, which monitors the formation of 
NADPH.  The production of NADPH is proportional to the aconitase activity. 
To perform the assay, mouse brain tissues were homogenised on ice in CellLytic MT 
Mammalian Tissue Lysis/Extraction buffer (SIGMA, C3228) to 10% w/v. Lysates were 
centrifuged at 800 x g for 10min at 4oC and used immediately. 
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A substrate reaction premix was made up as follows: 
 
Table 2.7 - Aconitase assay substrate reaction premix  
Component Final Concentration 
Tris/HCl (pH 7.4) 50mM 
NADP 0.4mM 
Na Citrate 5mM 
MgCl2 0.6mM 
Triton X-100 0.1% 
Isocitrate dehydrogenase 1U 
 
200µl of substrate premix was added to each well of a preheated 96 well plate, and 
reactions were initiated by adding 50µl of a 1 in 10 dilution of homogenised tissue sample. 
Reactions were incubated at 37oC for 15min in the dark and then the absorbance was 
measured once every minute at 340 nm for 15 min at 37oC using a spectrophotometer. The 
aconitase activity was determined from the slope of a graph by plotting the absorbance 
value over time. 
 
2.14 -  MethylScreen assay 
DNA methylation analysis was performed using the ‘methylscreen’ method described 
by Holemon et al. (2007), which uses combined restriction digestion of DNA with 
methylation sensitive and methylation dependent restriction enzymes, MSRE and MDRE 
respectively. 
Methylscreen was used to analyse the FXN CpG site 4 region upstream of the GAA 
repeat (Al-Mahdawi et al. 2008).  Specific MSRE, AjiI (Fermentas) and MDRE, McrBc 
(BioLabs), were used to perform four treatments of each DNA in the assay. All digestion 
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cocktails contained 1xTANGOTM with BSA (Fermentas). In addition, the McrBc digests 
required the use of 2mM GTP (guanosine-5’-triphosphate). 
In a typical experiment, genomic DNA was prepared by phenol/chloroform extraction 
and 0.5-1µg DNA was restricted in four separate eppendorf tubes as described in Table 2.8 
and adjusted the final volume to 100µl by PCR grade water. 
 
Table 2.8 - Preparation of restriction digestion samples for methylscreen assay  
Components Volume AjiI McrBc 
Double 
Digest 
Mock 
0.5 - 1µg DNA 1µl    
AjiI (5U/µl) 2µl    
McrBc (10U/µl) 1µl    
10X TANGOTM 10µl    
GTP (100mM) 1µl  
 
 
 
50% Glycerol 3µl 
   

 
Samples are incubated for 16 hours at 37oC. After incubation, enzyme was deactivated 
by heating to 65oC for 20min followed by placing the samples on ice. Spin the samples briefly 
and use 5µl to check efficiency of digestion on a 1% agarose gel.  
For QRT-PCR, 5µl of above digested sample was used with forward (Fmet 5’-
GATCCGTCTGGGCAAAGGCCAG-3’) and reverse (Rmet 5’-ATCCCAAAGTTTCTTCAAACACAATG-
3’) primers designed to amplify across the FXN CpG site 4. A 196bp product is expected when 
no digestion occurs (mock). Full digestion is expected in the double digest samples and 
hence no PCR product is obtained. 
For calculations, mock treated sample Ct values were normalized to 100% and MSRE, 
MDRE or double digested samples were expressed relative to mock treated sample. The 
percentage of densely methylated and unmethylated values were calculated by subtracting 
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MSRE and MDRE digested sample values from the double digested value, respectively. 
Intermediately methylated values were detected by subtracting the value of densely 
methylated plus unmethylated value from 100. In all methylscreen assays the mock sample 
showed a lower Ct value than the digested samples and the highest Ct value was reported in 
the sample digested with both enzymes (double digest) (Figure 2.6).  
 
 
Figure 2.6 - A typical QRT-PCR profile of methylscreen assay. Undigested sample (mock) 
showed a lower Ct value than the MSRE, MDRE or double digested (DD) sample. 
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2.15 -  Histological analysis of DRG sections 
This method was kindly performed by Lorraine Lawrence, Imperial College London. 
Preparation of vertebral column paraffin wax blocks 
Vertebral column samples were prepared for the histological analysis as described 
earlier (section 2.6) and placed in a tissue-tek cassette. Decalcification of vertebral column 
was done by immersing the cassettes in 500ml of Hillman and Lee’s EDTA for a minimum of 
five days. Then the cassettes were washed under running tap water for at least 4 hours 
followed by immersing the cassettes in increasing concentration of IMS (as described in 
Table 2.9) using an automated embedding unit (Hypercenter XP, Shandon). Afterwards, the 
cassettes were immersed in Histo-Clear (Sigma-Aldrich) and molten paraffin wax-based 
embedding medium (Kendall), followed by the final paraffin wax incubation under vacuum 
for the time durations specified in Table 2.9. The block was then allowed to cool down in a 
cold plate. 
 
Preparation and H&E staining of section slides  
Using a rotary microtome (AS 325, Shandon) DRG-containing vertebral columns were 
cut into thin (6µM) slices and briefly suspended on the surface of a 37°C water bath. The 
sections were then transferred to microscope slides and allowed to dry overnight at 37°C. To 
remove the excessive wax and staining solutions from the slides, sections were soaked twice 
(5min each) in Histo-Clear followed by immersion in 100% and 70% IMS giving a brief (2min) 
rinse with water between each solution. Then the sections were immersed in Haematoxylin 
Harris (BIOS Europe) for 2min and placed under running tap water until sections turn blue. 
The colour was then distained by dipping the sections twice in acid alcohol (1% HCl in 70% 
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IMS) and returned the sections to running tap water until sections went blue again. 
Afterwards, sections were incubated in 1% Eosin (BIOS, Europe) for 1min and washed once 
with running tap water. Subsequently, the sections were dehydrated by rinsing in increasing 
concentration of IMS (70%, 90% and 100%) for 30s each. Finally, the sections were washed 3 
times (5min each) in Histo-Clear and coverslips were applied using DPX mountant. 
 
Table 2.9 - Incubation schedule of H&E staining of DRG sections  
Solution* Duration 
Hillman & Lee's EDTA 5 days  
70% IMS Overnight 
90% IMS 4 hours 
100% IMS 1.5 hours 
100% IMS 1.5 hours 
100% IMS 1 hour 
Histo-Clear Overnight 
Histo-Clear 1 hour 
Paraffin Wax 1.5 hours 
Paraffin Wax 1.5 hours 
Paraffin Wax - Vacuum 1 hour 
*fresh solutions were used at each incubation step. 
The levels of DRG neurodegeneration were determined by counting the number of 
vacuoles in neuronal cell bodies as a percentage of the total number of DRG cells counted. 
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2.16 -  Immunofluorescence assay 
Cells were grown on poly-D-lysine coated coverslips until they reach 70-80% 
confluence and then the coverslips were transferred to a micro dish with cells facing up 
using a sterile tweezers. The cells were washed twice with sterile ice-cold PBS and fixed by 
incubating in 4% paraformaldehyde for 8 min at 4:C. Afterwards, cells were washed 3 times 
5 min each with sterile ice-cold PBS and then incubated with permeabilizing buffer for 5 min 
at room temperature. Again, cells were washed twice with sterile ice-cold PBS and incubated 
with blocking buffer in a humidified chamber at 4:C overnight.  
Next day, cells were washed twice with sterile ice-cold PBS and once with blocking 
buffer. Cells were incubated with appropriately diluted primary antibody (15-20µl/cover slip) 
for 2 hours at room temperature in the dark followed by three 5min washes with washing 
buffer. Then cells were coated with secondary antibody for 2 hours at room temperature in 
the dark. The washing steps were repeated again two times with washing buffer, as before, 
and once with sterile distilled water. A drop of mounting medium with DAPI stain was added 
to a clean and properly labelled microscopic slide.  Coverslips were transferred to the slide 
carefully with sterile tweezers facing with the cells facing downwards on the mounting 
medium. Excess mounting medium was removed with paper towels and cells were visualized 
with a fluorescent microscope.  
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2.17 -  Quantitative real-time RT PCR (QRT-PCR)  
Quantitative real-time reverse transcriptase PCR (QRT-PCR) was performed using 
SYBR® green master mix (Applied Biosystems) in a real time PCR machine (ABI Prism 7900HT, 
Applied Biosystems).  QRT-PCR reactions were carried out in 96-well plates (Microamp, 
Applied Biosystems) in triplicates. A final volume of 25µl mastermix was prepared containing 
12.5µl of 2x SYBR® green mastermix, 0.5-1.0µl of 2.5-5pmol of optimized respective forward 
and reverse primers (see Table 2.2 for primers used), 5µl of (5x diluted) cDNA and distilled 
water to make the final volume up to 25µl. Samples were minimized to light exposure. 
Target and endogenous mastermixes were prepared separately and added to the plate with 
a repetitive electronic pipette (Rainin) followed by adding the cDNA. Then the plate was 
sealed with real time plate sealers (MicroAmp, Applied Biosystems) and the contents were 
mixed gently by shaking the plate. The plate was then briefly (1min) centrifuged at 1K rpm to 
bring all the contents to the bottom of the well.  
The cycling conditions varied according to the application and were optimized to 
amplify the different targets with similar efficiencies. Following each real time PCR reaction a 
dissociation curve run was performed by increasing the temperatures gradually from 60°C to 
95°C. Relative quantification values were determined by 2-ΔΔCt method using SDS 2.1 
software (Applied Biosystems). 
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2.18 -  Statistical analysis 
Statistical analyses such as descriptive measurements and graphical visualization were 
done using Microsoft excel 2007 software.  Functional measurements of weight, rotarod 
performance, locomotor activity, average velocity, ambulatory distance and vertical counts 
were analysed using two way analysis of variance (ANOVA) for repeated measures. All other 
measurements comparing two sample groups were analysed using student’s t test to 
determine if the mean values differed significantly or not. In all cases a statistical significance 
level of 5% was chosen. 
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3.1 -  Introduction  
In order to gain further understanding of the physiological function of frataxin  and 
FRDA pathogenesis, and to develop an effective system for testing potential therapies, a 
model cell culture system is considered most useful. Although animal models are considered 
essential to study whole organism aspects of the disease, whenever possible, alternatives 
should also be used to ensure successful research, upholding the principles of the 3Rs 
(reduction, replacement and refinement). 
Cell culture was first devised at the beginning of this century (Harrison 1907) as a 
method for studying the behaviour of animal cells free of systematic variations. Cell culture 
systems are now used extensively in research for wide variety of diseases. Mammalian cell 
models are important to study the molecular mechanisms of the disease and are powerful 
tools for large-scale therapeutic screening approaches. 
As mentioned earlier, a FRDA YAC transgenic mouse model has been generated that 
exhibits FRDA-like pathology (Pook et al. 2001; Al-Mahdawi et al. 2004; Al-Mahdawi et al. 
2006; Al-Mahdawi et al. 2008).  The development of a model cell culture system from such 
animals is of paramount importance to study the in vivo trinucleotide dynamics in vitro. In 
addition, this cell culture system can create new avenues to investigate the multiple factors 
affecting FRDA pathogenesis under controlled conditions. Furthermore, these cells have the 
advantage of being readily renewable, easily accessible, and relatively inexpensive to 
maintain. Therefore, we have decided to establish a novel model cell culture system for 
FRDA in order to hasten therapeutic drug screening and to analyse the repeat dynamics over 
extensive periods of time.  
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3.2 -  Types of cells 
In FRDA it is difficult to obtain the critical affected tissues, such as DRG, heart and 
cerebellum, from FRDA patients. Therefore, we have performed experiments using various 
human and mouse cell types. Human primary fibroblasts were obtained from Coriell Cell 
Repository (USA) and as kind gift from Dr. Ian Kill (Brunel University). Mouse primary 
fibroblasts, embryonic fibroblasts, splenocytes, neural stem cells (NSCs), and fetal neural 
stem cells were established in our laboratory from the FRDA YAC transgenic mouse model as 
described earlier (chapter 2).  
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3.2.1 - Human primary fibroblasts  
Since FRDA patients are relatively rare, most initial experiments were conducted with 
fibroblasts from three healthy individuals (H.Normal, GM04503 and GM07492) and three 
FRDA patients (GM04078, GM03816 and GM03665) (Figure 3.1 and Table 3.1). The GAA size 
in FRDA primary fibroblasts was determined using expand long range PCR system as 
described (section 2.4). 
 
Figure 3.1 - Long-range PCR analysis of GAA repeat length in normal and FRDA patient 
primary fibroblasts.  DNA length markers (1kb plus and 100bp) are shown in bp. Left panel 
corresponds the GAA length of three normal primary fibroblasts (H.Normal, GM04503 and 
GM07492) and right panel consists the length of three FRDA patients fibroblasts GAA size 
(GM03816, GM04078 and GM03665).  
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Table 3.1 - Details of the human primary fibroblasts  
ID Sex Age (Yrs) Number of GAA repeats 
H.Normal Male 27 Normal 
GM04503 Female 31 Normal 
GM07492 Male 17 Normal 
GM03816 Female 36 330/380 
GM04078 Male 30 541/420 
GM03665 Female 13 445/740 
 
3.2.2 - Mouse adult and embryonic primary fibroblasts  
Mouse primary fibroblasts have a number of properties that make them an attractive 
culture models. They are relatively easy to establish and maintain, they proliferate rapidly 
and, as a result, large numbers of cells can be produced. Mouse adult primary kidney 
fibroblasts were established from the wild-type (WT), YG8 and YG22 mice (Figure 3.2), 
whereas embryonic fibroblasts were developed only from the WT and YG8 mice.   For each 
line of FRDA YAC transgenic mice, fibroblasts were derived from rescue and transgenic mice 
to compare the frataxin mRNA levels. It is important to understand the genotype of the mice 
which we used in the subsequent experiments. The transgenic mice have both human and 
mouse frataxin genes, whereas rescue mice possess only the human frataxin gene (FXN) and 
WT mice contain only the mouse frataxin gene (Fxn).  
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Figure 3.2 - Fibroblast cells of FRDA YAC transgenic mice.  The fibroblasts were established 
from the kidney and after 7 days in incubation, about 90% confluence was seen in YG8 and 
YG22 transgenic mice (a, c), and 40-50% in YG8 and YG22 rescue mice (b, d).  
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3.2.3 - Mouse adult and fetal neural stem cells (NSCs) 
Neural stem cells (NSCs) are immature cells with extended self-renewal capacity that 
are able to differentiate into neurons, astrocytes and oligodendrocytes (Abematsu et al. 
2010). These properties have led to expectations that NSCs might be useful to understand 
neurological disease mechanism. Most of the neurodegenerative disorders are characterized 
by a continuous loss of specific populations of neurons. Therefore, possible regenerative 
interventions include transplanting developing neural stem cells (NSCs) into the host brain or 
inducing the proliferation of endogenous stem cells by pharmacological manipulations. In 
fact, use of human embryos faces ethical controversies that hinder the applications of 
human stem cells, and it is difficult to generate patient or disease-specific stem cells, which 
are required for their successful implementation. Therefore, alternative methods are 
currently being developed and such methods include the use of cells from an animal model 
of disease or induced pluripotent stem cells (iPS) derived from fibroblasts of affected 
individuals (Abeliovich and Doege 2009).  
In order to study the effect of the GAA repeat expansion on FXN expression in CNS 
tissues, we have established adult NSCs from WT, YG8 and YG22 rescue mice, and fetal NSCs 
were produced from the WT and YG8 rescue mice, as described in section 2.9. Briefly, NSCs 
were isolated from the sub-ventricular zone of the brain and dissociated mechanically 
followed by enzymatic digestion of the tissue. Both adult and fetal NSCs were maintained in 
NSC medium with rhEGF and rhFGF growth factors. After 10-14 days in culture (6-8 days for 
fetal NSCs), free floating colonies were observed, with each colony containing approximately 
200-500 cells (Figure 3.3).  
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Figure 3.3 - Primary cultures of mouse neural stem cells in culture. A) The initial free 
floating cells were formed after 5-6 days of plating with NSC medium supplemented with 
rhEGF and rhFGF growth factors, and B) after 10-14 days, NSCs were approached their 
greatest diameter, and look like large spheres with sharp bright outer borders (10X). 
 
3.2.4 - Mouse primary splenocytes 
Splenocytes are white blood cells derived from the spleen and used for their similarity 
to human lymphocytes. Splenocytes consist of a variety of cell populations, such as T and B 
lymphocytes, dendritic cells and macrophages, which have different immune functions. In 
order to compare FXN expression between the murine splenocytes and human primary 
lymphocytes, we have established the splenocytes from WT and YG8 rescue mice. Currently 
no experiments have been performed with these cells, but we have developed the system to 
compare the level of frataxin mRNA or protein for future experiments.   
 
 
 
A B 
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3.3 -  Results 
3.3.1 - Quantification of FXN mRNA in human primary fibroblasts 
In order to verify the FXN mRNA levels in human primary fibroblasts of normal and 
FRDA cells, QRT-PCR measurements were performed as described in section 2.17.  Briefly, 
RNA was extracted from about 1 million cells by the Trizol® method and converted into 
cDNA, followed by QRT-PCR.  In order to account for possible differences in gene expression 
efficiency or RNA amounts, the Ct values obtained for FXN were normalized to GAPDH 
(human) or Gapdh (mouse) genes (endogenous control). Each sample was run in triplicate 
and each experiment was performed at least twice.  The mean value of each triplet was used 
for further calculations using the 2-ΔΔCt method to obtain relative quantification (RQ) values. 
The relative levels of mRNA expression in FRDA and normal fibroblasts were then calibrated 
by calculating the means of the RQ values, setting one group arbitrarily as 100%. The 
passage numbers of all primary fibroblasts were closely matched throughout all mRNA 
quantification experiments to avoid any possible cell culture variability. 
QRT-PCR analysis of human fibroblasts clearly indicated reduced levels of FXN 
expression in all three FRDA fibroblast cell lines, GM04078, GM03816 and GM03665, with 
41% (p<0.01), 48% (p<0.01) and 27% (p<0.001), respectively compared to one of the normal 
fibroblast cell lines, H.Normal (Figure 3.4A).  Although, there are slight fluctuations in FXN 
expression within the normal fibroblasts, no significant differences were identified.  The 
mean decreased level of FXN in FRDA fibroblasts was confirmed as 40% of normal fibroblast 
levels (p<0.001) (Figure 3.4B), consistent with previously published data (Pianese et al. 
2004).  
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Figure 3.4 - Quantification of FXN mRNA in human primary fibroblasts. QRT-PCR 
measurement of FXN mRNA expression in A-B) individual fibroblast cell lines, and C) average 
expression between the normal and FRDA primary fibroblasts. FXN expression values were 
first normalized to GAPDH and then calibrated to normal fibroblasts expression. Each result 
is the mean of two independent experiments. The error bars represents the SEM (*p<0.05, 
** p<0.01, ***p<0.001). 
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The comparatively small GAA repeat expansion containing cell line, GM03816 
(330/380), shows significantly (p<0.05) increased FXN expression compared to the large GAA 
repeat expansion containing cell line (GM03665, GAA repeats 445/740). This finding 
indicates that FXN expression in FRDA fibroblasts depends on the number of GAA repeats. 
Although there are variations in the number of GAA repeats between GM03816 and 
GM04078 (541/420) cell lines, no obvious difference in FXN expression was identified, 
suggesting that significant variations in FXN levels are achievable only when there is a big 
difference in number of GAA repeats.  
 
3.3.2 - Quantification of FXN mRNA in mouse primary fibroblasts 
The FXN mRNA expression in mouse adult and embryonic fibroblasts was quantified by 
QRT-PCR using primers that equally amplified that human and mouse frataxin genes and 
Gapdh was used as an endogenous control.  The WT values were used as a calibrator to 
express the YG8 and YG22 mice FXN values relatively.  
 
FXN mRNA in adult primary fibroblasts 
All fibroblasts derived from the FRDA YAC transgenic lines of mice have shown 
increased FXN expression compared to WT mouse fibroblasts. The YG8 rescue and 
transgenic mouse cells showed 2.6- and 4.3-fold increases, whereas the YG22 rescue and 
transgenic mouse cells showed 3.2- and 3.9-fold increases in FXN expression compared to 
WT mouse fibroblasts, respectively (Figure 3.5A). The smaller levels of FXN expression in 
rescue mouse fibroblasts compared with transgenic mouse fibroblasts are likely due to the 
fact that they only contain a single functioning human FXN transgene and no functioning 
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mouse Fxn genes. It is speculated that when the human FXN gene transferred into the 
mouse genome it perhaps became over expressed. However, it has also been reported that 
YG8 and YG22 rescue mice have greatly decreased mRNA levels compared to the normal 
GAA-containing Y47 rescue mice in vivo (Figure 1.17) (Al-Mahdawi et al. 2008).  Therefore, 
even though all FXN transgenes appear to show very high levels of mRNA expression in the 
mouse, this does not necessarily translate into increased levels of functional frataxin, which 
is why YG8 and YG22 rescue mice show FRDA-like disease. 
 
 
FXN mRNA in embryonic primary fibroblasts 
The quantification of FXN expression by QRT-PCR analysis in mouse embryonic 
fibroblasts (MEFs) has revealed that the YG8 MEFs show a similar pattern of FXN expression 
as adult fibroblasts. The FXN expression levels were significantly increased in YG8 rescue 
MEFs (1.5-fold) and transgenic MEFs (2.3-fold) as compared to WT MEFs (Figure 3.5B), but 
these increases are less than with the adult fibroblasts. However, an overall increased FXN 
expression was observed in MEFs compared with adult fibroblasts (Figure 3.5c).  In 
particular, the WT MEFs showed significant (2.3-fold, p<0.01) increase in FXN expression 
compared to adult WT fibroblasts (Figure 3.5C). This may be due to differential DNA 
methylation of the frataxin and other genes in MEFs compared to adult fibroblasts.   
A comparison of FXN expression between YG8 rescue and WT fibroblasts shows that 
there is much less increase of YG8 rescue FXN expression in the MEFs (1.5-fold) compared to 
adult fibroblasts (2.6-fold). Therefore, the two different systems may both have uses in 
future drug screening experiments. Although we have not yet determined the epigenetic 
status of these two cell types, such investigations may give additional information.  
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Figure 3.5 - FXN mRNA expression levels in mouse primary fibroblasts A) Quantification of 
FXN levels as determined by QRT-PCR in WT (control), YG8 and YG22 rescue and 
transgenic mice. B) FXN expression levels in MEFs of WT, YG8 rescue and transgenic mice. 
C) Comparison of FXN expression levels between adult and embryonic fibroblasts. All 
quantifications were done in triplicates, and values were expressed relative to Gapdh. 
Error bars represent the SEM. (*p<0.05, ** p<0.01, ***p<0.001). 
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3.3.3 - Oxidative stress in mouse primary fibroblasts 
Biochemical studies of mitochondrial enzymes have revealed that FRDA is the result of 
oxidative stress and mitochondrial dysfunction. Thus, the endomyocardial biopsies from two 
unrelated FRDA patients resulted in deficient activity of Fe-S containing enzymes but the 
enzyme activities were normal in skeletal muscle, lymphocytes, and fibroblasts (Rotig et al. 
1997). Also, human fibroblasts derived from FRDA patients showed sensitivity to hydrogen 
peroxide induced oxidative stress (Figure 3.6) (Wong et al. 1999). Additionally, the FRDA YAC 
transgenic mouse model also exhibited oxidative stress (Al-Mahdawi et al. 2006).  
 
 
Figure 3.6 - Sensitivity of FRDA fibroblasts to oxidative stress. Treatment of FRDA and 
normal fibroblasts with A) hydrogen peroxide, and B) Fe3+. Significant levels at each 
individual dose are represented by asterisks: *p<0.05 and **p<0.005 (Wong et al. 1999). 
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In order to find whether the fibroblasts derived from FRDA YAC transgenic mice show 
an oxidative stress as described in vivo (Al-Mahdawi et al. 2006), we have followed the same 
method as Wong et al. (1999) used to induce the oxidative stress in human fibroblasts. To do 
this experiment, we used all five types of mouse fibroblasts as mentioned earlier and the 
mean passage numbers for the WT, YG8 and YG22 mice were 7, 8 and 6, respectively. At 
first, the fibroblasts were grown in DMEM medium for 48 hours and then cells were treated 
with hydrogen peroxide continuously for six hours at the final concentrations of 0mM to 
0.8mM. At the end of the treatment, cells were washed once with PBS and collected by 
centrifugation. Cell viability was determined by trypan-blue exclusion assay.   
 The treatment of mouse primary fibroblasts with hydrogen peroxide resulted in both 
YG8 and YG22 rescue mouse cells exhibiting hypersensitivity to oxidative stress compared to 
WT and transgenic mouse cells.  At hydrogen peroxide concentrations of 0.15mM, 0.2mM 
and 0.3mM the viability in rescue mouse cells was significantly reduced to 36%, 29% and 
18%, respectively (Figure 3.7). At 0.8mM, the highest concentration tested, all the cells died 
including the WT fibroblasts. The bias in sensitivity to oxidative stress in rescue mouse cells 
started at a hydrogen peroxide concentration of 0.15mM, where a significant difference 
(p<0.001) in response to induced oxidative stress was identified between the rescue and WT 
mouse cells. In contrast, the transgenic mouse cells showed the same pattern of sensitivity 
to hydrogen peroxide as the WT cells.  
Although the WT mouse fibroblasts have shown reduced levels of FXN expression as 
compared to YG8 and YG22 rescue mouse fibroblasts, they tolerated the hydrogen peroxide 
induced oxidative stress well, suggesting that the human YG8 and YG22 transgenic frataxin 
may not be fully functional. It is also speculated that in the transgenic mouse cells which 
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have also shown resistance to oxidative stress, the sensitivity to oxidative stress with a single 
human FXN transgene is prevented by the endogenously expressing mouse frataxin gene.  
 
Figure 3.7 - Hydrogen peroxide induced oxidative stress in mouse fibroblasts as compared 
to WT mouse fibroblasts. Treatment of mouse primary fibroblasts resulted in increased 
sensitivity in both YG8 and YG22 rescue mice. The transgenic mouse of YG8 and YG22 
show relatively less sensitivity to oxidative stress as seen in WT fibroblasts. The errors bars 
represent SEM (*p<0.05 and **p<0.01). 
 
In summary, the cell lines we have established from the FRDA YAC transgenic mice 
have displayed an FRDA-associated phenotype of oxidative stress, suggesting that such cells 
are valuable resources to help in understanding the concealed pathogenesis of this disease. 
In future, it would also be important to quantify the oxidized proteins and MDA levels 
following treatment with hydrogen peroxide to support this hypothesis. 
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3.3.4 - Quantification of FXN mRNA in neural stem cells  
In order to examine the levels of FXN expression in NSCs, we have performed the QRT-
PCR analysis using Gapdh as an endogenous control.  All values were normalized to WT Fxn 
expression and experiments were carried out in triplicate. Interestingly, initial determination 
of FXN expression in YG8 and YG22 NSCs revealed decreased mRNA levels of 49% and 71%, 
respectively compared to WT mouse cells (Figure 3.8A). Remarkably, when compared to YG8 
rescue fibroblasts, the level of FXN expression in NSCs was considerably reduced to 30% 
(p<0.001) (Figure 3.8B). Although we do not know the exact explanation of why the NSCs 
have reduced levels of FXN expression compared to fibroblasts, it could be due to several 
factors. Firstly, it may be due to the expansion of GAA repeats during the establishment of 
NSCs, as reported previously for the conversion of fibroblasts to iPS cells (Ku et al. 2010) or 
secondly it could be due to the differential epigenetic changes between NSCs and 
fibroblasts. Therefore, future experiments need to be carried out to unravel any such 
changes in NSCs. However, the NSCs, in addition to primary fibroblasts, are an excellent 
model system for future FRDA pathogenesis and therapeutic studies.  
Subsequently, the levels of FXN mRNA expression in fetal NSCs have also been 
determined by QRT-PCR and the values were expressed relative to Gapdh gene (endogenous 
control). These findings have revealed 79% reduced levels of FXN expression (not significant) 
in YG8 rescue mice compared to WT mice (Figure 3.8C). We then assessed the FXN levels 
between the adult and fetal NSCs and found that fetal NSCs showed approximately 2.4- and 
2-fold increases in FXN expression in WT and YG8 rescue mice, respectively as compared to 
adult WT NSCs (Figure 3.8D). Similar to MEFs, fetal NSCs also showed an overall increased 
FXN expression compared to adult NSCs.  
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 Overall, these results reveal an age-related, neural cell specific decline in FXN 
expression that may be relevant of FRDA pathology. Further, comparison of fetal and adult 
NSCs may reveal other useful information concerning the nature of FRDA disease 
progression. Thus, future studies of these two cell types will include comparison of GAA 
repeat instability, mitochondrial function and oxidative stress. 
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Figure 3.8 - FXN mRNA expression levels in mouse neural stem cells A) Quantification of 
FXN levels in adult NSCs, B) comparison of FXN levels between NSCs and fibroblasts of WT 
and YG8 rescue mice as determined by QRT-PCR. C) Quantification of FXN levels in fetal 
NSCs of WT and YG8 rescue mice, and D) comparison of FXN levels between adult and 
fetal NSCs. All quantifications were done in triplicates, and values were expressed relative 
to Gapdh. Error bars represent the SEM. (*p<0.05, ** p<0.01, ***p<0.001). 
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3.3.5 - Differentiation and immunofluorescence assay of NSCs 
In order to determine whether the NSCs are capable of differentiating into neural 
cells, such as neurons, oligodendrocytes and astrocytes, we have induced differentiation as 
described earlier (section 2.9.5) (Figure 3.9). The differentiation was carried out in two ways, 
using either intact neurospheres or dissociated neurospheres as a starting cells. After 
differentiation, the resultant cells were subjected to immunofluorescence assays with cell 
specific antibodies: beta III-tubulin, Gal-C and GFAP primary antibodies for neurons, 
oligodendrocytes and astrocytes, respectively (Figure 3.10). For negative controls, a set of 
culture slides was incubated under similar conditions without the primary antibodies (Figure 
A.1 - see appendix). 
 
  
Figure 3.9 - Differentiation of mouse neural stem cells. The differentiation of NSCs was 
induced by incubating the cells in the NSC medium with differentiation supplements (Stem 
Cell Technologies).  The early stages of the differentiation (A and B), where mixed neuronal 
cells are seen emerging from the neurospheres. Image magnifications are 10X and 40X for A 
and B, respectively. 
 
A B 
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Figure 3.10 - Characterization of NSCs by immunofluorescence assay. NSCs were collected 
by centrifugation and dissociated by gently pipetting up and down several times until 
single cell suspension has been achieved followed by incubation with NSC dissociation 
medium for 48 hours on poly-D-lysine coated coverslips. After 48 hours in culture NSCs 
were positively stained with β III-tubulin (neuron), GFAP (astrocytes), and Gal-C 
(oligodendrocytes) and negatively stained with CD11b (microglia). The micrographs were 
taken at the magnification of 10X.  
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The immunofluorescence assays have clearly indicated the presence of neurons, 
oligodendrocytes and astrocytes in the differentiated NSCs. However, the labelling of 
differentiated NSCs with CD11b, a specific marker for microglia, was found to be absent in 
the differentiated NSCs, indicating that there are no microglia cells in NSCs (Figure 3.10), 
consistent with the previous results (Levison et al. 2003). These findings show that the 
neurospheres were able to differentiate into different neural and glial cell types and perhaps 
such cells can be isolated to serve as an essential source in understanding the pathogenesis 
of FRDA more precisely.  
Recently, the existence of a fifth cell type in the CNS, called ‘synantocyte’, has been 
reported (Butt et al. 2005). Therefore, for future immunofluorescence assays, a synantocyte 
specific marker should be used to investigate the possible presence of this cell type 
differentiating from our NSCs.   
Finally, in order to understand the molecular mechanism underlying FRDA 
pathogenesis, we are investigating ways to differentiate the NSCs to obtain pure cultures of 
differentiated neural cells. This will hopefully allow us to quantify FXN mRNA and protein 
from individual differentiated cell types rather than from an intact neurosphere. 
Most importantly, thus far our investigations have mainly focused on determining the 
levels of FXN expression. However, for future experiments it is of primary importance to 
quantify frataxin protein levels from these cells, since such results may provide additional 
information. Furthermore, evaluating all of these results in comparison with Y47 mouse cells 
rather than WT cells, when they are available, should be of paramount importance. 
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4.1 -  Therapeutic testing of DNA demethylating agents 
4.1.1 -  Introduction 
Recognition of the role of epigenetics in human disease started with oncology, but it 
has now extended to other disciplines, such as neurodevelopment and neurodegenerative 
disorders like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and FRDA. 
Epigenetic mechanisms, which involve DNA and histone modifications, result in the heritable 
silencing of genes without a change in their coding sequence. Chromatin had been viewed in 
the past as a static entity, which packaged DNA in a condensed form and maintained its 
integrity. A much more expanded view of epigenetics has recently emerged in which 
multiple mechanisms interact to collectively establish alternate states of chromatin 
structure, histone modification, associated protein composition, transcriptional activity, and 
in mammals, cytosine-5 DNA methylation at CpG dinucleotides (Ordway and Curran 2002; 
Felsenfeld and Groudine 2003; Freiman and Tjian 2003; Jaenisch and Bird 2003).  Histone 
modifications regulate chromatin function either by altering the accessibility of DNA to 
different trans-acting factors, or by recruiting specific proteins that recognize a single or 
conformational set of modifications (Strahl and Allis 2000).  
The methylation of DNA is a process shared by both eukaryotic and prokaryotic cells 
(Noyer-Weidner and Trautner 1993) and it serves as an epigenetic method of modulating 
gene expression. Methylation plays a role in genomic stability and carcinogenesis, and it 
offers a target for the treatment of malignancy (Colot and Rossignol 1999; Baylin and 
Herman 2000). The process of methylation is carried out by DNA methyltransferases 
(DNMT). These enzymes catalyze the covalent addition of a methyl group from a donor S-
adenosylmethionine (SAM) to the 5 position of cytosine, predominantly within the CpG 
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dinucleotide (Momparler et al. 2000; Robertson 2001).  Many lines of evidence demonstrate 
that the pattern of methylation can be stably inherited, through the action of a maintenance 
DNA methyltransferase (Holliday 1991; Holliday and Grigg 1993). Genetic analyses of the 
various DNMTs have established that DNA methylation is essential for vertebrate 
development. Loss of methylation causes apoptosis in embryos (Panning and Jaenisch 1996; 
Stancheva et al. 2001) and fibroblasts (Jackson-Grusby et al. 2001), but not in embryonic 
stem cells (Li et al. 1992; Lei et al. 1996; Albani et al. 2009) or in human cancer cells (Rhee et 
al. 2002). 
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4.1.2 -  DNA methyltransferases (DNMTs) 
The DNA methyltransferases (DNMTs) are enzymes which regulate DNA methylation 
and catalyse the transference of a methyl group from S-adenosyl-L-methionine (SAM) to a 
cytosine. In mammals, the DNMT family includes three functional proteins: DNMT1, 
DNMT3a and DNMT3b (Bestor 2000), the most abundant is the DNMT1 (Robertson 2001). 
DNMT1 preferentially methylates hemi-methylated DNA and is thus responsible for 
methylation during DNA replication (Pradhan et al. 1999). It plays a key role in imprinting 
and X-chromosome inactivation during embryogenesis (Beard et al. 1995). Other known 
functional methyltransferases are DNMT3a and DNMT3b, which are responsible for de novo 
methylation during embryogenesis (Okano et al. 1999). DNMT3a and DNMT3b have equal 
preference for hemi-methylated and non-methylated DNA, and so have been classified as de 
novo methyltransferases (Okano et al. 1998a). 
Non-functional homologs of the methyltransferases have also been identified, such as 
TRDMT1 and DNMT3L. TRDMT1 (formally known as DNMT2) does not appear to have 
significant methyltransferase activity (Okano et al. 1998b; Yoder and Bestor 1998), but it was 
shown to methylate position 38 in aspartic acid tRNA and does not methylate DNA (Goll et 
al. 2006). Therefore, to reflect the different function of this enzyme, the name for this 
methyltransferase has been changed to TRDMT1 (tRNA aspartic acid methyltransferase 1) 
(TRDMT1 2006). TRDMT1 is the first RNA cytosine methyltransferase to be identified in a 
human. Similarly, DNMT3L has a mutated active site and is likely to be non-functional 
(Aapola et al. 2000). It has been speculated that it may antagonize functional 
methyltransferase activity (Robertson 2001).  
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4.1.3 -  DNA methylation and transcriptional repression 
Transcriptional repression is an essential mechanism in the precise control of gene 
expression. DNA methylation could control gene activity either at a local level through 
effects at a single promoter and enhancer, or through global mechanisms that influence 
many genes within an entire chromosome or genome (Kass et al. 1997). The most direct 
mechanism by which DNA methylation can interfere with transcription is to prevent the 
binding of basal transcriptional machinery or ubiquitous transcriptional factors that require 
contact with cytosine in the major groove of the double helix (Maldonado et al. 1999). 
Transcriptionally active chromatin is predominantly unmethylated and has high levels of 
acetylated histone tails.  
Transcriptional repression takes place firstly by the deacetylation of histone tails 
followed by the methylation of CpG dinucleotides by one of the three human DNA 
methyltransferases (DNMT1, DNMT3a, and DNMT3b), resulting in DNA with high levels of 
CpG methylation (Razin 1998). CpG methylation induces chromatin remodelling and gene 
silencing through a transcription repressor complex that includes mSin3a and NURD complex 
with two HDAC enzymes, HDAC1 and HDAC2 (Zlatanova et al. 2000). The deacetylase 
activity, which accompanies the mSin3a complex renders the promoter of the gene 
inaccessible to transcription factors by deacetylating histone H3 and H4 (Razin 1998). DNA 
methylation-directed gene silencing can be alleviated by either inhibiting DNMT activity by 
DNA demethylating agents or by a specific inhibition of HDAC1 and/or HDAC2 activity by 
HDAC inhibitors. 
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4.1.4 -  DNA demethylating agents 
DNA demethylating agents are a class of substances that can inhibit methylation, 
resulting in expression of previously hypermethylated silenced genes. DNA demethylating 
agents are widely used in cancer therapy. Genes are silenced by a poorly understood process 
generally known as de novo DNA methylation. In many instances CpG islands that were 
originally unmethylated, with an associated active gene, become heavily methylated and 
inactivated, or silenced. Inhibitors of DNA methylation rapidly reactivate the expression of 
genes that have undergone epigenetic silencing, particularly if this silencing has occurred in a 
pathological situation. The prototype inhibitors, 5-azacytidine (5-aza-CR) and 5-aza-2’-
deoxycytidine (5-aza-CdR), were initially developed as cytotoxic agents (Sorm et al. 1964), 
but it was subsequently discovered that they are powerful inhibitors of DNA methylation 
and induce gene expression and differentiation in cultured cells (Constantinides et al. 1977; 
Jones and Taylor 1980). 
5-aza-CR and 5-aza-CdR are structurally related, but distinct, cytidine nucleoside 
analogs used clinically for the treatment of myelodysplastic syndromes (MDS) and acute 
myeloid leukemia (AML) (Saba 2007; Cataldo et al. 2009). Following cellular uptake and 
sequential phosphorylation, 5-aza-CR is incorporated into both RNA and DNA (Li et al. 1970; 
Glover and Leyland-Jones 1987; Stresemann et al. 2008), whereas 5-aza-CdR is incorporated 
solely into DNA (Stresemann et al. 2006)). Once incorporated, both compounds have related 
mechanisms of action, including depletion of DNMTs (Ghoshal et al. 2005; Stresemann et al. 
2006), hypomethylation of DNA (Stresemann et al. 2006; Flotho et al. 2009), and induction 
of DNA damage (Kiziltepe et al. 2007; Palii et al. 2008).  
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In addition, other potential compounds have been developed that are able to reduce 
the level of DNA methylation, such as zebularine (Zhou et al. 2002), hydralazine (Rubin 2005; 
Sarzi-Puttini et al. 2005), procaine (Rubin 2005; Sarzi-Puttini et al. 2005), and an anti-sense 
oligonucleotide MG98 (Goffin and Eisenhauer 2002). However, the role of these compounds 
needs to be assessed where hypermethylation-induced gene silencing play a crucial role in 
disease pathology, like FRDA. 
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4.1.5 -  DNA methylation and therapeutic testing in FRDA 
Exactly how FXN transcriptional silencing is achieved in FRDA is not well understood, 
however recent evidence indicates that an epigenetic abnormality is an important 
underlying mechanism (Greene et al. 2007; Al-Mahdawi et al. 2008). In principle, changes in 
chromatin modifications in non-coding sequence could affect transcription by affecting RNA 
polymerase II elongation or by changing the accessibility of this region to regulatory factors 
important for transcription initiation (Lorincz et al. 2004). It has been reported that the first 
intron of many genes contains regulatory sequences which are important for gene 
expression (De Jaco et al. 2005; Lee et al. 2005; LeBlanc et al. 2006; Zhao et al. 2006). 
Therefore, in FRDA, the sequences adjacent to the FXN GAA repeat within intron 1 are likely 
to be affected by chromatin changes. 
Greene et al. (2007) examined the DNA methylation status in intron 1 of the FXN gene 
in lymphoblast cells from unaffected individuals and individuals with FRDA. They reported 
that the region immediately upstream of GAA repeats showed increased DNA methylation in 
FRDA lymphoblast cells compared with cells derived from unaffected individuals. However, 
cultured cells are known to often develop non-physiological DNA methylation profiles. 
Furthermore, FRDA is a systemic disorder that is known to have differentially affected tissues 
and cell types. Therefore, Al-Mahdawi et al. (2008)  investigated the DNA methylation status 
in brain and heart, two of the primary affected tissues in FRDA. Bisulfite sequence analysis of 
the FXN flanking GAA regions in these tissues revealed a shift in the FRDA DNA methylation 
profile, where upstream CpG sites were consistently hypermethylated and downstream CpG 
sites were hypomethylated (Figure 4.1) (Al-Mahdawi et al. 2008).  
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Figure 4.1 - DNA methylation analysis of the FXN promoter (A and B), upstream GAA (C 
and D) and downstream GAA (E and F) regions of human brain and heart tissues. In each 
case for the FXN promoter and upstream GAA regions the mean percentage (+/- SEM) of 
methylated CpG sites is shown as determined from the analysis of two FRDA patients and 
two unaffected individuals, with 7–12 independent cloned DNA sequences analysed for 
each (Al-Mahdawi et al. 2008). 
 
 
   
                                                                                                 Chapter 4 - Therapeutic approaches in vitro 
   
      132 
Recently, De Biase et al. (2009) have reported that FRDA patients have high levels of 
FAST1 (frataxin antisense transcript 1) and heterochromatin protein 1 (HP1). In addition, 
they have also identified elevated levels of H3K9me3 and H3K27me3 at the +1 nucleosome 
region of FXN in primary fibroblasts from individuals with FRDA compared with normal 
individuals.  
Nevertheless, so far there are no reports of using DNA demethylating agents as a 
therapeutic approach for FRDA to decrease the levels of DNA methylation and thereby 
increase FXN transcription. Therefore, we have investigated the efficacy of DNA 
demethylating agents 5-aza-CdR, zebularine and hydralazine on FRDA mouse and human 
primary fibroblasts. Following treatment with various DNA demethylating compounds, we 
have investigated FXN mRNA levels by QRT-PCR, and changes in DNA methylation by a 
methylscreen assay. 
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4.1.5.1 - Therapeutic testing of 5-aza-2’-deoxycytidine (5-aza-CdR) 
The fact that many human diseases, including cancer, have an epigenetic aetiology has 
encouraged the development of a new therapeutic option that might be termed ‘epigenetic 
therapy.’ Many agents have been discovered that alter methylation patterns on DNA or the 
modification of histones, and several of these agents are currently being tested in clinical 
trials. 5-aza-2’-deoxycytidine (5-aza-CdR, or decitabine) has been tested in several Phase I, II 
and III clinical trials finding the most promising benefits in leukaemia patients (Jain et al. 
2009), especially those affected by myelodysplastic syndrome (MDS) (Issa et al. 2004; Saba 
and Wijermans 2005; Mund et al. 2006; Saba 2007). For this reason 5-aza-CdR has been 
approved for the treatment of MDS showing excellent capability to reactivate the expression 
of several methylated genes.  
As mentioned earlier, 5-aza-CdR only incorporates into DNA (Stresemann et al. 2006) 
in the place of cytosine into replicating DNA (Figure 4.2) (Egger et al. 2004). Therefore, it is 
active only in S-phase cells (Constantinides et al. 1977), where it serves as a powerful 
mechanism-based inhibitor of DNA methylation (Jones and Taylor 1980). DNMTs get trapped 
on DNA containing modified bases, resulting in the formation of heritably demethylated DNA 
(Jones and Taylor 1980; Zhou et al. 2002). Treatment of lymphoblastoid cells from FXS-
patients with 5-aza-CdR alone (Chiurazzi et al. 1998) or in combination with HDAC inhibitors 
(Chiurazzi et al. 1999) efficiently reverse the  FMR1 promoter hypermethylation and restores 
mRNA and protein levels to baseline.  
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Figure 4.2 - Mechanism of action of nucleoside analogue inhibitors. Deoxynucleoside 
analogue, 5-aza-2’-deoxycytidine (depicted by Z) is converted into the triphosphate inside 
S-phase cells and are incorporated in place of cytosine into DNA (Egger et al. 2004). 
 
 
In order to test the efficacy of the 5-aza-CdR in FRDA, we treated the mouse and 
human primary fibroblasts with 0.2µM and 1µM concentrations of 5-aza-CdR for 4 and 24 
hours along with a mock treatment. After the treatment, FXN mRNA expression was 
quantified by QRT-PCR, and the level of DNA methylation for drug-treated and untreated 
samples was detected by a methylscreen assay. It is important to note that the methylscreen 
results presented in this thesis were centred on CpG site 4 in the upstream region of the 
GAA repeats where we find differential methylation between normal and FRDA patients’ 
brain and heart tissues (Al-Mahdawi et al. 2008).  In addition, in all our methylscreen results 
WT mice samples were excluded due to the absence of the human-specific CpG site 4 in such 
mice.  
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Interestingly, FXN mRNA levels increased with 5-aza-CdR compared to mock-treated 
sample. In particular, significantly increased levels were observed with 0.2µM of 5-aza-CdR 
after 24 hours (1.6-fold, p<0.001) (Figure 4.3A). These elevated levels were not observed 
with 1µM of drug at any time point (4 and 24h), suggesting that low concentrations of 5-aza-
CdR are beneficial. Additionally, in order to find whether the endogenous control (Gapdh) 
that we are using is stable throughout the drug treatment we also quantified the Gapdh 
mRNA levels and found no difference (Figure A.2). 
 The methylscreen analysis revealed reduced DNA methylation levels in samples 
treated with 5-aza-CdR compared to vehicle-treated cells. Particularly, 0.2µM of 5-aza-CdR 
after 4 and 24 hours produced reduced levels of DNA methylation to 88% and 86%, 
respectively (Figure 4.3B). A 1µM (after 24 hours) concentration of 5-aza-CdR produced no 
significant effect compared to vehicle. At this concentration, trypan blue exclusion assay 
showed that the cell viability was reduced to 67% and 63% in WT and YG8 rescue mice, 
respectively, indicating that high concentration of this drug is toxic to the cells (Figure 4.4A). 
Interestingly, no differences in FXN expression were identified between vehicle and drug-
treated WT cells, suggesting somewhat a specific effect of 5-aza-CdR. 
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Figure 4.3 - The effect of 5-aza-CdR on mouse primary fibroblasts. A) Relative FXN mRNA 
expression, and B) change in methylation as determined by QRT-PCR and methylscreen 
assay, respectively following treatment with 5-aza-CdR. Each result displayed is the mean 
of two independent experiments. FXN mRNA expression was normalized to Gapdh. The 
values were expressed as a ratio to the corresponding untreated (vehicle) sample (* 
p<0.05, ** p<0.01, error bars ± 1 SEM). 
 
  
Figure 4.4 - Quantification of cell viability following treatment with 5-aza-CdR. The cell 
viability as determined by the trypan blue exclusion assay in A) mouse, and B) human 
primary fibroblasts (error bars ± 1 SEM). 
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Regarding human fibroblasts, obviously no apparent drug-induced effect in the level of 
FXN mRNA expression has been observed; rather reduced FXN expression was found in all 
samples treated with 5-aza-CdR. Particularly, statistically significantly reduced levels of FXN 
(50%) have been identified in cells treated with 1µM of 5-aza-CdR after 24 hours (Figure 4.5). 
The methylscreen assay clearly indicated reduced levels of DNA methylation in all samples 
treated with 5-aza-CdR in FRDA fibroblasts. Interestingly, the level of DNA methylation was 
reduced from 63% to 4.2% with 1µM of 5-aza-CdR after 24 hours and the unmethylated DNA 
levels rose from 2.1% to 72.4% in the FRDA fibroblasts (Figure 4.6B).  
In the normal fibroblasts, a detrimental effect with 5-aza-CdR was observed, as 
increased levels of DNA methylation (at 0.2µM 4h) and reduced levels of unmethylated DNA 
were displayed at 0.2µM after 24 hours and 1µM after 4 hours time point (Figure 4.6A). In 
fact, no increases in FXN expression were found even when the DNA methylation was 
reduced to normal or below normal with 5-aza-CdR. Similar to murine fibroblasts, cell 
viability was also reduced with increasing concentrations of the drug. At 24 hours treatment 
with 1µM of 5-aza-CdR, an average, the cell viability was decreased to 61% and 58% in 
human normal and FRDA fibroblasts, respectively (Figure 4.4B).  
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Figure 4.5 - Quantification of relative FXN mRNA expression in human normal and FRDA 
fibroblasts following treatment with 5-aza-CdR (*p<0.05, error bars ± 1 SEM). 
 
  
 
Figure 4.6 - The effect of 5-aza-CdR on DNA methylation. The analysis of changes in 
methylation as determined by methylscreen assay following treatment with increased 
concentrations of 5-aza-CdR (0-1µM) in A) normal, and B) FRDA primary fibroblasts (error 
bars ± 1 SEM). 
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4.1.5.2 - Therapeutic testing of zebularine 
In the case of 5-aza-CdR, toxicity and instability under physiological conditions may 
complicate their use in the clinical trial. Therefore, we have considered using zebularine as 
another therapeutic approach to reduce DNA methylation in FRDA. Zebularine, a cytidine 
deaminase inhibitor, contains a 2-(1H)-pyrimidine ring, and has been recently demonstrated 
as an effective hypomethylating agent (Cheng et al. 2003).   Unlike 5-aza-CdR, zebularine has 
the advantage of being stable in aqueous solutions and has half life of approximately 44 
hours at 37°C in PBS at pH 1.0 and approximately 508 hours at pH 7.0 (Kelley et al. 1986). 
Furthermore, oral administration of zebularine has been shown to cause DNA demethylation 
and reactivation of a silenced and hypermethylated p16 gene in human bladder tumour cells 
grown in nude mice (Cheng et al. 2004), suggesting that oral administration of the drug is 
possible.  
In addition, it has been reported that zebularine was minimally toxic by both in vitro 
and in vivo studies (Cheng et al. 2003), indicating a safe administration of the drug. 
Particularly, recent evidence has shown that continuous administration of low doses of DNA 
demethylating agents are more efficient at reducing DNA methylation (Cheng et al. 2004), 
and this is possible with zebularine because of its low toxicity.  Additionally, a combined 
study using 5-aza-cdR and zebularine has shown inhibition of DNA methylation and effective 
reactivation of silenced genes (Cheng et al. 2004). Therefore, in order to determine the 
efficacy of zebularine in FRDA, we have treated the human and mouse primary fibroblasts 
with 10µM and 100µM of zebularine for 24 and 48 hours, followed by FXN mRNA 
quantification, methylscreen analysis and cell viability assays.  
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Treatment of mouse fibroblasts with increased concentrations of zebularine (0-
100µM) has revealed a significant increase in FXN expression in all samples treated with 
zebularine as compared to vehicle-treated cells. At a 10µM concentration, 24 and 48 hours 
after treatment FXN levels were increased to 1.3- and 1.4-fold compared to vehicle-treated 
cells, respectively (Figure 4.7A). Although a slight increase in FXN expression was seen in 
cells treated with 100µM of zebularine at both time points tested, no statistically significant 
difference was observed. The methylscreen analysis revealed that the DNA methylation 
levels were reduced from 92% to 54% with 100µM drug after 24 hours treatment (Figure 
4.7B). Although slight fluctuations in DNA methylation were observed with 10µM of 
zebularine, no significant changes were detected. Also, no significant difference in DNA 
methylation was found at 48 hours treatment with 100µM of zebularine compared to 
vehicle-treated cells. 
 
 
Figure 4.7 - The effect of zebularine on mouse primary fibroblasts following treatment 
with zebularine. A) Relative FXN mRNA expression, and B) change in methylation as 
determined by QRT-PCR and methylscreen assay, respectively. The FXN mRNA expression 
was normalized to Gapdh. The values were expressed as a ratio to the corresponding 
untreated sample (* p<0.05, error bars ± 1 SEM). 
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In order to assess whether zebularine is capable of upregulating FXN mRNA expression 
in human fibroblasts, QRT-PCR was performed with GAPDH as an internal control. 
Quantification of the FXN mRNA levels derived from the treated cell lines revealed reduced 
levels of FXN expression in FRDA fibroblasts. FXN mRNA was significantly downregulated in 
cells treated with 10µM zebularine for 24 hours and 100µM zebularine for 48 hours (Figure 
4.8). In contrast, the normal fibroblasts showed an overall upregulation in FXN mRNA 
expression compared to vehicle-treated cells.  
 Regarding changes in DNA methylation as determined by methylscreen assay, the 
FRDA fibroblasts showed a reduction in DNA methylation to 42% and a 10-fold increase in 
the level of unmethylated DNA with 100µM of zebularine treatment for 48 hours as 
compared to vehicle-treated cells (Figure 4.9B). No changes were observed with other 
concentrations of the drug at any time points tested. In contrast, the level of DNA 
methylation increased in normal fibroblasts treated with 10µM of zebularine for 24 hours 
and 48 hours (Figure 4.9A). Similar to our previous findings with 5-aza-CdR, no correlation 
has been found between the level of DNA methylation and FXN expression at any 
concentration of drug and time point tested, suggesting that DNA methylation may be a 
secondary consequence in FRDA. 
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Figure 4.8 - Quantification of relative FXN mRNA expression in human normal and FRDA 
fibroblasts following treatment with zebularine (*p<0.05, error bars ± 1 SEM). 
 
  
 
Figure 4.9 - The effect of zebularine on DNA methylation. The analysis of changes in 
methylation as determined by methylscreen assay following treatment with increased 
concentrations of zebularine (0-100µM) in A) normal, and B) FRDA primary fibroblasts 
(error bars ± 1 SEM). 
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4.1.5.3 - Therapeutic testing of hydralazine 
Having obtained mixed results with the first two DNA demethylating agents, 5-aza-CdR 
and zebularine, we then tested the efficacy of hydralazine as a possible therapy for FRDA. 
Hydralazine (also known as apresoline) is a direct-acting smooth muscle relaxant used to 
treat hypertension by acting as a vasodilator (Herting and Hunter 1967; Klein et al. 2003). 
However, recently hydralazine has shown to inhibit the DNA methylation in various cancer 
cells, thereby reactivating the silenced genes (Segura-Pacheco et al. 2003; Zambrano et al. 
2005; Segura-Pacheco et al. 2006). Phase I and II clinical trials with hydralazine in cervical 
cancers have evaluated its tolerability and efficacy upon administration (Zambrano et al. 
2005; Candelaria et al. 2007). Despite many years of research, the mechanism of action of 
hydralazine has remained controversial, with uncertainty as to whether hydralazine directly 
inhibits DNMT enzymatic activity or not. However, recent findings have revealed reduced 
RNA methyltransferase 1 and 3a expression levels following treatment with hydralazine 
(Deng et al. 2003; Arce et al. 2006), suggesting that hydralazine does not directly inhibit DNA 
methyltransferase activities.  
In this current study, we have evaluated the effect of hydralazine on reactivation of 
the FXN gene in vitro. To do this end, we have treated the human and mouse primary 
fibroblasts with 5µM and 10µM of hydralazine over a period of 48 and 72 hours, together 
with a mock treatment. After the treatment, cells were washed once with PBS and collected 
by centrifugation followed by QRT-PCR analysis. Cell viability was assessed by trypan blue 
assay. The passage numbers for all cell lines used in this study were ranged between 7 and 
11.  
 
   
                                                                                                 Chapter 4 - Therapeutic approaches in vitro 
   
      144 
The relative quantification of FXN by QRT-PCR following treatment with hydralazine in 
mouse fibroblasts revealed an overall increase in FXN expression in all samples treated with 
hydralazine as compared to mock-treated cells. Strikingly, significant upregulation of FXN has 
been observed in cells treated with 5µM of hydralazine for 48 hours (Figure 4.10A). 
Interestingly, hydralazine does not seem to have a positive effect on WT cells, as slightly 
reduced FXN mRNA expression levels were found in all drug-treated samples compared to 
vehicle-treated cells. Regarding methylscreen analysis, significant reduction in DNA 
methylation was identified in all samples treated with hydralazine. Particularly, cells treated 
with 5µM of hydralazine for 72 hours have displayed lowest level of methylation where it 
dropped from 87% to 22% (p<0.001) (Figure 4.10B). 
 
  
Figure 4.10 - Relative FXN mRNA and methylation changes following treatment with 
hydralazine in mouse primary fibroblasts. A) FXN mRNA expression in WT and YG8 mice, 
and B) level of methylation in YG8 mice as determined by QRT-PCR and methylscreen 
assay following treatment with hydralazine, respectively. Each result displayed is the mean 
of two independent experiments and mRNA expression was normalized to Gapdh. The 
values were expressed as a ratio to the corresponding untreated sample (* p<0.05, error 
bars ± 1 SEM). 
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Regarding the effect of hydralazine on FXN mRNA in human fibroblasts, after 
treatment the level of FXN mRNA was quantified and expressed relative to an internal 
control (GAPDH). After 48 hours there were decreases in FXN expression as seen previously 
with 5-aza-CdR and zebularine. However, by extending the time duration to 72 hours we 
detected increased FXN expression. Although there were slight fluctuations within each cell 
type, significantly elevated levels (1.6-fold, p<0.05) of FXN were observed in FRDA cells 
treated with 10µM of hydralazine for 72 hours (Figure 4.11). It is possible that a shorter 
duration of drug may be causing a negative effect on FXN expression, as at 5µM hydralazine, 
FXN levels dropped to 67% at 48 hours, whereas at 72 hours it was increased by 
approximately 127% compared to vehicle-treated sample. The same effect was also found 
with 10µM of hydralazine, where downregulation of FXN was identified at 48 hours (58%), 
whereas upregulation of FXN (159%) was displayed at 72 hours. In the normal fibroblasts, 
overall reduced levels of FXN (except at 5µM 48h) were produced, suggesting that there is a 
specific effect of hydralazine towards FRDA cells.  
Regarding changes in DNA methylation, the methylscreen assay has revealed that 
normal fibroblasts have displayed increased DNA methylation in all cells treated with 
hydralazine compared to vehicle-treated cells (Figure 4.12A).  In contrast, reduced 
methylation was displayed in FRDA fibroblasts treated with 5µM of hydralazine for 72 hours 
(dropping from 61% to 12%), but there was no change in DNA methylation with any other 
concentrations and time points tested (Figure 4.12B).  
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Figure 4.11 - Quantification of relative FXN mRNA expression in human normal and FRDA 
fibroblasts following treatment with hydralazine (*p<0.05, error bars ± 1 SE). 
 
  
 
Figure 4.12 - The effect of hydralazine on DNA methylation. The analysis of changes in 
methylation as determined by methylscreen assay following treatment with increased 
concentrations of hydralazine (0-10µM) in A) normal, and B) FRDA primary fibroblasts. 
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4.1.6 -  Discussion 
Aberrant DNA methylation is recognized as a crucial component of the epigenetic 
mechanism underlying silencing of various genes. Despite many years of research, the 
precise mechanism of FXN gene silencing underlying FRDA is not yet understood, but it is 
currently generally accepted that FRDA may be caused by a heterochromatin-mediated 
silencing effect of the FXN gene (Festenstein 2006). This phenomenon is characterized by a 
differential DNA methylation profile accompanied by decreased histone acetylation and 
increased H3K9 trimethylation flanking the GAA repeat (Herman et al. 2006; Greene et al. 
2007; Al-Mahdawi et al. 2008). The rapidly developing field of epigenetics has provided new 
hints as to what mechanisms might contribute to FXN gene silencing.  
The mouse primary fibroblasts were derived from the FRDA YAC transgenic mouse (Al-
Mahdawi et al. 2006), which exhibits epigenetic modifications similar to those observed in 
FRDA patients (Al-Mahdawi et al. 2008), suggesting that such mouse cells would be ideal for 
the in vitro investigation of epigenetic based therapeutic approaches for FRDA. Initial 
characterization of all cell lines which we used for these drug therapies were very well 
studied as mentioned before (Chapter 3).  
The recently reported DNA demethylating agents, such as 5-aza-CdR, zebularine and 
hydralazine, alone or in combination with other compounds, have displayed encouraging 
results in cancer (Deng and Zhang 2009; Flotho et al. 2009; Wang et al. 2009) and in 
neurodegenerative disorders (Chiurazzi et al. 1999). Therefore, we have investigated such 
compounds in order to find their efficacy and tolerability as a possible therapy for FRDA.  
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The treatment of mouse cell lines with 5-aza-CdR has produced upregulation of FXN 
expression (at 0.2µM) in the YG8 rescue fibroblasts without any significant changes in the 
WT mice, suggesting a specific effect of this compound. The percentage of DNA methylation 
in YG8 rescue mice as studied by methylscreen assay revealed reduced levels of DNA 
methylation in a time dependent manner, especially with a low concentration of 0.2µM of 5-
aza-CdR. Interestingly, we have found an inverse relationship between the level of 
methylation and FXN expression, where decreased DNA methylation levels were associated 
with increased FXN expression. This finding suggested that DNA demethylating agents are 
potential candidates for FRDA therapy.  
Therefore, we further investigated the same compound in FRDA patient primary 
fibroblasts and found discrepant results between FXN expression levels and changes in DNA 
methylation. In contrast to the results found with mouse cell lines, reduced DNA methylation 
levels with 5-aza-CdR in the human FRDA fibroblasts did not seem to have promoted the FXN 
mRNA levels, rather FXN levels dropped. Although there is no obvious explanation for this 
effect, it could be due to many factors and one of the possibilities is that 5-aza-CdR may 
influence other genes which in turn perhaps negatively regulate the FXN expression. Recent 
microarray analysis on human fibroblasts following treatment with 5-aza-CdR has revealed 
22 upregulated and 72 downregulated genes (Vallender and Lahn 2006). In view of this, we 
have quantified the endogenous control (Gapdh) mRNA levels of samples which shown 
highest FXN increase and found no difference in expression levels. Nevertheless, the 
observed DNA methylation at site 4 of GAA upstream region may be important for the 
correct transcription of FXN. Consequently, big changes in DNA methylation following 
treatment with 5-aza-CdR (like in the human FRDA cells) might negatively regulate the FXN 
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expression, as small changes in YG8 mice cells did not show such drastic effects on FXN 
expression. Furthermore, so far we have investigated the DNA methylation changes only 
centred around one out of three differentially methylated CpG sites in the upstream GAA 
repeat region of intron 1 (Al-Mahdawi et al. 2008). Therefore, in order to asses such 
compounds more precisely, future studies should be conducted taking more sites into the 
consideration from either side of the GAA repeats, such as downstream and upstream 
regions, along with the 5’-UTR region of the FXN gene.  
Although we have found encouraging results with 5-aza-CdR, especially with mouse 
cell lines, in view of a prospective FRDA therapy in humans it has also been of paramount 
importance to select a stable and less toxic compounds. Therefore, we have subsequently 
investigated the ability of zebularine to inhibit the DNA methylation in the same way as 5-
aza-CdR. The preliminary investigations and current knowledge on this compound has 
revealed zebularine is less toxic and more stable compound than 5-aza-CdR (Kelley et al. 
1986). The treatment of varying concentrations of zebularine (0-100µM) in mouse cells 
significantly increased FXN expression, especially with low concentrations of zebularine 
(10µM) at both time-points tested. Interestingly, at these time-points no obvious changes in 
DNA methylation were identified. Although DNA methylation was reduced to 40% using 
100µM of zebularine after 48 hours treatment, the FXN expression did not seem to be 
upregulated, which is in consistent with our previous findings with 5-aza-CdR. Subsequently, 
the effect of zebularine was investigated in human cells. Like 5-aza-CdR treatment, FXN 
expression was also reduced in FRDA fibroblasts treated with zebularine. It is important to 
note that, although the level of DNA methylation was reduced using 100µM of zebularine 
after 48 hours treatment, no apparent increase in FXN was reported. Indeed, it was 
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significantly reduced compared to vehicle-treated controls. Furthermore, surplus levels of 
DNA methylation (66%) induced by 10µM of zebularine at 24 hours treatment  in normal 
fibroblasts did not seem to have any effect on FXN expression, indicating that FXN 
expression is primarily dependent on GAA repeat expansions not on DNA methylation. These 
findings support the hypothesis that DNA methylation and FXN expression are two 
independent mechanisms and perhaps DNA methylation is a secondary consequence of the 
disease.  
Regarding hydralazine, we found interesting results in both mouse and human cell 
lines. In YG8 rescue mice cells FXN expression was significantly increased when the level of 
DNA methylation reduced (5µM at 48h). However, when the DNA methylation was reduced 
further, a slight drop in FXN was reported. In WT cells the FXN expression was reduced with 
hydralazine, indicating a specific effect of this compound. In human cell lines, hydralazine 
seems to have a positive effect, as FXN levels were elevated with hydralazine in a time-
dependent manner.  In FRDA fibroblasts, a significant 1.6-fold increase in FXN expression 
was achieved after 72 hours of treatment, although this result did not correspond with any 
DNA methylation change. Therefore, it would be interesting to also examine the effect of 5-
aza-CdR and zebularine by conducting future experiments for more than 48 hours.  
In summary, mixed results were seen in mouse and human FXN expression profiles 
following treatment with three DNA demethylating agents. Overall, increased FXN 
expression was seen in mouse cells (YG8) and decreased FXN levels were found in human 
cells (FRDA). This is possibly due to the tight regulation of FXN to ensure low levels of FXN 
transcription in human cells, as over expression of FXN has been suggested to be toxic 
(Fleming et al. 2005). It is possible that perhaps such mechanisms may not be available or 
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not strongly regulated in mouse cells, whereby slight activation of this transcription 
machinery may provoke more FXN expression. However, findings using frataxin over-
expressing Y47 (Pook et al. 2001) and TgFxn mice (Miranda et al. 2004) indicate that 
increased FXN levels are not associated with any deleterious effects on phenotype. 
Therefore, the mechanism underlying these mouse and human cell line discrepancies should 
be assessed in future studies by taking more CpG sites into the consideration. Most 
importantly, fibroblasts from Y47 mice should be considered as an experimental control for 
future therapeutic testing of YG8 fibroblasts.  
Finally, sequence specific DNA demethylating agents, such as the oligonucleotide 
antisense inhibitor MG98 (Stewart et al. 2003; Winquist et al. 2006; Amato 2007; Plummer 
et al. 2009), may be useful for future therapeutic approaches in reducing specific DNA 
methylation. In addition, naturally available green tea and their derivatives have also shown 
beneficial effects in reducing the DNA methylation in various cancers (Kato et al. 2008; Dou 
2009; Yuasa et al. 2009; Pandey et al. 2010). Therefore, considering these compounds, which 
are already in clinical trials, for future FRDA therapy may be beneficial.  
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4.2 -  Therapeutic testing of GAA interacting compounds 
4.2.1 - Introduction 
Recent advances in understanding of the molecular mechanisms involved in FRDA 
allow the development of a set of new potential therapeutic interventions aimed at 
ameliorating secondary disease effects such as oxidative stress and mitochondrial iron 
accumulation. Thus, FRDA preclinical and clinical trials using antioxidants and iron chelators 
have demonstrated some limited success (Schulz et al. 2009). At the same time, other 
studies have demonstrated that DNA binding compounds are effective at increasing 
transcription through GAA repeats. Therefore, more effective and specific overall therapy 
may be achieved by targeting the immediate effects of the GAA repeat expansion mutation.  
Although the mechanisms by which the GAA repeat expansion leads to decreased 
levels of frataxin expression are currently not known, two distinct, but inter-related 
hypotheses have been put forward. In one model, it has been suggested that the GAA repeat 
expansion may adopt abnormal non-B DNA structures called ‘triplexes (or sticky DNA)’ or 
DNA RNA hybrid structures that directly impede with FXN gene transcription elongation 
(Grabczyk et al. 2007; Wells 2008). In the other model, there is evidence originally from 
position effect variegation (PEV) studies in transgenic mice that GAA repeat expansions 
somehow produce a heterochromatin-mediated gene silencing effect (Saveliev et al. 2003). 
Therefore, compounds which specifically target these consequences in FRDA would be 
considered beneficial in order to find a potential therapy. 
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4.2.2 - Targeting the gene in FRDA 
The accumulation of recent findings for a potential therapy of FRDA has revealed that 
certain compounds which specifically target the GAA repeats are capable of increasing 
transcription through GAA repeats. In addition, recent studies have revealed that some DNA 
binding compounds may displace proteins that promote heterochromatin formation, such as 
HP1, thereby resulting in a more open, transcriptionally active form of the FXN gene 
(reviewed by (Hebert 2008)).  Although FXN transcription has been increased by recently 
described small molecules, such as hemin (Sarsero et al. 2003), cisplatin (Ghazizadeh 2003), 
3-nitropropionic acid (Turano et al. 2003) and erythropoietin (Sturm et al. 2005), it has been 
postulated that this increase in FXN was due to the specific transcription factor activation, 
but not a direct consequence of increasing transcription through GAA repeats or inhibiting 
HDAC activity (Hebert 2008). 
Therefore, in order to find specific therapeutic interventions for FRDA, Gottesfeld and 
colleagues (2006) have shown that polyamides that bind specifically to GAA repeats 
increased the FXN mRNA and protein levels in an FRDA lymphoblastoid cell lines. These 
compounds were also shown to reverse the sticky DNA conformation adopted by GAA·TTC 
repeats in supercoiled plasmid DNA (Burnett et al. 2006). Importantly, microarray analysis 
has revealed that the polyamides had a limited effect on global gene expression, suggesting 
more specific and safe administration of the drug. Herbert and colleagues (2006) have 
recently reported the results of a rational screen of small molecule DNA ligands to alleviate 
GAA·TTC repeat-mediated gene silencing. Although some compounds have exhibited 
cytotoxic nature, the other compounds, such as DAPI, Hoeschst 33258, distamycin and 
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pentamidine, were found more effective in upregulating the FXN expression in (GAA·TTC)148-
EGFP cell line (Grant et al. 2006).   
Subsequently, other compounds were also screened in order to find their specificity 
and potentiality towards an effective therapeutic approach for FRDA. As a result two classes 
of polyamides were identified for gene targeting, such as hairpin polyamides and linear β-
alanine linked polyamides. Among them, β-linked polyamides have shown effective targeting 
of GAA·TTC repeats whereby enabling binding to different homopurine sequences in vitro 
(Janssen et al. 2000a; Urbach and Dervan 2001). In addition, these compounds also shown to 
interact with GAGAA repeats in Drosophila satellite DNA both in vitro and in Drosophila 
embryos (Janssen et al. 2000a). It has been reported that this satellite DNA-specific molecule 
induces chromatin opening and reverses heterochromatin-mediated PEV gene silencing 
when administered to Drosophila embryos (Janssen et al. 2000a; Janssen et al. 2000b), 
suggesting that similar molecules targeting GAA·TTC DNA could reverse FXN gene silencing.  
In this chapter we have investigated the efficacy and tolerability of two GAA 
interacting compounds, DB221 and pentamidine. DB221 is a novel compound with unknown 
efficacy and toxicity. The advantage of pentamidine is that it has already been approved by 
FDA to help prevent pneumonia in AIDS patients.  
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4.2.2.1 - Therapeutic testing of DB221 
DB221 is a novel, aromatic amidine and a specific DNA minor groove-binding 
compound (Figure 4.13). This compound was synthesized and kindly provided to us by Prof. 
David W. Boykin, Georgia State University, USA. Although little is known about this 
compound, preliminary investigation of DB221 on FRDA using a GAA148-GFP construct has 
revealed a 28-fold increase in GFP protein expression (M.D. Herbert, personal 
communication), suggesting that it may be an effective compound for FRDA therapy. 
However, the exact mechanism by which this compound increases transcription is still 
unknown, and awaits further characterization. In addition, it has also been proposed that 
DB221 might disrupt the triplex structures formed as a result of large GAA repeat expansions 
and thereby reverse the heterochromatin-mediated gene silencing.   
 
 
Figure 4.13 - The chemical structure of DB221. 
 
 In order to investigate the effect of DB221, WT and YG8 rescue mouse fibroblasts, and 
human normal and FRDA primary fibroblasts were treated with various concentrations of 
DB221 (0-5µM) for 4 and 24 hours. After the specified time, cells were collected by 
trypsinization and cell viability was determined by a trypan blue exclusion assay. Then, total 
RNA was extracted and converted into cDNA, followed by the quantification of FXN 
expression levels by QRT-PCR. In addition, changes in DNA methylation following treatment 
with DB221 were determined by methylscreen assay.  
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Quantification of FXN mRNA by QRT-PCR revealed a considerable increase in FXN 
expression levels in cells treated with DB221 (Figure 4.14). Especially, treatment of YG8 
rescue fibroblasts with 1µM of DB221 for a period of 4 and 24 hours showed significant 
(p<0.001) upregulation in FXN expression of 1.9- and 1.6-fold compared to vehicle, 
respectively. However, somewhat surprisingly, downregulation of FXN was found with high 
concentration of DB221 in a time dependent manner. Thus, 5µM of DB221 decreased the 
FXN expression to 70% and 40% after 4 and 24 hours treatment compared to mock-treated 
cells, respectively. The methylscreen assay revealed significantly reduced levels of DNA 
methylation with DB221 treatment.  At 1µM of DB221, the level of DNA methylation was 
reduced to 80% and 20% after 4 and 24 hours treatment compared to vehicle, respectively. 
No difference in methylation was detected with 5µM of DB221 at any time point tested 
(data not shown). 
  
Figure 4.14 - Relative FXN mRNA and methylation levels following treatment with DB221 
in mouse primary fibroblasts. A) FXN mRNA expression, and B) level of methylation as 
determined by QRT-PCR following treatment with DB221. Each result displayed is the 
mean of two independent experiments and mRNA expression was normalized to Gapdh. 
(** p<0.01, error bars ± 1 SEM). 
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Interestingly, no difference in FXN expression was identified in the WT mice fibroblasts 
at any concentration and time-point tested, suggesting a specific effect of DB221 in YG8, the 
GAA repeat expansion-containing rescue mice. 
Regarding the human fibroblasts, we found encouraging results with DB221 (Figure 
4.15). The QRT-PCR analysis following treatment with DB221 revealed increased FXN 
expression in all samples treated with DB221 in FRDA fibroblasts. The FXN expression was 
remarkably increased in cells treated with 1µM of DB221, where 2.2- and 2.9-fold increases 
in FXN expression were identified after 4 and 24 hours treatment compared to vehicle-
treated cells, respectively (Figure 4.15).  
With 5µM of DB221, lesser 1.7- and 1.2-fold increases in FXN expression were 
reported at 4 and 24 hours after treatment, respectively. Although it was unexpected, 
DB221 also showed an immense increase in FXN expression in human normal fibroblasts, 
especially 24 hours after treatment with 1µM and 5µM of DB221. It is possible that this is 
due to the presence of small GAA repeats (<9) in the normal fibroblasts compared to WT 
mice where there are no GAA repeats. 
The methylscreen analysis demonstrated that DB221 was able to reduce the level of 
DNA methylation, especially in FRDA fibroblasts (Figure 4.16). At 4 and 24 hours treatment 
with 1µM of DB221, the level of DNA methylation was reduced from 53% (vehicle) to 5.5% 
and 0.5%, respectively. A similar effect was also found with 5µM of DB221, where the level 
of methylation was reduced to 1.5% and 16.4% at 4 and 24 hours after treatment (Figure 
4.16). 
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Figure 4.15 - Quantification of relative FXN mRNA expression in human normal and FRDA 
fibroblasts following treatment with DB221. A) Level of FXN expression, and B) QRT-PCR 
profile of DB221-treated normal and FRDA fibroblasts (*p<0.05, ** p<0.01, error bars ± 1 
SEM). 
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 In addition, the unmethylated DNA levels were significantly increased with DB221 
after 4 (1µM and 5µM) and 24 hours (5µM) of the treatment, where 25-, 18- and 195-fold 
increases in unmethylated DNA were observed as compared to vehicle-treated samples, 
respectively. However, in contrast with our previous data using DNA demethylating agents, 
reduced levels of DNA methylation (or increased levels of unmethylated DNA) have a direct 
relationship with FXN upregulation in DB221-treated cells. 
 In normal human fibroblasts, the methylscreen analysis revealed increased levels of 
DNA methylation and decreased levels of unmethylated DNA with DB221, suggesting that 
there is somewhat specific effect of DB221 in FRDA cells.  
  
 
  
 
Figure 4.16 - The effect of DB221 on DNA methylation. The analysis of changes in 
methylation as determined by methylscreen assay following treatment with increased 
concentrations of Db221 (0-5µM) in A) normal, and B) FRDA primary fibroblasts (error bars 
± 1 SEM).  
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4.2.2.2 - Therapeutic testing of pentamidine 
Pentamidine (4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide) (Figure 4.17) 
is one of the most successful agents against eukaryotic parasites and has been used clinically 
against Pneumocystis pneumonia (PCP), a severe interstitial type of pneumonia often seen in 
patients with HIV infection, for over 70 years (Burchmore et al. 2002; Wilson et al. 2008). It 
has been reported that pentamidine is capable of binding to the minor groove of double 
strand DNA but not single strand DNA and inhibits protein synthesis, DNA synthesis and the 
activity of endo-exonuclease in Pneumocystis carini (Hildebrandt et al. 1998). It has also 
been reported that pentamidine is able to upregulate the FXN expression in FRDA patients’ 
lymphocytes (Grant et al. 2006). 
 
Figure 4.17 - Chemical structure of pentamidine. 
 
However, to date the efficacy and tolerability of pentamidine has not yet been tested 
in other FRDA cell types. Therefore, we have investigated the effectiveness of pentamidine 
as a therapy for FRDA using human and mouse primary fibroblasts. We have used 0-20µM 
concentrations of pentamidine and incubated the cells with the drug for 48 hours. After the 
treatment, cell viability was determined by trypan blue exclusion assay. Total RNA was 
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extracted, and cDNA was synthesized using first strand cDNA synthesis kit (Invitrogen) 
followed by FXN specific QRT-PCR. 
Generally there was little increase in FXN expression levels in drug-treated cells, but 
significant upregulation (1.3-fold) in FXN was identified in cells treated with 20µM of 
pentamidine compared with vehicle-treated cells in YG8 rescue mouse fibroblasts (Figure 
4.18). The WT fibroblasts showed no difference in the FXN expression. In human fibroblasts, 
contradictory results were obtained, as normal fibroblasts showed an overall increase in FXN 
expression, whereas FRDA fibroblasts displayed a general decrease in FXN expression in all 
drug-treated cells compared to vehicle-treated cells.  
 
  
Figure 4.18 - Quantification of relative FXN mRNA levels following treatment with 
pentamidine in A) mouse, and B)human primary fibroblasts. Each result displayed is the 
mean of two independent experiments and mRNA expression was normalized to 
Gapdh/GAPDH. The values were expressed as a ratio to the corresponding untreated 
(vehicle) sample (* p<0.05, error bars ± 1 SEM). 
 
 
0
50
100
150
200
250
300
350
Vehicle 5µM 10µM 20µM
R
el
a
ti
v
e 
m
R
N
A
 e
x
p
re
ss
io
n
 o
f 
F
X
N
% WT
YG8
0
50
100
150
Vehicle 5µM 10µM 20µM
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
r
e
ss
io
n
 o
f 
F
X
N
%
 
Normal
FRDA
B A 
* 
   
                                                                                                 Chapter 4 - Therapeutic approaches in vitro 
   
      162 
4.2.3 - Discussion 
Using rational selection and screening of potential FRDA therapeutic molecules  GAA 
repeat specific compounds have been identified and are being investigated (Sarsero et al. 
2005; Grant et al. 2006; Herman et al. 2006). Although the exact mechanism by which the 
GAA interacting compounds induce FXN expression is not known, it has been postulated that 
these compounds are able to disrupt the triple/sticky DNA structures formed as a result of 
GAA repeat expansion (Hebert and Whittom 2007; Hebert 2008). Another possibility may be 
that these compounds displace the proteins that promote the heterochromatin formation 
(HP1), thereby resulting in more open chromatin and transcriptionally accessible form of 
FXN gene (Hebert 2008). The analysis of data obtained from the first generation competition 
dialysis screening assay (Chaires 2005) has revealed the identification of several small 
molecules with the potential to bind selectively to the duplex form of the GAA repeat 
sequences.  In which, the interactions of 126 compounds with 13 nucleic acid structures 
were studied (Grant et al. 2006). 
We have tested two potential candidates, DB221 and pentamidine. These molecules 
are minor groove binders that prefer A-T rich duplex DNA over other DNA structures. 
Regarding DB221, we found most promising results in human and mouse cells with 
significant increase in FXN expression, especially with low concentrations of the drug (1µM). 
In mouse cells, a selective increase in FXN expression was seen only in YG8 rescue mice cells 
indicating a GAA repeat-specific effect of DB221. In addition, DB221 also produced reduced 
DNA methylation in mouse and human cell lines.  
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In contrast to DNA demethylating agents, the reduced DNA methylation with DB221 is 
associated with an increase in FXN expression in both mouse and human cells. Indeed, in 
human FRDA fibroblasts, the level of DNA methylation almost disappeared with DB221 
treatment, which resulted in increased the FXN levels. The reason for this differing effect to 
DNA demethylating agents could be that DB221 specifically targets triplex/sticky GAA repeat 
DNA causing a specific local inhibition of DNA methylation rather than a more generalized 
DNA methylation inhibition as seen with DNA demethylating agents.  
As DB221 is a GAA interacting compound, one can perhaps expect more FXN 
expression in treated cells that have more GAA repeats, like FRDA fibroblasts (>450 GAA 
repeats).  However, we found a massive increase in FXN levels in cells with a normal number 
of GAA repeats (<9) rather than in cells with longer GAA repeats. This leads me to speculate 
that DB221 may selectively target the GAA repeats, causing transcriptional activation, in a 
way that is inversely dependent upon the number of GAA repeats. Thus, for large GAA 
repeat FRDA fibroblasts, transcription activation may require more time than for normal 
fibroblasts. This would be consistent with our findings where more FXN levels were 
produced with 1µM of DB221 after 24 hours treatment compared to 4 hours treatment with 
the same concentration of the drug. However, such an increase in FXN expression did not 
appeared with 5µM of DB221, but perhaps higher concentrations of DB221 negatively 
regulate FXN expression.  
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We next analysed the effect of pentamidine, used on the basis of its known DNA 
minor-groove binding properties (Neidle 2001) and previous gene expression activation 
results (Grant et al. 2006). In addition, pentamidine was chosen because it is a FDA approved 
drug for the treatment of infections in patients with HIV and thus can be easily tried in FRDA 
patients. No apparent effect was seen in human cells treated with pentamidine. However, in 
YG8 rescue mice a moderate but significant increase in FXN expression was produced only 
with high concentration of the drug (20µM). Therefore, we have investigated the effect of 
this compound with even higher concentration (30µM), but 90% of the cells died within 24 
hours after the treatment, indicating that high concentrations of pentamidine are toxic to 
cells.  Recently reported data using a GAA148-GFP construct has demonstrated that 
pentamidine significantly increased the GFP signal in cells treated intermittently with 
pentamidine, compared to the cells treated with pentamidine continuously (Grant et al. 
2006). Therefore, such a strategy could be applied in future drug therapy investigations with 
pentamidine.  
Previous studies have indicated that healthy FRDA carriers show about 40% of the 
normal FXN mRNA levels (Pianese et al. 2004), suggesting that a modest increase in FXN 
levels, such as that induced by pentamidine (in mouse), may be sufficient to reverse the 
FRDA-associated phenotype. Herbert and colleagues (2006) reported that a DNA binding 
protein, Hoechst 33258, has significantly increased the GFP levels in a GAA148-GFP construct. 
Although there are no explicit data for the preferential binding of Hoechst 33258 to GAA 
repeats, considering such compounds for future FRDA therapy may also be useful.   
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In summary, our findings suggest that the GAA interacting compounds we have 
investigated, especially DB221, may prove useful as therapeutics for FRDA. It seems to be 
that we do not have a simple scenario whereby DB221 can target non-B DNA forms 
specifically in FRDA cells, inducing FXN transcription and hence raising frataxin levels. Other 
unknown mechanisms must clearly be at play. Finally, although we have investigated the 
effect of DB221 in a preliminary short-term in vivo study and seen no effect (Appendix Figure 
B.5), it will be very important to consider long term in vivo studies in future to determine the 
bioavailability and efficacy of these compounds. Consequently, it will also be essential for 
future studies to ascertain the precise contribution of triplex/sticky GAA DNA structures and 
heterochromatin mechanisms in silencing the FXN gene. 
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4.3 -  Therapeutic testing of histone deacetylase (HDAC) inhibitors  
4.3.1 - Introduction 
Epigenetic modifications are increasingly recognized as having a substantial role to 
play in both normal cellular physiology and disease processes. Histone deacetylases (HDAC) 
are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic 
regulation of gene expression. In mammalian cells, they are responsible for the 
deacetylation of N-terminal lysine residues in histones, particularly the core histones H2A, 
H2B, H3 and H4.  Histones are also distinguished by the fact that they undergo abundant 
post-translational modifications to both the globular and tail domains. The combination of 
such histone modifications is indicative of whether a gene is transcriptionally active or 
inactive (Grant 2001; Goll and Bestor 2002). To date, more than 60 different modifications 
have been detected and these include acetylation, methylation, ubiquitynation, 
phosphorylation, and sumoylation (Table 4.1), all of which serve as epigenetic tags (reviewed 
by Kouzarides 2007).  
Table 4.1 – Different classes of histone modifications (Kouzarides 2007) 
Chromatin Modifications Residues Modified Functions Regulated* 
Acetylation K-ac Trans, Rep, Repli, Cond 
Methylation (lysines) K-ac1 K-me2 K-me3 Trans, Rep 
Methylation (arginines)) R-ac1 R-me2 R-me3 Trans 
Phosphorylation S-ph T-ph Trans, Rep, Cond 
Ubiquitylation K-ub Trans, Rep 
Sumoylation K-su Trans 
ADP ribosylation E-ar Trans 
Deimination R > Cit Trans 
Proline Isomerization P-cis > P-trans Trans 
      
* - Trans = Transcription, Rep = Repair, Repli = Replication, Cond = Condensation 
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4.3.2 - Classification of HDACs 
Based on the homologies to yeast HDACs, 18 HDAC enzymes have been identified in 
mammals and divided into four classes (Table 4.2) (Blander and Guarente 2004; Bhalla 2005; 
Marks and Dokmanovic 2005; Glaser 2007); Class I HDACs include HDACs 1, 2, 3, and 8, 
which are related to yeast RPD3 deacetylase. Class II HDACs are related to yeast Hda1 and 
include HDACs 4, 5, 6, 7, 9, and 10. This class is further divided into class IIa, consisting of 
HDAC 4, 5, 7 and 9, and class IIb, consisting of HDAC6 and 10. All class I and II HDACs are 
zinc-dependent enzymes. Class III HDACs, sirtuins (sir 1-7), require NAD+ for their enzyme 
activity (Blander and Guarente 2004). Class IV HDAC represented by HDAC 11, which, like 
yeast Had 1 similar 3.  
 
Table 4.2 – Classification of HDACs in mammals (Pan et al. 2007)  
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4.3.3 - Mechanisms of histone modifications and transcriptional regulation 
Histone modifications regulate gene expression in three mechanistic ways (Jenuwein 
and Allis 2001; Berger 2007; Kouzarides 2007). Firstly, they regulate chromatin structure, 
making genetic loci more or less accessible to the transcriptional machinery. Secondly, they 
serve as a signalling role by integrating responses to multiple biochemical signalling cascades 
and recruit or repel the transcriptional machinery and chromatin remodelling complexes 
(Abel and Zukin 2008). Thirdly, and perhaps more interestingly, histone modifications 
mediate epigenetic changes in gene expression that provide a mechanism by which neural 
function and behaviour are stably altered for long periods of time in response to transient 
experience or neuronal insult (Abel and Zukin 2008). 
Histone modifications may affect higher-order chromatin structure by affecting the 
contact between different histones in adjacent nucleosome or the interaction of histones 
with DNA (Kouzarides 2007). Of all the known modifications, acetylation has the most 
potential to unfold chromatin since it neutralizes the basic charge of the lysine. This function 
is not easy to observe in vivo, but biophysical studies indicate that inter-nucleosome 
contacts are important for stabilization of higher-order chromatin structure (Kouzarides 
2007; Abel and Zukin 2008).   
Acetylation of core histones is catalyzed by transcriptional coactivators such as CREB-
binding protein (CBP), which possess histone acetyl transferase (HAT) activity (Lee and 
Workman 2007). Histone acetylation remodels chromatin structure, thereby modulating 
transcription. Specificity of gene regulation is achieved by the recruitment of HATs by 
transcription factors to specific genetic loci, where they locally modify histones (Abel and 
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Zukin 2008).  Importantly, HATS interact with a large number of transcription factors and 
thus serve as critical hubs, integrating the activity of multiple signalling cascades.  
The activity of HATs can be reversed by HDACs, which remove acetyl groups from 
lysine/arginine residues in the amino-terminal tails of core histones. Deacetylation of histone 
proteins shifts the balance towards chromatin condensation and thereby silences gene 
expression (Abel and Zukin 2008). Unlike HATs, HDACs have a rich structural diversity, which 
confers diversity of function and renders HDACs promising targets for drug discovery and 
therapeutic intervention. 
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4.3.4 - Histone modifications in FRDA 
Epigenetic mechanisms, such as histone deacetylation and methylation are known to 
affect gene expression by chromatin remodelling (Egger et al. 2004), and these epigenetic 
changes are likely to underpin any GAA repeat-induced heterochromatin-mediated gene 
silencing effects. Recent findings consensually implicate chromatin modifications in the 
aetiology of FRDA (Herman et al. 2006; Greene et al. 2007; Al-Mahdawi et al. 2008).  
The histone acetylation state of the FXN gene in a lymphoblastoid cell line derived 
from a FRDA patient (GAA650/1030) showed significantly lower levels of histone acetylation in 
H3K9, H3K14, H4K5, H4K8, H4K12 and H4K16 surrounding the GAA repeat, compared to a 
normal cell line (Figure 4.19a)(Herman et al. 2006). No significant difference was observed at 
the FXN promoter region. Additionally, the levels of H3K9 mono-, di- and trimethylation for 
the region upstream of the GAA repeat were also reported to be significantly higher in the 
FRDA cell line, particularly those of H3K9 trimethylation (Figure 4.19b). Similarly, Greene et 
al. (2007) reported significantly elevated levels of H3K9 dimethylation upstream of the GAA 
repeat in lymphoblasts from four FRDA patients, when compared to those of unaffected 
individuals. 
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Figure 4.19 - Analysis of histone modifications in FXN gene by ChIP experiments in FRDA 
(GM15850) versus a normal (GM15851) individual lymphoblastoid cell lines. In FRDA, (a) 
histone acetylation levels at specified lysine residues are generally lower immediately 
upstream and downstream of the GAA repeat, (b) while levels of H3K9 methylation are 
significantly higher in upstream of the GAA., when compared to the normal cell line 
(Herman et al. 2006) 
 
Later, Al-Mahdawi et al. (2008) investigated the acetylated histone H3 and H4 and 
methylated histone H3K9 by ChIP analysis of the FXN promoter, upstream GAA and 
downstream GAA regions in autopsy brain tissues from two FRDA and two unaffected 
individuals. Overall decreased acetylation of histone H3 and H4 was confirmed, particularly 
in the downstream GAA region. The six acetylated histone residues (H3: K9, K14, H4: K5, K8, 
K12, and K16), showed a GAA-induced gradient of comparative acetylation that is highest in 
the FXN 5’UTR and lowest in the downstream GAA region, with the single most altered 
residue being H3K9. Interestingly, H3K9 also showed consistently increased levels of di- and 
trimethylation in all three of the FXN regions (Figure 4.20) (Al-Mahdawi et al. 2008).  
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Figure 4.20 - Analysis of histone modifications in human brain tissue. ChIP quantitative 
PCR results for the FXN promoter/exon1 (Pro), upstream GAA (Up) and downstream GAA 
(Down) amplified regions are represented as the relative amount of immunoprecipitated 
DNA compared with input DNA, having taken negligible -Ab control values into account. 
FXN values were normalized with human GAPDH and all values have been adjusted so that 
all of the Upstream GAA mean values from the unaffected individuals are 100%. In each 
case two individual ChIP samples from two FRDA patients and two unaffected controls 
were analysed in triplicate. The means and SEMs of these values are shown (Al-Mahdawi 
et al. 2008). 
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4.3.5 - Use of HDAC inhibitors as a therapy in FRDA 
There has been substantial progress in the development of drugs that target 
epigenetic control processes as a new class of mechanism-based therapeutics (McLaughlin 
and La Thangue 2004; Inche and La Thangue 2006), and one of the fastest moving areas is 
the development of HDAC inhibitors (HDACi). Acetylation and deacetylation of histones play 
an important role in transcription regulation of eukaryotic cell (Lehrmann et al. 2002; Mai et 
al. 2005). Over the last 10 years, many different types of HDAC inhibitors have been 
developed, ranging from complicated structures of bacterial or fungal origin (TSA) to the 
very simple butyrate. HDAC inhibitors can affect transcription by inducing acetylation of 
histones, transcription factors and other proteins regulating transcription (Glozak et al. 2005; 
Marks and Dokmanovic 2005; Bolden et al. 2006; Minucci and Pelicci 2006). Inhibition of 
HDACs can result in a general hyperacetylation of histones, which is followed by the 
transcriptional activation of certain genes through relaxation of DNA conformation (Suenaga 
et al. 2002).  Chemically, the HDAC inhibitors can be classified into six structural groups: the 
small carboxylates, the hydroxamic acids, the benzamides, the epoxyketones, the cyclic 
peptides, and hybrid molecules containing cyclic peptide motifs and hydroxamic acid 
moieties (Drummond et al. 2005; also reviewed in Gottesfeld 2007).  
Considering the recent identification of alterations in histone acetylation and 
methylation profile in FRDA, which resulted in heterochromatin mediated FXN gene 
silencing, it was postulated that the reversal or inhibition of these histone modifications 
could represent a potential therapeutic route for FRDA (Figure 4.21)(Herman et al. 2006). A 
number of studies have focused in the use of HDAC inhibitors as therapy for restoring 
histone acetylation and transcriptional activation in neurodegenerative mouse models 
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(Langley et al. 2005). HDAC inhibitors have been shown to cross blood-brain barrier, to 
ameliorate motor deficits in mouse models for Huntington disease (Ferrante et al. 2003; 
Hockly et al. 2003; Gardian et al. 2005), and to increase expression of the SMN2 gene in 
spinal muscular atrophy (Kernochan et al. 2005; Riessland et al. 2006). Thus, interest in this 
class of compounds as therapeutics for other neurological diseases has emerged (Di 
Prospero and Fischbeck 2005; reviewed in Gottesfeld 2007). 
 
Figure 4.21 - Heterochromatin-mediated silencing pathway in FRDA may be reversed by 
HDAC inhibitor (Festenstein 2006). 
 
An earlier study demonstrated a small effect of the general HDAC inhibitor, sodium 
butyrate, on FXN gene activity in an EGFP reporter cell line (Sarsero et al. 2003). Later, the 
potential of HDAC inhibitor use in FRDA therapy was investigated by monitoring the effects 
of a range of commercial HDAC inhibitors on both the levels of histone acetylation and FXN 
transcription in an FRDA lymphoblastoid cell line from donor FRDA patient blood (Herman et 
al. 2006). This study showed that of the tested compounds, the benzamide-type SAHA 
derivative BML-210 was the only HDAC inhibitors to significantly increase (~2-fold) the level 
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of FXN mRNA in the FRDA cell line (Figure 4.22b), even though other HDAC inhibitors 
produced much higher levels of total acetylated histone (Figure 4.22a). 
 
 
Figure 4.22 - Effect of HDAC inhibitor on acetylation and FXN mRNA in FRDA. a) The levels 
of H3 and H4 acetylation, b) FXN mRNA levels (Herman et al. 2006).  
 
Subsequent synthesis of analogues of BML-210 identified a pimelic diphenylamide 
compound, 4b (N1-(2-aminophenyl)-N7-phenylheptanediamide), that was shown to act on 
FRDA primary lymphocytes to significantly increase the acetylation levels of H3K14, H4K5 
and H4K12 in the FXN upstream GAA region and to increase FXN mRNA levels by 2.5-fold, 
approximately 80% of that in unaffected individuals and to at least those of carriers, without 
apparent toxicity (Herman et al. 2006).  
Recently, Rai et al. (2008) explored the use of HDAC inhibitors as a potential therapy in 
FRDA patients’ primary lymphocytes, fibroblasts and mouse model of FRDA (KIKI, GAA230/230). 
Initially they used the HDAC inhibitor 106, a derivative of 4b, and showed a significant 
increase in FXN mRNA expression, especially in the cerebellum and heart tissues of the KIKI 
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mice. Additionally, this compound resulted in increased acetylation of histone H3 and H4 in 
the mouse Fxn intron 1 region just upstream of the knocked-in GAA repeat (Rai et al. 2008). 
Interestingly, microarray analysis revealed that drug-treated mouse genes (67% in brain, 
84% in cerebellum, and 67% in heart) showed coordinate changes towards normal levels 
after 106 treatment (Rai et al. 2008) 
The same research group also investigated the efficacy of another two HDAC inhibitors 
in FRDA, 136 and 109, structurally similar novel pimelic diphenylamides, and found up 
regulation of frataxin mRNA and protein expression in vitro (Rai et al. 2010). In addition, an 
in vivo pilot study using the same compounds also showed significantly increased FXN mRNA 
and acetylation of histones H3K14 and H4K5 expression in the FRDA mouse model (Rai et al. 
2010). However, long term in vivo studies are needed to confirm the effectiveness of these 
two compounds as a potential therapy for FRDA. 
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4.3.5.1 - Therapeutic testing of sirtinol 
Since commonly used HDAC class I and II inhibitors such as TSA, VPA and SAHA are not 
effective in enhancing FXN transcription, we decided to investigate the effect of certain class 
III HDAC inhibitors. Sirtinol is an inhibitor of Sirt1, which is a mammalian NAD+-dependent 
deacetylase that belongs to class III histone deacetylases (HDACs) (Imai et al. 2000; Landry et 
al. 2000b; Blander and Guarente 2004). These enzymes, also known as sirtuins, have 
multiple targets, act NAD+-dependently and are implicated in telomeric and rDNA silencing 
in humans (Grozinger et al. 2001). Most HDAC inhibitors, including the mammalian sirtuins, 
have a number of different targets, one of them being histones. The use of sirtinol in cancer 
therapy has been very well explored and shown promising results for use as an anticancer 
agent (Ota et al. 2006; Kojima et al. 2008). 
Here, the focus will lie on the activity of sirtuins on histones, since opening up the 
chromatin structure via acetylation of FXN might facilitate its expression. So far, the most 
characterised histone target of sirtuins is the deacetylation of the H4K16 modification. In 
Drosophila it was shown that this modification correlates best with processes thought to 
“open” chromatin structure (Taipale and Akhtar 2005). Thus, it seemed reasonable to treat 
FRDA mouse and human cell lines with sirtuin inhibitors, despite their diverse functions, to 
determine whether simply “opening up” the FXN locus would be sufficient to relieve the 
hampered FXN transcription in FRDA patients. 
In order to test the effect of sirtinol, mouse and human primary fibroblasts (normal 
and FRDA) were treated with a 10µM, 50µM and 100µM sirtinol for 48 hours followed by the 
quantification of FXN mRNA expression by QRT-PCR (Figure 4.23).  
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Treatment of cells with sirtinol significantly (p<0.05) up regulated the FXN mRNA 
expression in a dose dependent manner. At 50µM concentration of sirtinol, FXN expression 
levels were increased to approximately 1.8-fold in YG8 mouse fibroblasts and 3-fold in 
human FRDA fibroblasts, compared to their respective vehicle-treated cells. Surprisingly, 
sirtinol also produced a significant increase of FXN mRNA expression (~2-fold) in human 
normal primary fibroblasts, suggesting some non-specific activity.  Nevertheless, high 
concentrations of the drug reduced the FXN mRNA expression in both WT and YG8 mouse 
and human FRDA primary fibroblasts. Finally, no cell toxicity was detected with any 
concentrations tested. 
 
  
Figure 4.23 - Relative FXN mRNA levels following treatment with sirtinol in mouse and 
human primary fibroblasts. Displayed are the levels of FXN mRNA expression, as 
determined by QRT-PCR following treatment with sirtinol in A) mouse, and B) human. 
Each result displayed is the mean of two independent experiments and each sample was 
normalized to Gapdh/GAPDH. The values were expressed as a ratio to the corresponding 
untreated (vehicle) sample of WT/normal fibroblasts (* p<0.05, error bars ± 1 SEM). 
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4.3.5.2 - Therapeutic testing of splitomicin 
Splitomicin, a compound with a saturated six-membered lactone ring, is a more 
specific inhibitor of Class III HDACs and is thought to have a mechanism distinct from that of 
other class III HDAC inhibitors, inhibiting these enzymes by competing for binding of the 
acetylated substrate (Da Costa et al. 1996; Bedalov et al. 2001; Posakony et al. 2004). It was 
initially recognized as a potent, selective inhibitor of SIR2, which is a member of the class III 
HDAC protein family (Frye 1999; North and Verdin 2004; Kruszewski and Szumiel 2005). 
Subsequently, it has been demonstrated that splitomicin is also able to inhibit Sirt2, whose 
biological functions are relevant to genomic stability, DNA repair, p53-mediated apoptosis 
and adipogenesis (Guarente 2006; Haigis and Guarente 2006; Longo and Kennedy 2006). 
Biacsi et al. (2008) have recently reported that splitomicin has increased the FMR1 
mRNA expression by 200-600 fold in Fragile X mental retardation syndrome (FXS), alleviating 
the heterochromatin-mediated silencing effect in FXS. Since FRDA and FXS are both 
trinucleotide repeat disorders and share some common features, we considered using 
splitomicin as a potential therapy for FRDA. 
In order to assess the effectiveness of splitomicin treatment, both mouse and human 
(normal and FRDA) primary fibroblast cells were cultured in DMEM medium with 0.5mM, 
0.75mM and 1mM splitomicin (Figure 4.24) for 48 hours. After the treatment, the cells were 
collected and cell viability was tested, followed by quantification of FXN mRNA expression by 
QRT-PCR.  
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Splitomicin treatment of mouse primary fibroblasts produced a dose dependent 
increase of FXN mRNA expression at 0.5mM and 0.75mM concentrations in YG8 mouse cells 
with a maximal increase of ≈1.6-fold at 0.75mM. FXN levels then dropped when using 1mM.  
No significant differences in FXN mRNA expression were detected between vehicle and drug-
treated samples in WT mouse fibroblasts (Figure 4.24), suggesting a specific effect of 
splitomicin on FRDA.  Unexpectedly, splitomicin did not produce any increase in FXN 
expression in the human fibroblasts (Figure 4.24) at any concentration tested. This 
difference may possibly be due to the larger GAA repeats (>450) in human fibroblasts 
compared with YG8 (<250) mice fibroblasts. However, no cell toxicity was detected with 
splitomicin, proposing a safe administering of the drug. 
 
  
Figure 4.24 - Relative FXN mRNA levels following treatment with splitomicin in mouse and 
human primary fibroblasts. Displayed are the increases in FXN mRNA expression in A) 
mice, and B) human primary fibroblasts as determined by QRT-PCR following treatment 
with splitomicin. Each result displayed is the mean of two independent experiments and 
each sample was normalized to Gapdh. The values were expressed as a ratio to the 
corresponding untreated (vehicle) sample of WT/normal fibroblasts (* p<0.05, error bars ± 
1 SEM). 
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4.3.5.3 - Therapeutic testing of nicotinamide 
Nicotinamide is a precursor of nicotinamide adenine dinucleotide (NADH), which is a 
substrate for complex I of the electron transport chain. Nicotinamide is an inhibitor of the 
NAD+-dependent or Class III HDAC sirtuin family and is the biologically active form of niacin 
(vitamin B3) (Fuller and Dietrich 1971), which has been widely used clinically for >40 years 
(Knip et al. 2000). Ghosh et al. (2004) reported that nicotinamide substantially rescued the 
neuronal loss in a drosophila model of spinocerebellar ataxia-3. Furthermore, nicotinamide is 
currently in clinical trials as a therapy for cancer and type I diabetes (Kaanders et al. 2002). 
However, the long term safety of the high doses used in these treatments has been 
questioned (Knip et al. 2000).  
Treatment of cardiomyocytes with nicotinamide significantly increased the acetylation 
of histone H3 and H4 (Imai et al. 2000). As sirtuins act NAD+-dependently, nicotinamide can 
also inhibit the deacetylation of H4K16ac, a product of the SIRT- mediated deacetylation 
reaction. Here, nicotinamide directly competes with NAD+ for binding to the pocket of the 
Sir2-family catalytic domain (Landry et al. 2000a; Landry et al. 2000b). Nicotinamide is also 
thought to be more stable under cell culture conditions than splitomicin or sirtinol 
(Posakony et al. 2004).  
 The effect of nicotinamide on FRDA was subsequently investigated by treating the 
mouse and human primary fibroblasts with a range of drug concentrations (0 - 10mM) for 72 
hours. After drug treatment, FXN mRNA expression was quantified with QRT-PCR. 
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Nicotinamide produced no change in FXN expression at lower concentrations, but 
10mM nicotinamide produced significant increase of approximately 1.8-fold in YG8 mouse 
fibroblasts and 2-fold in human FRDA cells (Figure 4.25). No FXN upregulation was found in 
either mouse (WT) or human normal fibroblasts, indicating a specific effect of nicotinamide 
on FRDA. However, a major concern with nicotinamide is the high concentrations of the drug 
needed to upregulate the FXN mRNA expression, as highlighted by the adverse effects seen 
in previous clinical trials of nicotinamide for cancer and type I diabetes (Knip et al. 2000).  
However, in our testing no cell toxicity was detected even with the highest tested 
concentration (10mM) of nicotinamide. 
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Figure 4.25 - Relative FXN mRNA levels following treatment with nicotinamide in mouse 
and human primary fibroblasts. Percentage changes in FXN mRNA expression, as 
determined by QRT-PCR following treatment with nicotinamide in A) mice, and B) human 
were displayed. C) QRT-PCR profile of nicotinamide-treated mouse and human fibroblasts. 
Each result displayed is the mean of two independent experiments and each sample was 
normalized to Gapdh/GAPDH. The values were expressed as a ratio to the corresponding 
untreated (vehicle) sample of WT/normal fibroblasts (** p<0.01, error bars ± 1 SEM). 
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4.3.5.4 - Therapeutic testing of oxamflatin 
Oxamflatin is an aromatic sulfonamide derivative with a hydroxamic acid group.  The 
use of oxamflatin as an anti-cancer agent has been very well studied in breast cancer (Restall 
et al. 2009) and uterine cancer (Jiang et al. 2007). Oxamflatin induces transcriptional 
activation of JunD and morphological reversion in various NIH3T3-derived transformed cell 
lines (Sonoda et al. 1996). Oxamflatin induces morphological change of HeLa cells similar to 
that induced by the HDAC inhibitor TSA, and indeed showed inhibition of HDAC activity in 
vivo and in vitro (Kim et al. 1999).  
Recently, Soragni et al. (2008) reported that oxamflatin significantly increased (P<0.05) 
the expression of the GFP_ (GAA·TTC)560 reporter 1.4- to 2.5-fold. Also, this compound 
induced expression of the FXN gene harbouring expanded GAA·TTC repeats in the two 
lymphoblastoid cell lines derived from FRDA patients (P<0.05) (Soragni et al. 2008). 
However, the molecular mechanism of oxamflatin is still unknown and more in vitro and in 
vivo long term studies are needed to confirm the efficacy of this novel HDAC inhibitor as a 
therapy for FRDA.  
Mouse and human primary fibroblasts were treated with oxamflatin at 50nM, 100nM 
and 500nM concentrations (Figure 4.26) for 72 hours followed by the FXN mRNA 
quantification by QRT-PCR. Cell viability was measured by trypan blue exclusion assay and no 
difference in cell viability was detected in between vehicle and drug-treated samples. 
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Oxamflatin selectively increased FXN expression in the YG8 FRDA mouse model and no 
effect on FXN expression was observed in human FRDA primary fibroblasts (Figure 4.26). A 
significant increase (≈1.5-fold) in FXN expression was identified with 100nM of oxamflatin in 
YG8 mouse cells, and with high concentration of drug (500nM) these levels dropped to 66% 
of those observed in vehicle-treated cells. Interestingly, a slightly reduced (but not 
significant) FXN expression was identified in WT mouse primary fibroblasts. This indicates 
that oxamflatin may have a specific effect in mouse FRDA cells with smaller GAA repeats and 
not the human FRDA cells with larger GAA repeats. Similar to splitomicin, FXN mRNA 
expression was significantly increased in human normal primary fibroblasts with oxamflatin 
and this is possibly due to fewer GAA repeats in human normal fibroblasts.  
 
  
Figure 4.26 - Oxamflatin treatment of normal and FRDA primary fibroblasts of A) mouse 
and B) human. FXN mRNA expression was determined by QRT-PCR following treatment 
with oxamflatin. Each QRT-PCR was done twice in triplicate. All values were normalized to 
Gapdh/GAPDH and the values were expressed as a ratio to the corresponding untreated 
(vehicle) sample of WT/normal fibroblasts (* p<0.05, error bars ± 1 SEM). 
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4.3.6 - Discussion 
Acetylation and deacetylation of histone proteins play crucial roles in transcriptional 
regulation thereby regulating the gene expression. Recent studies show that in FRDA 
transcriptional repression of the FXN gene is consistent with heterochromatin-mediated 
silencing, as indicated by increased trimethylation of H3 and decreased acetylation of H3 and 
H4 histone tails immediately surrounding the expanded GAA repeats (Herman et al. 2006; 
Greene et al. 2007; Al-Mahdawi et al. 2008). 
 Over the past ten years, numerous HDAC inhibitors have been clinically evaluated for 
the treatment of cancer and these are proving to be generally well tolerated (Cang et al. 
2009; Prince et al. 2009). New uses of HDAC inhibitors appear to confer significant 
neuroprotection in several experimental models of neurodegenerative diseases such as 
spinal muscular atrophy (Riessland et al. 2006; Garbes et al. 2009), Huntington disease 
(Hockly et al. 2003; Butler and Bates 2006; Thomas et al. 2008), cardiac hypertrophy (Antos 
et al. 2003) and cystic fibrosis (Hutt et al. 2010). Therefore, there is ample evidence to 
propose the use of HDAC inhibitors to reverse FXN gene silencing as a potential FRDA 
therapy. 
Recent studies using FRDA patient cell lines have suggested that common inhibitors 
targeting HDAC class I and II enzymes are generally not sufficient to reverse the 
downregulation of FXN (Herman et al. 2006 and see review Gottesfeld 2007). Therefore, in 
this study we have tested the efficacy of class III HDAC inhibitors such as sirtinol, splitomicin 
and nicotinamide, and the novel HDAC inhibitor, oxamflatin, as potential therapeutic 
approaches for FRDA.  All of our preliminary cell culture experiments with these HDAC 
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inhibitors resulted in a significant increase in FXN expression in mouse and/or human 
fibroblasts. 
We have shown that sirtinol increases FXN mRNA expression in mouse and human 
fibroblasts.  In YG8 rescue mouse cells, the FXN expression was increased in a dose 
dependant manner. However, such an effect was not seen in human FRDA cell lines and this 
is probably due to the more number of GAA repeats (<450) in FRDA fibroblasts compared to 
YG8 rescue fibroblasts (>250). In human FRDA fibroblasts, increased FXN expression (~1.5-
fold) was achieved only with 50µM concentration and this was again reduced to baseline 
levels with higher concentration (100µM) of drug. Surprisingly, the level of FXN expression in 
normal cell lines was increased by approximately 2-fold, with the lowest concentration 
(10µM) of sirtinol maintaining the same level throughout.  
Like sirtinol, splitomicin also increased FXN expression significantly (p<0.05) in mouse 
cell lines, displaying an almost linear dose-response relation. With WT and human normal 
fibroblasts, no detectable changes in FXN expression were found between drug-treated and 
vehicle-treated samples. Importantly, no cell toxicity was found at any concentration tested 
with both sirtinol and splitomicin, suggesting a safe administration of these compounds. 
However, to confirm that the observed effect in FXN expression is due to solely to Sirt1 
inhibition, future RNA interference-mediated knockdown of the Sirt1 gene in FRDA cells 
could be investigated. 
The exact mechanism by which Sirt1 inhibitors leads to increased FXN expression is 
unknown. Since most Sirt1 inhibitors do not require DNA replication to be effective, these 
compounds may have a better therapeutic potential than DNA demethylating agents in 
increasing FXN expression in neurons, which no longer divide and where FXN expression is 
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more essential. The controversial role of Sirt1 activity is a hindrance to finding the exact 
mechanism of how Sirt1 inhibition upregulates FXN expression and thereby could be used to 
reverse FRDA pathology. Indeed, a large number of studies using pharmacological and/or 
genetic manipulation of Sirt1 activity have revealed that Sirt1 activation, rather than 
inhibition, could be a general neuroprotective outcome. Thus, resveratrol, a Sirt1 activator, 
has displayed beneficial effects in various in vitro and in vivo models of central nervous 
system (CNS) neuron death and degeneration (Kiziltepe et al. 2004; Kaplan et al. 2005; Tsai 
et al. 2007). As explained earlier, Sirt1 inhibitors have also been shown neuroprotective 
effect. These conflicting results leave us with an apparently irreconcilable paradox of how 
the Sirt1 activators and inhibitors are both able to ameliorate the neurodegeneration in 
certain neurodegenerative disorders. However, recent studies of resveratrol have clearly 
indicated that resveratrol is not a direct activator of Sirt1, but does increase AMPK activity 
(Dasgupta and Milbrandt 2007; Beher et al. 2009; Tang 2010). Furthermore, it has been 
reported that AMPK enhances Sirt1 activity indirectly by increasing cellular NAD+ levels 
(Canto and Auwerx 2009; Canto et al. 2009).  
Although sirtinol and splitomicin have produced increased FXN expression, these 
expression levels were either non-statistically significant or just above the significance levels. 
Therefore, we investigated the effect of nicotinamide using our novel cell culture system and 
we found encouraging results. Treatment of mouse and human fibroblast cells with 10mM 
nicotinamide for 72 hours successfully upregulated FXN expression by ~2-fold in YG8 mouse 
and FRDA fibroblasts. Interestingly, no differences in FXN expression were detected in the 
normal fibroblasts suggesting that nicotinamide exhibits a specific effect in FRDA cells. 
However, the use of such a high concentration of nicotinamide may be a major disadvantage 
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in using this drug for FRDA therapy. In the present study, the specific mechanism whereby 
nicotinamide enhances FXN expression remains to be determined. A recent study has shown 
that physiological concentrations of nicotinamide noncompetitively inhibit Sirt1 in vitro, 
suggesting that nicotinamide is a physiologically relevant regulator of Sirt1 enzymes 
(Bitterman et al. 2002). In addition, nicotinamide, as precursor of NAD synthesis, acts to 
maintain NAD+ levels and the bioenergetics state of neurons.  
The other HDAC inhibitor used in this study, oxamflatin, also showed interesting 
results, especially in the mouse cell lines. 100nM oxamflatin significantly (p<0.05) increased 
FXN mRNA expression by  approximately 150% and this level dropped to 86% and 73% with 
50nM and 500nM of drug, respectively. This indicates that the ideal concentration to 
stimulate FXN expression seems to be 100nM. On the other hand, oxamflatin did not show 
any effect on FRDA human cell lines. However, a non-specific effect of oxamflatin was 
identified in human normal cells, where it significantly increased the FXN mRNA expression 
levels by almost 2-fold compared with vehicle. 
HDAC inhibitors are believed to act by increasing global histone acetylation and 
thereby reactivating epigenetically silenced genes. However, the accumulation of recent 
epigenetic studies has revealed that certain HDAC inhibitors have also been reported to 
decrease histone acetylation and down-regulate genes (Rada-Iglesias et al. 2007). Thus, 
HDAC inhibitors can both increase and decrease gene transcription (Drummond et al. 2005; 
Reid et al. 2005; Rai et al. 2008), and this may include up-regulation of certain HDACs 
themselves (Reid et al. 2005).  
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Recent studies of Sirt1 have revealed that it also deacetylates the peroxisome 
proliferator-activated receptor gamma (PPAR-γ) (Picard et al. 2004) and its transcriptional 
coactivators PPAR-γ coactivator-1α (PGC-1α) (Nemoto et al. 2005; Rodgers et al. 2005; 
Lagouge et al. 2006), which regulate a wide range of metabolic activities. Furthermore, in a  
recent study using human fibroblasts it was revealed that PGC-1α expression was 
downregulated when the FXN expression was specifically inhibited by shRNA (Coppola et al. 
2009) and vice versa (Marmolino et al. 2010). This indicates the likelihood that a direct 
mechanism may exist between PGC-1α and FXN expression. In addition, increased FXN 
expression was achieved by the treatment of PPAR-γ agonist compounds in FRDA cells 
(Marmolino et al. 2009). In this scenario, consistent with our data, it has been suggested that 
Sirt1 inhibitors such as sirtinol, splitomicin and nicotinamide presumably increase acetylation 
of PGC-1α by inhibiting Sirt1 activity, thereby increasing the PGC-1α function, which in turn 
can increase FXN expression.  
However, there are significant barriers to using Sirt1 inhibitors for FRDA therapy. 
Firstly, the yeast Sir2p protein, a homologue of Sirt1, extends the life span in yeast 
(Kaeberlein et al. 1999) raising the concern that inhibition of Sirt1 may shorten the lifespan 
in humans. In contrast, Chua et al. (2005) has showed that Sirt1 actually limits the life span in 
mammals in response to genotoxic stress. In addition, it could be possible that HDAC 
inhibition may lead to inappropriate expression of other genes, which may be quite 
deleterious.  
Recently, high throughput chromatin immunoprecipitation (ChIP) experiments have 
shown that HDAC inhibitors can, somewhat surprisingly, elicit decreases of histone 
acetylation rather than the expected increases of histone acetylation (Rada-Iglesias et al. 
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2007). Although we have not yet quantified the frataxin protein levels following treatment(s) 
with HDAC inhibitors, it was clear that certain HDAC inhibitors have also been able to 
increase protein levels by enhancing stability (Garbes et al. 2009) or conversely decrease 
protein levels by suppressing translation (Kawamata et al. 2007). Furthermore, HDAC 
inhibitors also have the capability of affecting the acetylation status of non-histone proteins 
including transcription factors and transcription co-regulators (Butler and Bates 2006). 
Further studies will be required to uncover any such mechanisms of action of Sirt1 inhibitors 
with regard to frataxin expression. 
So far, our analysis of HDAC inhibitors has focused on their potential to upregulate 
FXN mRNA expression. Therefore, future investigations should be performed to characterize 
the potential effects of HDAC inhibitors at the post-transcriptional level and their effect on 
local histone modifications in the FXN gene. To begin with, frataxin protein quantification 
and ChIP analysis using antibodies specific for individual histone modifications (e.g. H3K9ac, 
H4K12ac, H4K16ac and H3K9me3) should be performed. DNA methylation alterations, as 
secondary effects, should also be considered either by “bisulfite sequencing” or 
“methylscreen” approaches. 
In conclusion, all of our results clearly confirm that HDAC inhibitors are able to 
upregulate the FXN expression, particularly nicotinamide. Therefore, a future in vivo study 
with nicotinamide will be performed to monitor the efficacy of such compounds in long term 
studies. Although we obtained some encouraging results with human fibroblasts using HDAC 
inhibitors, the FXN levels did not seem to be increased as high as they were in mouse cells. 
Therefore, to investigate the upregulation of FXN expression in human cell lines more 
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efficiently, further studies are in progress using drug concentrations on either side of the 
optimal concentration found in mouse fibroblasts.  
Finally, the GAA repeat sizes within our mouse cells  are comparatively small (90 to 
200) and longer GAA repeats in FRDA patients are associated with a more severe phenotype 
and greater histone modifications (Saveliev et al. 2003; Rai et al. 2008; Soragni et al. 2008). 
Therefore, for future in vivo or in vitro studies the use of a model containing larger GAA 
repeats is of paramount importance and this will hopefully be achieved soon in our 
laboratory as studies are ongoing to develop such an FRDA model.  
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5.1 -  RGFA 136 therapeutic testing in FRDA mice 
5.1.1 - Introduction 
 It is essential to understand the mechanism of GAA-induced inhibition of FXN gene 
transcription for the consideration of future FRDA therapy.  Previous studies have implicated 
epigenetic changes, including increased DNA methylation of specific CpG sites upstream of 
the GAA repeat and histone modifications in regions flanking the GAA repeat that are both 
consistent with transcription inhibition (Herman et al. 2006; Greene et al. 2007). HDAC 
inhibitors are a structurally diverse group of compounds that are believed to act by 
increasing global histone acetylation and thereby reactivating epigenetically silenced genes, 
although some HDAC inhibitors have been reported to decrease histone acetylation and 
down-regulate genes (Rada-Iglesias et al. 2007). Thus far HDAC inhibitors have primarily 
been used in the treatment of various human cancers (Monneret 2005; Cang et al. 2009; 
Prince et al. 2009).  
 We have generated a GAA repeat expansion mutation-based mouse model of FRDA 
in a null mouse frataxin background, designated YG8 (Al-Mahdawi et al. 2006). Although the 
YG8 mice do not appear to show any marked reduction of FXN mRNA or frataxin protein 
compared to wild type mice, they show decreased frataxin mRNA and protein levels 
compared to Y47 mice that contain a normal-sized GAA FXN transgene (Al-Mahdawi et al. 
2008). Furthermore, YG8 mice also display progressive functional FRDA-like deficits, 
including impaired coordination ability, together with biochemical and histopathological 
features consistent with FRDA (Al-Mahdawi et al. 2006). In addition, YG8 rescue mice exhibit 
an FRDA-like molecular disease phenotype that includes intergenerational and somatic 
instability of the GAA repeat expansion mutation (Al-Mahdawi et al. 2004; Clark et al. 2007), 
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together with increased DNA methylation, reduced histone H3 and H4 acetylation and 
increased di- and trimethylated H3K9 at the FXN upstream GAA region (Al-Mahdawi et al. 
2008). Therefore, we consider YG8 mice to be a suitable mouse model in which to 
investigate potential FRDA therapies. 
Although encouraging results have been obtained using HDAC inhibitors in vitro by 
ourselves (in chapter 4) or others (Herman et al. 2006), and in vivo pilot studies (Rai et al. 
2008; Rai et al. 2010) using mouse models (KIKI), the lack of long-term studies has been a 
drawback in understanding the long-term efficacy of these compounds. Therefore, initial 
long term studies were performed on our FRDA YAC transgenic mice with the class I HDAC 
inhibitor 106. After the 106 treatment period, we observed increased histone H3 and H4 
acetylation in brain, consistent with the previous observation in acute FRDA KIKI mouse 
studies (Rai et al. 2008) that 106 can cross the blood-brain barrier to exert its effect. In 
addition, we identified general 106-induced increases in brain frataxin expression, together 
with improved motor coordination performance, both beneficial effects for FRDA therapy (R. 
Mouro Pinto, PhD thesis). 
Recent investigations have determined that 106 has a slow and potent inhibitory effect 
on class I HDACs, particularly on HDAC3 (Chou et al. 2008). Thus it is possible that specific 
inhibition of HDAC3 may have a significant impact on the expression of many genes other 
than FXN. Therefore, novel formulations of 106 are currently being developed in order to 
improve the specificity and potency (Hu et al. 2009). As a result, two derivatives of 106, 
designated RGFA 136 and RGFP 109, have recently been generated and subsequently used in 
our FRDA YAC transgenic mice.  
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5.1.2 - Materials and methods 
5.1.2.1 - RGFA 136 structure and drug preparation 
RGFA 136, N-(6-(2-amino-4-fluorophenylamino)-6-oxohexyl)-4-methylbenzamide, is a 
novel pimelic diphenylamide compound and structurally similar to HDAC inhibitor 106 
(Figure 5.1).  
 
 
Figure 5.1 - Chemical structure of RGFA 136  
 
The IC50 and Ki values of RGFA 136 as determined by purified recombinant HDAC 
enzymes with a fluorescent substrate indicated that the IC50 values of RGFA 136 for HDAC1 
and HDAC3 are 1.14µM and 560nM, respectively (Rai et al. 2010). The Ki (dissociation 
constant) values of RGFA 136 were expressed as a ratio of HDAC1/HDAC3 activity and 
mentioned in Table 5.1. RGFA 136 was synthesized and made available to us by Repligen 
Corporation (USA). The drug was provided in the form solid HCl powder and stored at -80°C 
until required to use. 
 
Table 5.1 - Kinetic properties of RGFA 136   
IC50 HDAC1 1.14µM 
IC50 HDAC3 560nM 
Ki HDAC1 630nM 
Ki HDAC3 196nM 
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5.1.2.2 - Formulation of the drug 
All the drug formulations were carried out according to the manufacturers’ 
recommendations and were freshly prepared in a weekly basis.  Initially, 200mg of RGFA 136 
was weighed and resuspended in 1 ml of DMSO (prewarmed at 37°C). Then, the required 
amount of diluent (20% glycerol, 20% PEG 400, 20% propylene glycol and 100mM acetate 
buffer) was added to the solution to make a final volume of 20ml drug solution (10mg/ml 
stock). A placebo/vehicle solution was also prepared in the same way by mixing 1ml of 
DMSO and 19ml of diluent without drug. Both drug and vehicle solutions were stored at 4°C.  
 
5.1.2.3 - Study design: drug administration and sample collection 
A long term study with RGFA 136 was performed on WT and YG8 rescue mice. The 
average ages of the mice subjected to this treatment were 3-4 months of old. 10 WT mice 
and 20 YG8 rescue mice were used in each group (vehicle and drug) (Table 5.2) and all the 
mice were matched to their age, sex and initial functional studies. RGFA 136 (50mg/kg/d and 
150mg/kg/d) has previously been administered subcutaneously to KIKI mice in a pilot study 
without any toxic effects (Rai et al. 2010). We wanted to determine if this lack of acute 
toxicity could be maintained throughout a long-term RGFA 136 dosing regimen. Therefore, 
we injected the mice with 50mg/kg RGFA 136 (10mg/ml) 5 times per week. A corresponding 
volume of vehicle solution was administered to the control group of mice. Such long-term 
administrations of 50mg/kg RGFA 136 were well tolerated. No overt toxicity was observed in 
any of the mice given subcutaneous dosing throughout the entire 5-month period of this 
study.  
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After treatment, several tissues were collected from the drug- and vehicle-treated 
mice for molecular biology, biochemistry and histological analysis. It is important to note 
that the whole RGFA 136 study was repeated to validate our findings and very consistent 
results were obtained (see appendix B).  
 
 
Table 5.2 - Long term Study design of RGFA 136 in WT and YG8 rescue mice 
Group Genotype Male Female 
Vehicle 
WT 5 5 
YG8 R 10 10 
RGFA 136 - 50mg/kg 
WT 5 5 
YG8 R 10 10 
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5.1.3 - Results 
5.1.3.1 - Functional studies during the drug treatment 
Functional studies such as weight, rotarod, locomotor and beam breaker 
measurements were taken just before the start of the drug treatment and were repeated on 
a monthly basis until completion of the treatment. All procedures were carried out in 
accordance with the UK Home Office ‘Animals (Scientific Procedures) Act 1986’. The analysis 
of functional data was measured as fold change taking the initial value as 1 (Table 5.3). 
 
Table 5.3 - Absolute values of functional data (RGFA 136). 
Parameter Group Initial Value Final Value 
Weight (g) 
WT vehicle 27.4 34.9 
WT RGFA 136 26.6 33.4 
YG8 Vehicle 27.3 33.3 
YG8 RGFA 136 26.0 30.8 
Rotarod (s) 
WT vehicle 284 276 
WT RGFA 136 293 331 
YG8 Vehicle 269 231 
YG8 RGFA 136 270 280 
Locomotor 
(no. squares in 30s) 
WT vehicle N/A N/A 
WT RGFA 136 N/A N/A 
YG8 Vehicle 9.60 8.70 
YG8 RGFA 136 9.50 10.90 
Average velocity 
(cm/s) 
WT vehicle 21.20 21.38 
WT RGFA 136 21.81 23.35 
YG8 Vehicle 21.55 21.15 
YG8 RGFA 136 21.49 24.42 
Ambulatory distance  
(cm) 
WT vehicle 527.11 366.96 
WT RGFA 136 628.84 411.95 
YG8 Vehicle 516.42 301.17 
YG8 RGFA 136 518.00 411.87 
Vertical counts 
WT vehicle 16.20 12.00 
WT RGFA 136 23.85 9.25 
YG8 Vehicle 14.85 6.10 
YG8 RGFA 136 16.05 16.87 
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Weight analysis 
At the start of drug treatment, vehicle and drug-treated mice showed similar weight 
distributions. However, considerable differences were noticed between the vehicle and 
drug-treated YG8 mice over time (Figure 5.2), but no obvious differences were detected in 
between vehicle-treated and drug-treated WT mice. Two-factor ANOVA with replication 
analysis confirmed that the age of the mice (time point) had a significant effect on the 
weight gain on both WT (F=6.1, p<0.001) and YG8 mice (F=6.3, p<0.001). However, a 
significant drug-induced effect (treatment) over the time point was identified in the YG8 
mice (F=5.01, p=0.02) (Table B.1). 
Subsequently, the difference in male and female weight gain/loss was also analysed 
within each group (Figure 5.3). Body weight analysis of male and female mice by two way 
ANOVA confirmed that the age of the mice (time point) and treatment effect was 
significantly different in both the YG8 male (F=10.7, 9.3,  p<0.001 and p<0.002) and YG8 
female mice (F=8.4, 3.8, P<0.001 and p=0.05). However, the WT male and female mice only 
displayed a significant effect with time point (F=18.4, 9.5, both p<0.001) (Figure 5.3A-B), but 
not with treatment, suggesting a specific effect of RGFA 136.  
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Figure 5.2 - Body weight analysis during treatment with RGFA 136 in WT and YG8 rescue 
mice showing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.3 - Body weight analysis of male and female mice during treatment with RGFA 
136. The average fold changes of weight in A) male and B) female WT and YG8 rescue 
mice are shown (error bars represents SEM). 
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Rotarod analysis 
The motor coordination performances of both WT and YG8 mice were determined by 
change in rotarod performance (fold change) at time points throughout the treatment 
period. Up to the 2-month time point, no detectable changes were observed between YG8 
vehicle and RGFA 136-treated mice. After this time, drug-treated YG8 mice showed a 
significant improvement in rotarod performance, compared to vehicle group (F=9.09, 
p=0.002) (Figure 5.4). Although performance then slightly declined, the RGFA 136-treated 
mice always performed better than the vehicle-treated controls. The similar effect was also 
observed between WT vehicle and drug-treated mice, with exceptions that the significant 
differences were found from the beginning (at 1 month) of the experiment and maintained 
throughout.  
 
 
Figure 5.4 - Rotarod analysis during treatment with RGFA 136 in WT and YG8 rescue mice 
showing mean fold change values of vehicle and drug-treated groups (error bars 
represents SEM). 
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Both WT and YG8 vehicle groups showed a similar rotarod performance with 
interchangeable values. Somewhat surprisingly, the rotarod performance of WT vehicle-
treated mice slightly declined (but not significantly) at some time points compared to YG8 
vehicle group. In fact, although the age of the mice (time point) produced a significant 
increase in rotarod performance over 5 month time point, a significant genotype effect (WT 
vs YG8) was observed in mice treated with RGFA 136 (F=22, p<0.001), but not in the vehicle-
treated mice (Table B.2). 
The possible differences between male and female mice within each group were then 
analysed and a significant gender effect on rotarod performance was detected. In the male 
mice, continual decline of rotarod performance in both vehicle-treated WT and YG8 mice 
was detected across time. However, treatment with RGFA 136 not only ameliorated the 
decline, but actually induced an initial improvement in rotarod performance at the 2-month 
time point, and the maximum rotarod performance (1.3-fold, p<0.001) was observed at the 
3-month time point in both WT and YG8 mice (Figure 5.5A). Although rotarod performance 
then slightly declined, significant changes were maintained between vehicle and RGFA 136-
treated mice throughout the treatment.  
In contrast, female YG8 vehicle-treated mice had a much worse rotarod performance 
compared to the female WT vehicle group, indicating a specific disease effect in the YG8 
female mice (Figure 5.5B). Two way ANOVA confirmed a significant gender effect on rotarod 
performance between WT (F=9.3, p<0.002) and YG8 mice (F=53.9, p<0.001) (Table B.5). In 
contrast, no major changes were observed between vehicle and RGFA 136-treated female 
WT and YG8 mice, indicating that there was little drug effect on these female mice.  
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Figure 5.5 - Rotarod analysis of male and female mice during treatment with RGFA 136. 
The average fold changes of rotarod performance in A) male and B) female WT and YG8 
rescue mice are shown (error bars represents SEM). 
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Locomotor analysis 
Locomotor activity analysis was performed only with YG8 mice for a direct comparison 
with previous RGFA 136 long-term studies, which did not contain any WT mice. Analysis 
confirmed significant increases in locomotor activity in the RGFA 136-treated YG8 mice 
compared to vehicle-treated mice (F=17.7, p<0.001) (Figure 5.6).  Especially from the 2-
month time point, RGFA 136-treated mice displayed a significant effect on locomotor 
performance and this persisted throughout the experiment.  
 
 
Figure 5.6 - Locomotor activity analysis during treatment with RGFA 136 in YG8 rescue 
mice showing mean fold change values of vehicle and drug-treated groups (error bars 
represents SEM). 
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Interesting results were found with male and female mice segregation analysis (Figure 
5.7). RGFA 136 had a more significant effect on locomotor activity in male mice (F=14.3, 
p<0.001) than female mice (F=5.8, p=0.016), compared to vehicle-treated mice.  
 
 
Figure 5.7 - Locomotor activity analysis of male and female mice during treatment with 
RGFA 136. The average fold changes of activity in male and female YG8 rescue mice are 
shown (error bars represents SEM). 
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5.1.3.2 - Open-field activity monitor 
All mice were subsequently analysed by using a more precise and sophisticated 
method for effective monitoring of the functional data, called ‘open-field activity monitor’ or 
‘beam-breaker’. By using open-field activity monitor functional measurements, such as 
average velocity, ambulatory distance and vertical counts of the mice were examined. 
 
 Average velocity 
The average velocity is defined as ‘the total distance covered divided by the total time 
elapsed’. This can be expressed either by meters per second (m/s) or inches/s. The average 
velocity was calculated by using beam breaker apparatus as mentioned earlier (section 2.5).  
In general, the average velocity was significantly improved throughout the study in 
YG8 RGFA 136-treated mice (F=28.9, p<0.001) compared to WT vehicle control mice (Figure 
5.8), suggesting a specific effect of RGFA 136 in YG8 mice. Although RGFA 136-treated WT 
mice performed better than the vehicle-treated WT mice, no statistical significant difference 
was observed at any time point tested compared to YG8 RGFA 136-treated mice.  
The gender specific analysis of average velocity showed that RGFA 136-treated YG8 
male and female mice showed an overall increased performance across the time compared 
to their respective vehicle-treated YG8 mice (F=15, 12.7, both p<0.001) (Figure 5.9A-B). In 
addition, two way ANOVA also confirmed that the genotype had a significant effect on 
average velocity (Table B.7-B.9). 
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Figure 5.8 - Average velocity analysis during treatment with RGFA 136 in WT and YG8 
rescue mice showing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.9 - Average velocity analysis of male and female mice during treatment with RGFA 
136. The average fold changes of average velocity in A) male and B) female WT and YG8 
rescue mice are shown (error bars represents SEM). 
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Ambulatory distance 
Ambulatory distance is the total distance covered by the mice within a specific time, 
expressed in terms of centimetres (cm). Regarding ambulatory distance, two factor ANOVA 
analysis revealed a significant increase in ambulatory distance in RGFA 136-treated YG8 mice 
(F=13.5, p<0.001) from the 2-month time point and persisting throughout the treatment, 
compared to vehicle-treated YG8 mice (Figure 5.10). Interestingly, no difference in 
ambulatory distance was identified between the drug-treated and vehicle-treated WT mice, 
suggesting a specific effect of RGFA 136 on YG8 mice.  
Subsequently, the effects of RGFA 136 on separate groups of male or female mice 
were analysed. Although male and female drug-treated YG8 mice showed better ambulatory 
distance compared to the vehicle-treated mice, significantly improved ambulatory distance 
was mainly seen in female mice (F=15.2, p<0.01) (Figure 5.11A).. However, none of these 
mice sustained their initial perform. A similar effect was also displayed by the WT mice. 
RGFA 136-treated WT female mice showed a constant decline in ambulatory distance 
compared to vehicle-treated WT mice (Figure 5.11B). Although the age of the mice (time 
point) had a significant effect on the ambulatory distance of both WT and YG8 mice 
(p<0.001), the drug-induced effect was mainly observed in the YG8 mice (genotype), 
suggesting a strong genotype effect on the performance.  
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Figure 5.10 - Ambulatory distance analysis during treatment with RGFA 136 in WT and YG8 
rescue mice showing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.11 - Ambulatory distance analysis of male and female mice during treatment with 
RGFA 136. The average fold changes of ambulatory distance in A) male and B) female WT 
and YG8 rescue mice are shown (error bars represents SEM). 
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Vertical counts 
The vertical counts are the continuous beam breaks reported by the ‘Z’ I/R array strips, 
which occurs when the mouse stands with the hind legs. A significant increase of vertical 
counts was detected in RGFA 136-treated YG8 mice (F=67.3, p<0.001) compared to YG8 
vehicle-treated mice, and this effect was maintained throughout the treatment period. 
However, the greatest variability was found at the 3-month time point where RGFA 136-
treated YG8 mice showed 3.2-fold increase (p<0.001) in vertical counts compared to vehicle 
group (Figure 5.12). Interestingly, the RGFA 136-treated WT mice showed a constant drop in 
vertical counts, even lower than the vehicle-treated WT mice. At the end of the treatment 
period, the vertical counts of RGFA 136-treated WT mice were reduced to 48%, compared to 
the WT vehicle-treated mice (F=8.6, p=0.004). However, the WT vehicle group always 
performed better than (p<0.05) the YG8 vehicle group.  
The analysis of separate male and female groups of mice demonstrated significantly 
increased number of vertical counts in both male (F=9.4, p=0.002) and female (F=78.2, 
p<0.001) RGFA 136-treated YG8 mice, compared to their respective vehicle control mice 
(Figure 5.13A-B). In contrast, RGFA 136-treated WT male and female mice showed reduced 
number of vertical counts compared to the WT vehicle-treated mice, suggesting a specific 
effect of RGFA 136 on YG8 mice. The comparison between the male and female RGFA 136-
treated WT mice has revealed that a significant drop in vertical counts was observed in the 
female mice compared to the male mice (F=48.2, p<0.001) (Table B.10). 
   
                                                                                                      Chapter 5 - Therapeutic approaches in vivo                                                                                     
   
      212 
 
Figure 5.12 - Vertical count analysis during treatment with RGFA 136 in WT and YG8 
rescue mice showing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.13 - Vertical count analysis of male and female mice during treatment with RGFA 
136. The average fold change of vertical count in A) male and B) female WT and YG8 
rescue mice are shown (error bars represents SEM). 
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5.1.3.3 - Investigation of FXN mRNA  
Following treatment with RGFA 136, the levels of FXN mRNA expression were 
measured in brain, cerebellum, spinal cord and DRG of the drug-treated and vehicle-treated 
mice by QRT-PCR analysis. The relative FXN expression level was quantified using mRNA-
specific primers for FXN, and mouse Gapdh was used as an endogenous control.  Relative 
quantification values were determined by the 2-ΔΔCt method using SDS 2.1 software (Applied 
Biosystems). Four mice from each group were used for the analysis (Table 5.4) and triplicate 
QRT-PCRs were performed for each sample. However, due to the limited availability of DRG, 
all of the DRGs from 4 mice were pooled and then subjected to the mRNA analysis.  
 
Table 5.4 - Number of mice investigated for the FXN mRNA quantification 
Group Genotype Brain 
Spinal 
cord 
DRG* Cerebellum 
Vehicle 
WT 4 4 4 4 
YG8 R 4 4 4 4 
    
  
RGFA 136 - 
50mg/kg 
WT 4 4 4 4 
YG8 R 4 4 4 4 
*-Collective DRGs from 4 mice 
 
The FXN QRT-PCR analysis following sub-cutaneous treatment with RGFA 136 in WT 
and YG8 mice revealed reduced FXN mRNA expression in the drug-treated WT mice 
compared to the vehicle-treated WT mice. Although the level of FXN expression was slightly 
reduced in the brain, spinal cord and cerebellum in RGFA 136-treated WT mice, significantly 
reduced level of FXN expression (23% lower than vehicle, P<0.05) was reported in the DRG 
(Figure 5.14). In contrast, FXN mRNA expression levels were slightly increased in all tissues 
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(except brain) from the RGFA 136-treated YG8 mice compared to the vehicle-treated mice. 
However, none of these increases reached a level of statistical significance (Figure 5.15).  
 
 
Figure 5.14 - Relative FXN mRNA levels in WT mice  following treatment with RGFA 136 in 
brain, spinal cord, DRG and cerebellum (n=4, *p<0.05, error bars ± 1 SEM). 
 
 
Figure 5.15 - Relative FXN mRNA levels in YG8 mice  following treatment with RGFA 136 in 
brain, spinal cord, DRG and cerebellum (n=4, error bars ± 1 SEM). 
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5.1.3.4 - Investigation of frataxin protein 
The comparative levels of human frataxin protein expression were determined from 
the brain tissues of WT and YG8 vehicle and RGFA 136 treated mice by western blot analysis 
(experiments were performed by Dr. Sahar Al-Mahdawi). The frataxin western blot analysis 
was carried out using an anti-frataxin rabbit polyclonal antibody (Santa Cruz) and the values 
were normalized to an anti-tubulin rabbit polyclonal antibody (Sigma). Densitometry was 
carried out using UN-SCAN-IT software (Silk Scientific Corporation) and in all cases n=4.  
The western blot analysis revealed no difference in frataxin protein levels between the 
vehicle and drug-treated YG8 mice. However, somewhat unexpectedly, the frataxin protein 
levels were significantly increased (1.8-fold, p<0.05) in RGFA 136-treated WT mice compared 
to vehicle-treated mice (Figure 5.16), suggesting a non-specific effect of RGFA 136.  
Furthermore, reduced FXN mRNA expression associated with increased frataxin protein in 
RGFA 136-treated WT mice (Figure 5.14 and Figure 5.16) suggests that RGFA 136 may 
perhaps act at a post-transcriptional level and has limited activity at the transcriptional level. 
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Figure 5.16 - Relative frataxin protein levels in brain tissues from WT and YG8 mice following 
treatment with RGFA 136. A) Western blot showing frataxin protein expression together 
with α-tubulin controls, and B) densitometry calculations of frataxin levels are shown for 
vehicle and RGFA 136-treated WT and YG8 rescue mice (n=3, error bars ± 1 SEM). 
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5.1.3.5 - Investigation of global histone acetylation changes 
To examine the effects of chronic subcutaneous dosing of RGFA 136 on global histone 
acetylation within the brain tissue of WT and YG8 rescue mice throughout the treatment, H3 
acetylation and H4 acetylation levels were determined by western blotting analysis 
(experiments were performed by Dr. Sahar Al-Mahdawi).  Histone H3 and H4 acetylation 
levels were determined using anti-acetyl-histone H3 (Upstate) and anti-acetyl-histone H4 
(Upstate) antibodies, respectively.  
The analysis, which was carried out on four mice from each of vehicle and drug-
treated groups, revealed no significant difference in H3 acetylated histone protein levels 
between the vehicle and RGFA 136-treated YG8 mice. However, in the WT mice reduced 
levels of acetylated H3 protein (81%) were observed in RGFA 136-treated mice compared to 
vehicle group. Regarding acetylated H4 protein, although no difference was seen between 
vehicle and drug-treated WT mice, H4 acetylated protein levels were significantly increased 
(32%, p<0.05) in the RGFA 136-treated YG8 samples compared to vehicle-treated YG8 mice 
(Figure 5.17).  
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Figure 5.17 - Relative levels of acetylated H3 and acetylated H4 histone proteins in WT and 
YG8 mice following treatment with RGFA 136 in brain tissues. A) Western blot showing 
acetylated H3 histones (H3ac) and acetylated H4 histones (H4ac) of YG8 rescue mice only. 
Densitometry calculations of H3ac and H4ac (B) are shown for vehicle-treated and RGFA 
136-treated WT and YG8 rescue mice (n=4, *p<0.05, error bars ± 1 SEM). 
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5.1.3.6 - Biochemical analysis following treatment with RGFA 136 
It has been reported that FRDA patient and mouse model tissues have exhibited 
impaired activities of several Fe-S containing enzymes, such as aconitase and MRC 
complexes I, II, and III (Bradley et al. 2000; Puccio et al. 2001).  Therefore, we have 
investigated whether RGFA 136 treatment is able to ameliorate such abnormalities in the 
YG8 mice by assessing aconitase enzyme activity in the brain tissues of WT and YG8 mice 
(experiments were performed by Dr. Sahar Al-Mahdawi).  
The assay consisted of four mice from each vehicle and drug-treated group and the 
experiment was repeated twice with values being expressed relative to citrate synthase 
activity. Our findings showed significantly decrease in aconitase activity in the YG8 vehicle 
mice by approximately 18% compared to WT vehicle mice (Figure 5.18) resembling with our 
previous results of aconitase activity in YG8 heart tissue (Al-Mahdawi et al. 2006). Although 
this level of activity slightly increased in RGFA 136-treated mice, no statistically significant 
effect was observed. Interestingly, the relative aconitase activity was decreased in the RGFA 
136-treated WT mice by approximately 16% (non-significant) compared to WT vehicle 
control mice (Figure 5.18) suggesting a specific effect of RGFA 136 in YG8 mice.  
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Figure 5.18 - The relative levels of aconitase in WT and YG8 mice brain tissues following 
treatment with RGFA 136 (n=4, ***p<0.001, error bars ± 1 SEM). 
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5.1.3.7 - Histological analysis following treatment with RGFA 136  
In order to find possible histopathology changes following treatment with RGFA 136, 
we have analysed DRG paraffin-embedded sections by standard H&E histology. This 
investigation was carried out only on two mice from each group. The selected mice were 
culled immediately after the treatment and fixed in the 4% paraformaldehyde.  The level of 
neurodegeneration was determined by counting the number of vacuoles within each DRG 
neuronal cell body and representing this as a percentage of all DRG cells counted. 
The histological analysis following treatment with RGFA 136 revealed a significant 
reduction (p<0.05) in the number of vacuoles in the DRG of RGFA 136-treated YG8 mice 
compared to vehicle-treated YG8 mice, suggesting that RGFA 136 has to certain extent 
successfully ameliorated the FRDA pathology by reducing the DRG neurodegeneration 
(Figure 5.20). Although the number of vacuoles was reduced in the RGFA 136-treated mice, 
it was not reduced sufficiently to reach the WT mice levels. We also found a significantly 
higher number of vacuoles in the DRG of YG8 vehicle mice compared to WT mice (Figure 
5.19), in agreement with our previous findings (Al-Mahdawi et al. 2006).  Interestingly, RGFA 
136-treated WT mice showed an approximately 4-fold increase in the number of vacuoles 
compared to vehicle-treated WT mice (Figure 5.20). These contradictory RGFA 136 effects, 
such as reduced DRG neurodegeneration in YG8 mice and increased DRG neurodegeneration 
in WT mice, indicate that RGFA 136 may have detrimental as well as beneficial effect, 
although the overall effect in the YG8 disease state is beneficial. 
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Figure 5.19 - The paraffin embedded H&E stained DRG sections of WT and YG8 mice. 
Arrow heads indicate the position of vacuoles in the DRG cell bodies (40X). 
 
  
Figure 5.20 - The level of DRG neurodegeneration following treatment with RGFA 136 
(n=2, ***p<0.0001, *p<0.05, error bars represents SEM). 
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5.2 -  RGFP 109 therapeutic testing in FRDA mice 
5.2.1 - Introduction 
In an effort to further improve the pharmacological profile of HDAC inhibitors as a 
potential therapy for FRDA, we have investigated several HDAC inhibitors in vitro and in vivo.  
The recently described RGFA 136 has displayed promising results in long term in vivo studies. 
Therefore, we have investigated the efficacy and toxicity of the other derivative of 106, RGFP 
109, in our FRDA YAC transgenic mice. A previous study using RGFP 109 in FRDA patients 
PBMCs and KIKI mice indicated a significant increase in frataxin mRNA, protein and global 
histone acetylation of H3 and H4 histone proteins (Rai et al. 2010). In the same study, the 
lack of effect of RGFP 109 on expression levels in wild type mice again indicated specificity of 
RGFP 109 towards GAA repeat expansion-containing FXN sequence.  
Treatment of FRDA KIKI mice with 150mg/kg RGFP 109 subcutaneously showed RGFP 
109 to be non-toxic and able to cross the blood-brain barrier, as determined by increases in 
FXN mRNA and acetylation of histone H3 and H4 proteins in mouse brain tissue (Rai et al. 
2010).  Thus, many of the outcomes from short-term treatments with the HDAC inhibitor 
RGFP 109 indicated that this compound should be investigated further for long-term FRDA 
therapy. Therefore, this project aimed to examine both the short-term and long-term 
efficacy of HDAC inhibitor RGFP 109 in the FRDA YAC transgenic mice.  
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5.2.2 - Materials and methods 
5.2.2.1 - RGFP 109 structure  
RGFP 109, N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide, is also a 
novel pimelic diphenylamide compound and structurally similar to HDAC inhibitor RGFA 136 
and 106 (Figure 5.21).  
 
Figure 5.21 - The chemical structure of RGFP 109.  
 
Similar to HDAC inhibitor RGFA 136, the Ki and IC50 values for RGFP 109 were also 
identified and expressed as a ratio of HDAC1/HDAC3 by using recombinant HDAC enzymes 
with a fluorescent substrate. This finding has revealed RGFP 109 shown to have doubled the 
Ki value and reduced IC50 value compared to RGFA 136 (Table 5.5) (Rai et al. 2010), indicating 
that RGFP 109 is more effective even with small concentrations of the drug.  
 
Table 5.5 - Kinetic properties of RGFP 109   
IC50 HDAC1 60nM 
IC50 HDAC3 50nM 
Ki HDAC1 32nM 
Ki HDAC3 5nM 
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5.2.2.2 - Formulation of the drug 
RGFP 109 was also synthesized and provided to us by Repligen Corporation (USA). The 
drug was supplied in the form solid HCl powder and stored at -80°C until required to use. All 
the drug formulations were carried out according to the manufacturer’s recommendations 
and were freshly prepared in a weekly basis.  RGFP 109 was administered in two different 
concentrations, such as 100mg/kg/day and 150mg/kg/day. 
 
Preparation of 150mg/kg/day of RGFP 109 
At first, 600mg of RGFP 109 was weighed and resuspended in 1ml of DMSO 
(prewarmed to 37°C), followed by 19ml of diluent (prewarmed to 37°C) resulting in 30mg/ml 
RGFP 109 solution and stored at 4°C until required to use. The diluent for RGFP 109 is the 
same as RGFA 136 diluent (see 5.1.1.2).   
 
Preparation of 100mg/kg/day of RGFP 109 
To begin with, the drug stock (30mg/ml) prepared above was diluted 1.5 times with 
diluent resulting in 20mg/ml RGFP 109 solution and stored at 4°C until required to use. A 
placebo/vehicle solution was also prepared in the same way by mixing 1ml of DMSO and 
19ml of diluent without drug. Both drug and vehicle solutions were stored at 4°C.  
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5.2.2.3 - Study design: drug administration and sample collection 
Preliminary studies 
Initial short-term studies were performed only on YG8 rescue mice exploring sub-
cutaneous injection of RGFP 109 with two different concentrations, 15mg/kg and 50mg/kg, 
along with a vehicle group. In each group 10 mice were included with an average age of 6-7 
months old and treatment consisted of 3 consecutive daily doses of RGFP 109 sub-cutaneous 
injection. The drug was prepared in dilutions of 10mg/ml for 50mg/kg concentration and 
3mg/ml for 15mg/kg concentration of RGFP 109. A corresponding volume of diluent was 
injected into vehicle control YG8 mice. The RGFP 109 compound was found to be well 
tolerated, with no mouse deaths or adverse effects noticed. 
 
Long-term studies 
Based on the previous study with RGFA 136, we have carried out treatment of RGFP 
109 on groups of 20 YG8 mice and 10 WT mice (Table 5.6). At the start of the experiment, 
the average age of the mice was in between 3.4 to 3.9 months. All mice were matched by 
their age, sex and initial functional studies. As the short-term sub-cutaneous administration 
of RGFP 109 into our FRDA YAC transgenic mice and also into KIKI mice (Rai et al. 2010) have 
previously been well tolerated, we wanted to find if this could be maintained in a long term 
dosing regimen. Therefore, we injected the mice subcutaneously with 100mg/kg 5 times per 
week or 150mg/kg 3 times per week. A corresponding volume of vehicle solution was 
administered to a control group. Such long-term administrations of 100mg/kg or 150mg/kg 
of RGFP 109 were well tolerated. No toxicity was observed in any of the mice given 
subcutaneous dosing throughout the entire 5-month period of this study.  
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Table 5.6 - Long term Study design of RGFP 109 in WT and YG8 rescue mice 
Group Genotype Male Female 
Vehicle 
WT 5 5 
YG8 R 10 10 
    
RGFP 109 100mg/kg 
WT 5 5 
YG8 R 10 10 
    
RGFP 109 150mg/kg WT - - 
 YG8 R 10 10 
  
At the end of the treatment in both short-term and long-term treatments, the mice 
were culled and all the required tissues were collected and processed for molecular biology, 
biochemistry and histological analysis.  
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5.2.3 - Results - preliminary short-term RGFP 109 studies  
5.2.3.1 - Investigation of FXN mRNA expression 
Short-term preliminary studies were performed on a relatively small number of YG8 
rescue mice (n=10). Following 3 consecutive sub-cutaneous injections of RGFP 109 the level 
of FXN mRNA expression was investigated in the brain and cerebellum tissues of vehicle-
treated and both concentrations of RGFP 109 treated samples by QRT-PCR. This analysis 
revealed an increased FXN expression in 15mg/kg treated mice by approximately 34% and 
31% in the brain and cerebellum tissues, respectively compared to vehicle control mice 
(Figure 5.22). In contrast, the FXN levels were slightly reduced (~6%-10%) with 50mg/kg of 
RGFP 109, suggesting that a high concentration of the drug is not beneficial on FXN mRNA 
expression. 
 
Figure 5.22 - Relative FXN mRNA quantification in YG8 rescue mice following short-term 
treatment of vehicle and RGFP 109 in YG8 rescue mice (error bars represents SEM). 
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5.2.3.2 - Investigation of frataxin protein 
 Subsequently, we also quantified the amount of frataxin protein in YG8 brain samples 
by western blot analysis (experiments were performed by Dr. Sahar Al-Mahdawi). The sub-
cutaneous injection of RGFP 109 revealed a slight (but not significant) increase (17%) of 
frataxin protein in mice treated with 50mg/kg concentration of the drug. However, with low 
concentration of the drug (15mg/kg) the protein levels dropped by approximately 12%. 
These contradictory results displayed by RGFP 109 such as mice expressing more FXN mRNA 
showing reduced frataxin protein and vice versa have questioned the exact effect of this 
compound. Further studies on KIKI mice and advice from Repligen Corporation suggested 
that doses of RGFP 109 higher than 50mg/kg may be more effective. Therefore, we have 
investigated RGFP 109 with even higher concentrations of 100mg/kg and 150mg/kg per day 
on our subsequent long-term studies. 
 
Figure 5.23 - Relative frataxin protein quantification in YG8 rescue mouse brain tissue 
following short-term treatment of vehicle and RGFP 109 in YG8 rescue mice (error bars 
represents SEM). 
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5.2.4 - Results - long-term RGFP 109 studies 
5.2.4.1 - Functional studies during the drug treatment 
The functional studies, such as weight, rotarod analysis, locomotor activity, and beam 
breaker measurements were taken just before the start of the treatment and repeated 
monthly during the entire 5-month RGFP 109 treatment period. As mentioned earlier that all 
functional data were measured as fold change considering the initial value as 1 (Table 5.7). 
 
 
Table 5.7 - Absolute values of functional data (RGFP 109). 
Parameter Group Initial Value Final Value 
Weight (g) 
WT vehicle 27.4 34.9 
WT RGFA 109 (100mg/kg) 27.1 32.9 
YG8 Vehicle 27.3 33.3 
YG8 RGFP 109 (100mg/kg) 28.9 35.1 
YG8 RGFP 109 (150mg/kg) 27.3 31.7 
Rotarod (s) 
WT vehicle 284 276 
WT RGFA 109 (100mg/kg) 303 296 
YG8 Vehicle 269 231 
YG8 RGFP 109 (100mg/kg) 269 236 
YG8 RGFP 109 (150mg/kg) 265 251 
Average velocity 
(cm/s) 
WT vehicle 21.20 21.38 
WT RGFA 109 (100mg/kg) 22.20 21.80 
YG8 Vehicle 21.55 21.15 
YG8 RGFP 109 (100mg/kg) 22.85 19.93 
YG8 RGFP 109 (150mg/kg) 22.80 21.20 
Ambulatory distance 
(cm) 
WT vehicle 527.11 366.96 
WT RGFA 109 (100mg/kg) 612.55 475.35 
YG8 Vehicle 516.42 301.17 
YG8 RGFP 109 (100mg/kg) 367.00 256.74 
YG8 RGFP 109 (150mg/kg) 401.00 242.70 
Vertical counts 
WT vehicle 16.20 12.00 
WT RGFA 109 (100mg/kg) 26.20 16.69 
YG8 Vehicle 14.85 6.10 
YG8 RGFP 109 (100mg/kg) 14.44 5.41 
YG8 RGFP 109 (150mg/kg) 14.18 6.05 
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Weight analysis 
All mice were showed similar weight distributions at the start of the experiment. 
However, when the drug treatment progressed, significant variations in weights were 
observed between the groups. In general, the WT vehicle mice showed significantly 
increased weight gain compared with the remaining groups. The analysis of body weight by 
two way ANOVA revealed that age of the mice (time point) had a significant effect on weight 
gain on both WT (F=3.5, p=0.006) and both YG8 groups of mice (F=5.2, 7.4, both p<0.001, 
Table B.11) (Figure 5.24). However, significantly reduced weight gain during the treatment 
was mainly seen in YG8 mice treated with 150mg/kg of RGFP 109 compared to vehicle-
treated YG8 mice (F=4.7, p<0.001).  
The weight analysis of male and female mice demonstrated a similar effect between 
the male and female mice showing a significant effect in weight gain over the time point 
(p<0.001). However, during the treatment significantly less weight gain was mainly observed 
in WT female mice (F=4.8, p=0.033) (Table B.13) and RGFP 109 (150mg/kg)-treated YG8 male 
mice (F=6.8, p=0.01) (Figure 5.25A-B).  
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Figure 5.24 - Body weight analysis during treatment with RGFP 109 in WT and YG8 rescue 
mice comparing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.25 - Body weight analysis of male and female mice during treatment with RGFP 
109. The average fold changes of weight in A) male and B) female WT and YG8 rescue 
mice are shown (error bars represents SEM). 
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Rotarod analysis 
The motor coordination performances of RGFP 109-treated WT and YG8 mice were 
determined by rotarod analysis at time points throughout the treatment period. The vehicle-
treated WT and YG8 mice exhibited a decline in rotarod performance, which was 
significantly ameliorated (WT p=0.004 and YG8 both p<0.001) (Table B.11) by both 
concentrations of RGFP 109 treatment (Figure 5.26). Although both the vehicle-treated mice 
(WT and YG8) showed reduced rotarod performance, at some time-points the WT mice 
displayed somewhat reduced rotarod performance compared to YG8 vehicle (not 
significant).  
 Subsequently, we have also analysed the possible differences between male and 
female mouse rotarod performances. This revealed a drastic decline in rotarod performance 
in male WT vehicle control mice, significantly lower than that of YG8 vehicle group (F=15.6, 
p<0.001). In contrast, female WT vehicle-treated mice showed improved rotarod 
performance, significantly higher than all drug-treated mice (F=35.9, p<0.001), suggesting 
that the overall drop in rotarod performance was originally due to the male mice (Figure 
5.27A-B). Remarkably, a constantly improved rotarod performance was observed in both 
male (F=0.65, p<0.05) and female (F=20, p<0.001) RGFP 109 (100mg/kg)-treated YG8 mice, 
compared to their respective vehicle-treated controls (Figure 5.27A-B). However, with RGFP 
109 (150mg/kg) treatment, significantly increased rotarod performance was seen only in the 
female mice (F=8.6, p<0.001), suggesting a gender specific effect of this compound. In fact, 
two way ANOVA confirmed a significant genotype effect over the time point on rotarod 
performance following RGFP 109 treatment only in male mice (F=6.4, p=0.011, Table B.12). 
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Figure 5.26 - Rotarod analysis during treatment with RGFP 109 in WT and YG8 rescue mice 
comparing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.27 - Rotarod analysis of male and female mice during treatment with RGFP 109. 
The average fold changes of rotarod in A) male and B) female WT and YG8 rescue mice are 
shown (error bars represents SEM). 
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5.2.4.2 - Open-field activity monitor 
Average velocity 
The average velocity during the treatment with RGFP 109 did not reveal any obvious 
changes between the vehicle and drug-treated WT mice (Figure 5.28).  However, RGFP 109 
(150mg/kg)-treated YG8 mice showed significantly reduced average velocity compared to 
the YG8 vehicle control group (F=4.1, p=0.042). The analysis by two way ANOVA confirmed 
that neither the time point nor the genotype had a significant effect on the average velocity 
performance (Table B.16-B20). Although slight changes were observed between the vehicle 
and drug-treated male and female mice, none of them reached a significant effect (Figure 
5.29A-B). However, a significantly gender specific effect was mainly observed between the 
male and female WT mice (F=6.5, p=0.011) (Figure 5.29A-B). 
 
Figure 5.28 - Average velocity analysis during treatment with RGFP 109 in WT and YG8 
rescue mice comparing vehicle and drug-treated groups (error bars represents SEM). 
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Figure 5.29 - Average velocity analysis of male and female mice during treatment with 
RGFP 109. The average fold changes of average velocity in A) male and B) female WT and 
YG8 rescue mice are shown (error bars represents SEM). 
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Ambulatory distance 
 Both the YG8 groups of mice treated with RGFP 109 (100mg/kg and 150mg/kg) 
showed significantly increased ambulatory distance compared to the YG8 vehicle control 
mice (F=22.2, 19.8, both p<0.001) (Figure 5.30). However, none of these mice sustained their 
initial levels of performance. Interestingly, no obvious changes were observed between the 
vehicle and drug-treated WT mice.  
 The analysis of male and female mice following treatment with RGFP 109 revealed 
that female mice displayed interesting results compared to male mice for both WT and YG8 
mice. In the female mice, both the vehicle groups (WT and YG8) showed constant decline in 
ambulatory distance and this was successfully ameliorated with RGFP 109 treatments (Figure 
5.31B). Although, RGFP 109 (150mg/kg)-treated YG8 female mice displayed significantly 
improved ambulatory distance (F=26.3, p<0.001) compared to YG8 vehicle-treated mice, no 
significant effect in male mice was observed. In contrast, a significant improvement in 
ambulatory distance was observed in RGFP 109 (100mg/kg)-treated YG8 male (F=6.3, both 
p=0.01) and female mice (F=9.3, p=0.02) (Table B.18), suggesting that a low concentration of 
RGFP 109 is beneficial (Figure 5.31A-B). Two way ANOVA confirmed that the age of the mice 
(time point) had a significant effect on ambulatory distance in both male and female YG8 
mice (Table B.18).  
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Figure 5.30 - Ambulatory distance analysis during treatment with RGFP 109 in WT and YG8 
rescue mice comparing vehicle and drug-treated groups (error bars represents SEM). 
 
  
 
Figure 5.31 - Ambulatory distance analysis of male and female mice during treatment with 
RGFP 109. The average fold changes of ambulatory distance in A) male and B) female WT 
and YG8 rescue mice are shown (error bars represents SEM). 
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Vertical counts analysis 
Regarding the vertical counts, WT and YG8 vehicle-treated mice displayed significantly 
different performances. The YG8 vehicle-treated mice showed considerable reduction in 
vertical counts compared to the WT vehicle-treated control mice (F=24.5, P<0.001) (Figure 
5.32), indicating an FRDA-like disease effect. No evidence of a drug effect was detected with 
any concentration of RGFP 109 used in the YG8 mice.  
However, interesting results were displayed by female mice when the data was 
analysed for male and female mice. The WT male vehicle mice displayed an overall increased 
number of vertical counts, even higher than the initial performance, and higher than the 
remaining three groups (Figure 5.31A). In the female mice, a significant effect of the drug 
was observed in the YG8 mice treated with RGFP 109 (150mg/kg) (F=9.1, p=0.002). However, 
the performance of these mice reduced to the level of vehicle-treated female mice when the 
treatment reached the 4-month time point (Figure 5.31B).  
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Figure 5.32 - Vertical count analysis during treatment with RGFP 109 in WT and YG8 
rescue mice comparing vehicle and drug-treated group (error bars represents SEM). 
 
  
 
Figure 5.33 - Vertical count analysis of male and female mice during treatment with RGFP 
109. The average fold changes of vertical count in A) male and B) female WT and YG8 
rescue mice are shown (error bars represents SEM). 
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5.2.4.3 - Investigation of FXN mRNA following treatment with RGFP 109 
FXN mRNA expression levels following treatment with RGFP 109 were investigated in 
brain, spinal cord, DRG and cerebellum tissues of vehicle and drug-treated WT and YG8 mice 
by QRT-PCR. In general, the FXN levels were reduced in WT RGFP 109 (100mg/kg) treated 
mice compared to the vehicle-treated mice by approximately 76%, 78% and 71% in the 
brain, DRG and cerebellum tissues, respectively (Figure 5.34). These findings suggest that 
RGFP 109, to some extent, had a detrimental effect in the normal mice. In contrast, a slight 
increase (not significant) in FXN expression (121%) was noticed in the spinal cord tissues of 
WT RGFP 109 (100mg/kg) treated mice.   
No significant drug-induced effects were observed in the YG8 mice tissues tested. 
However, rather surprisingly, reduced FXN mRNA expression levels were obtained in the 
brain tissues of mice treated with both concentrations of RGFP 109. In addition, the 
cerebellum tissues also showed a decrease in FXN levels in the RGFP 109 (150mg/kg) treated 
mice to approximately 77% of those observed in the vehicle-treated cerebellum tissues 
(Figure 5.35). We also assessed the brain Gapdh levels, but detected no significant changes 
between the vehicle-treated and drug-treated mice (Figure B.6). 
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Figure 5.34 - Relative FXN mRNA levels in WT mice  following treatment with RGFP 109 in 
brain, spinal cord, DRG and cerebellum tissues (n=4, *p<0.05, error bars ± 1 SEM). 
 
 
Figure 5.35 - Relative FXN mRNA levels in YG8 rescue mice  following treatment with RGFP 
109 in brain, spinal cord, DRG and cerebellum tissues (n=4, error bars ± 1 SEM). 
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5.2.4.4 - Investigation of frataxin protein  
The relative levels of frataxin protein expression were investigated from the brain 
tissues of WT and YG8 mice by western blot analysis. The frataxin western blot analysis was 
carried out using an anti-frataxin rabbit polyclonal antibody (Santa Cruz) and the values were 
normalized to an anti-tubulin rabbit polyclonal antibody (Sigma) (experiments were 
performed by Dr. Sahar Al-Mahdawi). Densitometry was carried out using UN-SCAN-IT 
software (Silk Scientific Corporation). The western blot analysis, using 4 mice from each 
group, identified a significant increase in frataxin protein levels in both the YG8 groups 
treated with RGFP 109 (100mg/kg) and RGFP 109 (150mg/kg) compared to the WT vehicle 
group by approximately 1.6-fold (p<0.05) and 1.8-fold (p<0.001), respectively (Figure 5.36). 
Lesser increases in endogenous mouse frataxin levels were also seen in RGFP 109 
(100mg/kg)-treated WT mice, indicating a general frataxin-increasing effect of these drugs. 
No obvious changes were identified between the WT and YG8 vehicle groups. 
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Figure 5.36 - Relative frataxin protein levels in brain tissues from WT and YG8 mice 
following treatment with RGFP 109. A) Western blot showing frataxin protein expression 
together with α-tubulin controls, and B) densitometry calculations of frataxin levels are 
shown for vehicle and RGFP 109-treated WT and YG8 rescue mice (n=3-4, error bars ± 1 
SEM, *p<0.05, **p<0.01). 
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5.2.4.5 - Investigation of global histone acetylation changes 
In order to find the long-term effect of RGFP 109 on histone acetylation changes, we 
have investigated the changes in global histone protein levels by western blot analysis. The 
analysis was carried out on brain tissues from four mice from each group.  The western 
blotting analysis for global histone changes showed small decreases (non-significant) in both 
acetylated H3 and acetylated H4 protein of YG8 vehicle-treated mice compared with WT 
vehicle-treated mice (experiments were performed by Dr. Sahar Al-Mahdawi).  
Increased acetylated histone H3 protein levels were found in both RGFP 109-treated 
YG8 mice with increases of 52% and 41% higher than vehicle-treated YG8 mice, respectively 
(p<0.05 for RGFP 109 (150mg/kg)) (Figure 5.37). Acetylated H4 histone proteins showed 
non-significant increases of 14% and 36% higher than vehicle-treated YG8 mice in both of 
RGFP 109-treated YG8 mice, respectively (Figure 5.37). Overall, these results are consistent 
with RGFP 109 crossing the blood brain-barrier to cause global increases in histone 
acetylation. 
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Figure 5.37 - Relative levels of acetylated H3 and acetylated H4 histone proteins in WT and 
YG8 mice following treatment with RGFP 109 in brain tissues. A) Western blot showing 
acetylated H3 histones (H3ac) and acetylated H4 histones (H4ac) of RGFP 109 (100mg/kg)-
treated YG8 rescue mice. Densitometry calculations of H3ac and H4ac (B) are shown for 
vehicle-treated and RGFP 109-treated WT and YG8 rescue mice (n=3-4, *p<0.05, error bars 
± 1 SEM). 
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5.2.4.6 - Biochemical studies following treatment with RGFP 109 
Subsequently, we have also investigated the possible biochemical changes of 
aconitase enzyme activity following treatment with RGFP 109 in the brain tissues of WT 
(vehicle only) and YG8 mice. The aconitase assay showed significantly reduced levels of 
aconitase enzyme in the vehicle-treated YG8 mice to approximately 18% (p<0.001) of the WT 
vehicle control mouse levels. Treatment with RGFP 109 significantly increased the aconitase 
levels to 67% and 57% of WT vehicle levels in mice treated with 100mg/kg and 150mg/kg of 
RGFP 109, respectively (both p<0.001) (Figure 5.38). These levels are approximately 3.8 and 
3.2-fold higher than YG8 vehicle mice indicating beneficial effect of RGFP 109 on aconitase 
enzyme activity. 
 
 
 
Figure 5.38 - The relative levels of aconitase activity following treatment with RGFP 109 in 
WT (vehicle only) and YG8 mice (n=4, ***p<0.01, error bars ± 1 SEM). 
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5.2.4.7 - Histological analysis following treatment with RGFP 109 
In order to find whether the long-term treatment of RGFP 109 is able to ameliorate 
the FRDA-associated pathology of DRG neurodegeneration, we have analysed the DRG 
paraffin embedded sections by standard H&E staining. The levels of DRG neurodegeneration 
were determined by counting the number vacuoles in neuronal cell bodies as a percentage 
of the total number of DRG cells counted (Figure 5.19).  
 Subsequent analysis revealed that YG8 vehicle-treated mice showed an increased 
number of vacuoles in the DRG cells by approximately 19-fold higher than in the WT vehicle-
treated mice (p<0.001) (Figure 5.39), in agreement with our previous results (Al-Mahdawi et 
al. 2006). Treatment with RGFP 109 successfully ameliorated this FRDA-associated 
phenotype to a large extent by reducing the number of vacuoles significantly by 
approximately 5.2-fold (to 28% of YG8 vehicle values) and 5.4-fold (to 26% of YG8 vehicle 
values) with 100mg/kg and 150mg/kg, respectively (Figure 5.39). Although the number of 
vacuoles was significantly reduced with RGFP 109 treatments, none of the values have 
reached the WT level, so amelioration of the neurodegenerative disease effect is not 
complete.  
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Figure 5.39 - The level of DRG neurodegeneration in WT and YG8 rescue mice as 
quantified by the percentage of vacuole-containing DRG cells following treatment with 
RGFP 109 (n=2, ***p<0.001, error bars represents SEM). 
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5.2.5 - Discussion 
It has been shown that 98% of the FRDA patients have hyper-expanded GAA repeats in 
the intron 1 of the FXN gene, leading to reduced expression of frataxin (Campuzano et al. 
1996). Although the mechanisms by which the GAA repeat expansion leads to decreased 
levels of frataxin expression are currently not known, it is generally currently accepted that 
FRDA may be caused by a heterochromatin-mediated silencing effect of the FXN gene 
(Saveliev et al. 2003; Festenstein 2006). In support of this hypothesis, differential DNA 
methylation in FRDA patients accompanied by decreased levels of acetylated H3 and H4 
histone proteins were identified flanking the GAA repeats (Herman et al. 2006; Greene et al. 
2007; Al-Mahdawi et al. 2008).  
In addition, there is also evidence that the GAA repeat expansion may adopt abnormal 
non-B DNA structures (triplexes or “sticky DNA”) or DNA RNA hybrid structures that directly 
interfere with FXN gene transcription elongation (Grabczyk et al. 2007; Wells 2008). 
Therefore, any therapies aiming to target these consequences may prove to be of benefit. 
 Recently, epigenetic therapies using DNA demethylating agents and HDAC inhibitors 
have received considerable attention as potential therapeutics for cancer (Marks and 
Dokmanovic 2005) and for wide variety of neurological and neurodegenerative diseases 
(Kazantsev and Thompson 2008). 
In the present study we have demonstrated the in vivo feasibility of using two HDAC 
inhibitors, RGFA 136 and RGFP 109, in long-term sub-cutaneous dosing regimens to 
potentially activate the FXN gene and ameliorate the disease phenotype in a mouse model 
that recapitulates the genetic and epigenetic features of FRDA. Previous short-term studies 
using these two compounds had already demonstrated increased frataxin mRNA and protein 
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expression along with elevated levels of acetylated H3 and H4 histone proteins in the brain 
and heart tissues of KIKI mouse (Rai et al. 2010), indicating the ability of these two 
compounds to cross the blood-brain barrier.  
An initial long-term study with RGFA 136 and a short-term study with RGFP 109 
showed no signs of toxicity indicating the safe administration of these two compounds. 
Therefore, we have used the same sub-cutaneous regimen throughout the long-term RGFA 
136 and RGFP 109 treatments (5 months). Such long-term administration of RGFA 136 
(50mg/kg) or RGFP 109 (100mg/kg and 150mg/kg) were well tolerated. No apparent toxicity 
was observed in any of the mice given subcutaneous dosing throughout the entire 5-month 
period of this study. 
We previously reported that the WT mice have mean decreased weight gain compared 
to YG8 rescue mice (Al-Mahdawi et al. 2006). In contrast, the analysis of body weight by two-
way ANOVA in this present study detected increased weight gain in WT mice and this was 
significantly reduced in YG8 rescue mice in both RGFA 136 and RGFP 109 treatment groups. 
In particular, we found considerably less weight gain in RGFA 136- and RGFP 109 
(150mg/kg)-treated YG8 rescue mice throughout the treatment. The similar effect in body 
weight was also seen in male and female mice of RGFA 136 and RGFP 109 treatment groups. 
At this time the most likely explanation for such a discrepancy in weight gain/loss between 
WT and YG8 rescue mice is the fact that the initially reported WT mice were YG8 littermates 
of mixed CBA/C57BL6/J genetic background, whereas the WT mice used in this thesis were 
exclusively C57BL6/J. 
The additional weight loss observed in RGFA 136 and RGFP 109-treated YG8 mice may 
be due to several possible drug effects. One of the possibilities is that since FRDA is 
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associated with diabetes (Pandolfo 2003; Ristow et al. 2003), the YG8 mice are actually 
overweight, as previously reported (Al-Mahdawi et al. 2006). Treatment with either RGFA 
136 or RGFP 109 may perhaps reverse the diabetes effects (obesity), and consequently 
reduced weight gain is observed in the drug-treated YG8 mice compared to vehicle-treated 
YG8 mice. Additionally, HDAC inhibitors are likely to affect many genes that are involved in 
general body metabolism, with the overall effect being weight loss. 
The motor coordination performance as determined by rotarod analysis confirmed a 
significant drug-induced effect by both drugs, particularly with RGFA 136. Interestingly, we 
found a strong gender effect on the rotarod performance, which has not been previously 
reported. Although the rotarod performance was significantly increased in the drug-treated 
YG8 rescue male mice, it was also significantly increased in WT male mice, suggesting a non-
specific effect. Furthermore, no significant changes were detected between the WT vehicle 
and YG8 vehicle, indicating no overt FRDA-associated motor coordination deficit in these 
male mice. However, it is possible that a potential YG8 motor coordination deficit is masked 
by the weight differences between WT and YG8 male mice, with the heavier WT male mice 
performing worse on the rotarod due to an obesity problem and not a coordination 
problem. 
In contrast, YG8 female vehicle mice have shown reduced rotarod performance 
compared to WT vehicle mice and this reduction in rotarod performance was successfully 
ameliorated by both RGFP 109 treatments and no explicit difference was observed with 
RGFA 136. Therefore, treatment with 109 may prove beneficial to improve the ataxic motor 
coordination deficits associated with FRDA. Furthermore, as a consequence of these studies, 
it is proposed that YG8 female mice should be used for any future rotarod experiments 
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rather than using YG8 male mice, since they alone show a motor coordination deficit 
compared to WT mice. Locomotor activity was investigated only in the YG8 mice (RGFA 136 
only) and a significant drug-induced effect was observed in both male and female mice, 
suggesting that RGFA 136 is a potential therapeutic drug to improve locomotor deficits in 
FRDA.  
 The average velocity and ambulatory distance (measures of muscle strength and 
stamina) as determined by open-field monitor machine (beam-breaker) both showed 
significantly improved performances by RGFA 136 treatment. In comparison, 109 treatment 
had no effect on average velocity, but significantly improved ambulatory distance. Analyses 
of vertical counts (measures hind limb muscle strength) produced some interesting results. 
The YG8 vehicle-treated mice displayed continuous decline and significantly reduced number 
of vertical counts compared to WT vehicle control mice. Treatment with RGFA 136 not only 
ameliorated this decline, but actually induced significant improvement in vertical counts. A 
similar significant effect was also seen in male and female mice when analysed separately. 
No explicit effect of RGFP 109 was observed in the performance of vertical counts, although 
some improvement was observed in the separately analysed female mice.  Therefore, both 
RGFA 136 and RGFP 109 may prove to be beneficial in improving the muscle strength and 
stamina deficits associated with FRDA. 
In summary both drugs exhibited some improved performances with rotarod, manual 
activity or beam-breaker based functional measurements. RGFA 136 perhaps elicited the 
more substantial improvements, which were consistent with the previous study. 
Importantly, a strong gender effect was revealed, particularly with rotarod performance. 
Therefore, future rotarod analysis should only be carried out with YG8 female mice. In 
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addition, quite high levels of variability were observed within the same group (same gender) 
in these functional measurements. Therefore, more sensitive and accurate methods of 
functional measurements which are specifically designed to measure ataxia in mice such as 
the “parallel rod floor” apparatus (Kamens et al. 2005; Kamens and Crabbe 2007) should also 
be considered for any future experiments.  
After RGFA 136 and RGFP 109 treatments, we observed general decrease in FXN 
mRNA expression in drug-treated WT mice compared to vehicle-treated WT mice suggesting 
these drugs have a negative effect on normal mice. Surprisingly, although some slight  
increases in FXN mRNA expression were observed in the drug-treated YG8 mice, none of 
these values reached significant difference after 5 months of treatment, in contrast to 
results from a recent short-term study (Rai et al. 2010). In addition, no explicit difference in 
frataxin protein has been observed between RGFA 136-treated and vehicle-treated YG8 
mice. However, the frataxin protein levels were significantly increased in the RGFP 109 
treated YG8 mice with both 100mg/kg and 150mg/kg concentrations, suggesting RGFP 109 
may perhaps involve, as yet undetermined, post-transcriptional or translational levels.  
The discrepancies between RGFP 109-treated FXN mRNA and frataxin expression 
levels may be explained by the fact that HDAC inhibitors can both increase and decrease 
gene transcription (Drummond et al. 2005; Reid et al. 2005; Rai et al. 2008), and this may 
include up-regulation of certain HDACs themselves (Reid et al. 2005). In addition, certain 
HDAC inhibitors have also been shown to increase protein levels by enhancing stability 
(Garbes et al. 2009) or conversely decrease protein levels by inhibition of translation or 
some post-transcription RNA processing steps (Kawamata et al. 2007). Furthermore, it has 
recently been suggested that intermittent dosing of HDAC inhibitors may preferentially 
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increased frataxin mRNA and protein levels (Rai et al. 2010). Therefore, intermittent 
administration of drug, possibly once or twice a week, should be considered for any future 
experiments. Such dosing regimen would minimize any toxic side effects by reducing drug 
exposure and may hopefully be associated with sustained upregulation of frataxin mRNA 
and protein. In support of this, we found more frataxin protein expression with intermittent 
dosing of RGFP 109 (150mg/kg) than with daily doses of RGFP 109 (100mg/kg), although no 
overt difference in FXN mRNA expression observed. However, whether this increase in 
frataxin protein with RGFP 109 (150mg/kg) is exclusively due to the intermittent dosage or 
due to use of high concentration of drug has, yet to be determined.  
We also identified increased global acetylated H3 and H4 histone proteins in brain 
tissue, particularly with RGFP 109 treatment of the YG8 mice. However, with RGFA 136 these 
levels were also increased marginally to just above the minimum statistical significance 
(p=0.05). This suggests that RGFP 109 may be a more potent HDAC inhibitor than RGFA 136 
or is better at crossing blood brain-barrier. Additionally, the histone acetylation levels that 
were measured are general and not specific for FXN locus. Therefore, specific histone 
acetylation changes particularly for H3K9, H4K5 and H4K16, the main histone changes of 
FRDA, flanking either side of the GAA repeats and at the 5’-UTR region could be investigated 
by future ChIP experiments. Particularly, investigating these changes in brain tissue confirm 
the ability to cross the blood brain-barrier of such compounds. 
In general, HDAC inhibitors are believed to act by increasing global histone acetylation 
and thereby reactivating epigenetically silenced genes. However, some HDAC inhibitors have 
also been reported to decrease histone acetylation and down-regulate genes (Rada-Iglesias 
et al. 2007). Additionally, it has also been described that global histone acetylation and 
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deacetylation is associated with upregulation and downregulation of several specific genes 
(Vogelauer et al. 2000), one of which could be a negative regulator of FXN expression. 
Therefore, further studies, such as microarray expression analysis, will be required to 
uncover any such mechanisms of action of RGFA 136 and RGFP 109 with regard to FXN 
expression.  
As known, reduced frataxin expression is associated with impaired activity of 
mitochondrial and cytosolic aconitases (Rotig et al. 1997; Puccio et al. 2001; Stehling et al. 
2004). Therefore, we have investigated the effect of RGFA 136 and RGFP 109 on aconitase 
activity following treatment and we found significantly reduced levels of aconitase activity in 
the YG8 vehicle-treated mice compared to WT vehicle-treated control mice, in agreement 
with our previous findings (Al-Mahdawi et al. 2006). Notably, the aconitase activity levels 
were significantly increased by RGFP 109 treatment (both concentrations) and marginally 
increased by RGFA 136 treatment in the YG8 mice, suggesting that RGFP 109 is a somewhat 
more potent drug in ameliorating the FRDA-associated phenotype than RGFA 136. These 
findings give an additional support to the idea that aconitase activity is dependent on 
frataxin expression, since RGFP 109-treated mice with elevated levels of frataxin protein also 
had more aconitase activity compared to RGFA 136-treated mice.  
 Neurodegeneration is a hallmark of the FRDA pathology, particularly in DRG, the 
primary site of the disease. The investigation of DRG neurodegeneration following 
treatments with RGFA 136 and RGFP 109 by H&E staining of paraffin embedded DRG 
sections have shown higher levels of DRG neurodegeneration in YG8 mice compared to WT 
mice, consistent with our previous data (Al-Mahdawi et al. 2006). These levels were 
significantly reduced with HDAC inhibitors RGFA 136 and RGFP 109 treatments, but more 
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efficiently with RGFP 109. These findings indicate that both drugs may be capable of 
ameliorating the “dying-back” neurodegenerative phenomenon as seen in FRDA patients, 
with RGFP 109 again likely being more potent than RGFA 136. 
 Overall, although functional rotarod and activity improvements have been obtained 
with both drugs, higher levels of significance were mainly achieved in RGFA 136-treated 
mice. In contrast, the molecular, biochemical and histological abnormalities which are 
associated with FRDA-pathology were successfully ameliorated by RGFP 109 treatment and 
very little improvement was displayed by RGFA 136. The discrepancies between the effects 
of these two compounds indicate that although these two compounds have structural 
similarities, their mode of action seems to differ. It has been reported that the synergistic 
use of DNA demethylating agents and HDAC inhibitors have produced promising results in 
various cancer (Cecconi et al. 2009; Chen et al. 2009) and neurodegenerative disorders 
(Chiurazzi et al. 1999). Therefore, it is also speculated that the use of these two HDAC 
inhibitors together rather than individually for future experiment(s) could be beneficial in 
simultaneously improving functional and molecular abnormalities of FRDA.  
 Recent findings have suggested that HDAC3 is the main target for RGFA 136 and RGFP 
109, and therefore HDAC3 may also be involved in the silencing of FXN gene (Herman et al. 
2006; Chou et al. 2008; Rai et al. 2008). However, this conclusion does not exclude the 
possible involvement of other HDACs. The kinetic properties of RGFA 136 and RGFP 109 have 
shown 3-fold and 6-fold specificity towards HDAC3 over HDAC1, respectively (Rai et al. 2008) 
and perhaps this can explain how HDAC inhibitor RGFP 109 is more effective in reversing 
FRDA-associated abnormalities than RGFA 136. Recently, Gottesfeld and colleagues have 
reported the synthesis and use of specific HDAC3 inhibitor, HDACi 3. Although this 
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compound has been shown to increase the acetylation of H3 histone proteins, no overt 
effect in increasing either frataxin mRNA or protein were found (Xu et al. 2009). Therefore, 
future investigation should be focused on the compounds which can specifically inhibit the 
HDAC3 activity as well as increase the frataxin mRNA and protein levels.  
In conclusion, the benzamide group of class I HDAC inhibitors are generally well 
tolerated and they elicit improved motor coordination and locomotor activity deficits, 
together with elevated levels of frataxin protein, global acetylated histone proteins (H3 and 
H4), aconitase enzyme activity, and a significant decrease in DRG neurodegeneration. 
Therefore, together with previous data (Rai et al. 2010), the present findings support the use 
of such compounds, particularly RGFP 109, in clinical development in order to provide 
potential therapeutics for FRDA.   
 Finally, since larger expanded GAA repeat tracts are associated with greater 
heterochromatin mediated silencing of the FXN gene and a more severe phenotype in FRDA 
(Saveliev et al. 2003; Soragni et al. 2008), it is of paramount importance to use a larger GAA 
repeat-containing mouse model for future in vivo experiments. As mentioned earlier we are 
currently investigating possible methods of increasing GAA repeats within our FRDA YAC 
transgenic mouse model and this will hopefully be achieved soon. Validating any future 
experiments with Y47 mice rather than WT mice should also be considered essential. 
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Friedreich ataxia is an autosomal recessive neurodegenerative disease affecting the 
central and peripheral nervous system (Harding 1981; Harding 1993) for which currently 
there is no therapy. Although FRDA has been classified as a rare disorder, the carrier 
frequency is approximately 1:120 individuals (Cossee et al. 1999). The most common 
mutation causing the disease is a large trinucleotide GAA repeat expansion in the first intron 
of FXN gene encoding ‘frataxin’, a mitochondrial protein. Although the mechanism by which 
the GAA repeat expansion induces silencing of FXN gene is currently not known, recent in 
vitro and in vivo investigations has been put forward that FRDA is associated with non-B DNA 
conformation (Ohshima et al. 1998) and/or heterochromatin-mediated FXN gene silencing 
(Saveliev et al. 2003; Festenstein 2006). In support to the later hypothesis, differential DNA 
methylation of CpG islands and histone modifications such as increased DNA methylation 
and decreased acetylation have been reported in FRDA (Herman et al. 2006; Greene et al. 
2007; Al-Mahdawi et al. 2008).  
 The above mentioned consequences in association with FRDA have encouraged us to 
test compounds which can potentially directly reverse the abnormal phenotype of FRDA. 
Therefore, in order to find an effective therapy for FRDA we have investigated several DNA 
demethylating agents, HDAC inhibitors and GAA interacting compounds using our in vitro 
and/or in vivo model systems. 
 In order to hasten the drug screening and to find any molecular abnormalities 
associated with FRDA pathogenesis, we have established cell culture systems which include 
primary fibroblasts from unaffected human individuals and FRDA patients, mouse fibroblasts 
and neural stem cells (fetal and adult) from WT, YG8 and YG22 mice. Using mouse primary 
fibroblats we have shown that both YG8 and YG22 rescue mouse cells are more sensitive to 
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hydrogen peroxide induced oxidative stress, as seen in FRDA patient fibroblasts (Wong et al. 
1999). Furthermore, we have also described the differentiation of NSC in to various neural 
cells such as neurons, oligodendrocytes and astrocytes and the presence of these cells has 
been confirmed using cell specific antibodies by immunoflourescence assay.  
To date, the mechanism(s) responsible for the demyelination and neurodegeneration 
of DRG neurons in FRDA are poorly understood. Recently, it has been reported that frataxin 
deficiency results in significant inhibition of proliferation of Schwann cells, myelinating 
supporting cells of the PNS, without affecting DRG neural cells (Lu et al. 2009), indicating the 
importance of supporting cells in FRDA pathology. Therefore, future work should be focused 
on the quantification of GAA repeat expansions and frataxin mRNA and protein levels in 
each individual neural cell type to unravel any such mechanisms in the FRDA YAC transgenic 
mice.  
The use of DNA demethylating agents, such as 5-aza-CdR, zebularine and hydralazine, 
have shown significantly increased FXN expression and reduced DNA methylation, 
particularly in mouse cells. However, the elevated levels of FXN expression were produced 
independent of DNA methylation, suggesting DNA methylation in FRDA is a secondary 
consequence of the disease. In addition, since the DNA demethylating agents used in these 
experiments are non-specific, they are likely to reduce global DNA methylation and perhaps 
affect the regulation of several genes, concurring with previous results (Vallender and Lahn 
2006). Therefore, use of sequence specific DNA demethylating agents such as MG98 
(antisense oligonucleotide) should be considered for future experiments. Additionally, since 
we only quantified FXN mRNA expression at the transcription level following treatment with 
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DNA demethylating agents, it is also essential to find any post-transcriptional effects of DNA 
demethylating agents and this could be done by future frataxin protein quantification.  
The use of GAA interacting compounds, such as DB221 and pentamidine, has also 
given interesting results. Particularly, with DB221 we found a significant increase in FXN 
mRNA expression in both mouse and human fibroblasts together with reduced DNA 
methylation. This finding adds support the hypothesized association between GAA repeat 
expansions, DNA methylation and FXN expression (Saveliev et al. 2003; Al-Mahdawi et al. 
2008).  Curiously, we also investigated the efficacy of DB221 in a short-term preliminary 
study using 10mg/kg of DB221 along with a mock treatment. No obvious changes in FXN 
mRNA expression were detected in both brain and heart tissues tested between vehicle and 
drug-treated mice (Figure B.5). It could be possible that a sub-optimal concentration of the 
drug was incapable of provoking FXN expression in such a short period of time (3-days 
consecutive injection). Therefore, further DB221 treatments need to be assessed in future, 
possibly with longer-term in vivo experiments.  
Although the mechanism by which the GAA interacting compounds increase FXN 
expression is currently not known, it is believed to involve reversing the non-B DNA 
structures associated with FRDA-pathology (Grant et al. 2006; Hebert and Whittom 2007; 
Hebert 2008; Bergquist et al. 2009). In future experiments these compounds could be tested 
for their ability to possibly result in histone modification changes to help unravel any FRDA-
associated disease mechanisms. If these compounds do not give significantly increased the 
levels of acetylated histones in FRDA cells or patients, but do cause increased FXN 
expression, this could be imply that the FXN silencing in FRDA is a direct effect on non-B DNA 
structure formation. On the other hand, if these compounds are able to increase the FXN 
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expression and also acetylate histones in FRDA then it could be postulated that non-B DNA 
structures trigger deacetylated histone-induced heterochromatin-mediated silencing in 
FRDA, in agreement with previously proposed hypothesis (Saveliev et al. 2003).  
Since the investigation of DNA demethylating agents revealed that DNA methylation is 
likely a secondary consequence in FRDA, we further investigated the possible therapy for 
FRDA using HDAC inhibitors. We found encouraging results using class III HDAC inhibitors 
particularly in mouse cells and probably this is due to small number of GAA repeats (<250) in 
mouse cells compared to human FRDA fibroblasts (>450). In contrast, we obtained similar 
results in mouse and human fibroblasts cells with nicotinamide, where FXN expression was 
increased by approximately 2-fold. However, the necessary use of high concentrations of 
nicotinamide (≥10mM) to induce the FXN expression strongly limits the use of such 
compound in a clinical setting.  
 Additionally, we have also investigated the long-term efficacy of two class I HDAC 
inhibitors, RGFA 136 and RGFP 109, which have previously been shown increased frataxin 
mRNA and protein levels, together with significant increases in acetylated H3 and H4 
histones in brain tissues of KIKI mice and FRDA patient primary lymphocytes (Rai et al. 2010). 
These findings suggested to us that such compounds would be capable of crossing blood-
brain barrier and induce drug-mediated effect. During the drug treatments with both 
compounds, we monitored the functional analysis of the mice in regular intervals by rotarod, 
locomotor activity and beam-breaker testing. The analysis by two way ANOVA detected a 
significant improvement in functional analysis with both drugs, but mainly RGFA 136, 
suggesting that these drugs are effective in ameliorating the FRDA-associated YG8 mouse 
phenotype.  
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However, none of these compounds significantly increased the FXN mRNA expression 
in brain tissues indicating little effect of these compounds at the transcriptional level. It is 
also possible that the activity of RGFA 136 and RGFP 109 to cross the blood brain-barrier is 
not as good as has been inferred from the previous KIKI mouse studies (Rai et al. 2010). 
Therefore, future studies should also investigate the frataxin mRNA and protein levels in 
non-CNS tissues of the YG8 mouse such as heart, liver and skeletal muscle. A potential 
beneficial effect of RGFA 136 and RGFP 109 in skeletal muscle tissue is certainly implied by 
the improvements observed in locomotor activity and beam-breaker measurements, which 
involve muscle strength.  
 Nevertheless, significant increases in frataxin protein, aconitase enzyme activity and 
considerably reduced DRG neurodegeneration were observed in the brain tissues of mice, 
particularly when treated with RGFP 109. In contrast, such parameters were only marginally 
increased in mice treated with RGFA 136, suggesting that RGFP 109 treatment may be better 
at crossing blood brain-barrier and may be potentially beneficial in reversing the FRDA 
pathology. RGFA 136 and RGFP 109 have shown distinctly different effects when taking both 
the functional and molecular analysis into the consideration. Therefore, it may be beneficial 
to use these two compounds together for any future experiments in order to hopefully 
obtain a much more prominent synergistic effect.  
In order to find an effective drug screening use of positive controls is of paramount 
importance. The positive control confirms that the given drug is competent in observing the 
effect therefore it reduces the false negatives. The lack of use of positive controls may be 
perhaps a negative aspect in our drug screening tests. Therefore, for any future therapeutic 
testing use of positive control(s) need to be considered essential.  
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 In conclusion, a number of compounds tested as part of this thesis show good promise 
for FRDA therapy. It is hoped that at least one of these compounds will soon be taken 
forward into FRDA clinical trials and may eventually help to cure this disease. 
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A.1 - Negative control staining of NSCs 
A.2 - Endogenous control test QRT-PCR 
 
Figure A.1 - Negative antibody staining of NSCs. 
 NSCs were collected by centrifugation and dissociated by gently pipetting up and down 
several times until single cell suspension has been achieved followed by incubation with 
NSC dissociation medium for 48 hours on poly-D-lysine coated coverslips. After 48 hours in 
culture, NSCs were stained with secondary antibodies of FITC (neurons) and CY3 
(astrocytes, oligodendrocytes and microglia) without primary antibodies. The micrographs 
were taken at the magnification of 10X.  
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Figure A.2 - Gapdh mRNA expression levels. Relative Gapdh mRNA expression as 
determined by QRT-PCR of YG8 rescue mouse primary fibroblasts treated with various 
compounds, compared with a vehicle-treated control set at 100%. RER1 used as an 
endogenous control. Error bars represent s.e.m. 
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B.1 - Previous long-term study functional results of RGFA 136 
  
Figure B.1 - Weight analysis during treatment with RGFA 136 in YG8 rescue mice showing 
vehicle and drug-treated groups (n=20, error bars ± 1 SEM). 
 
  
Figure B.2 - Rotarod analysis during treatment with RGFA 136 in YG8 rescue mice showing 
vehicle and drug-treated groups (n=20, error bars ± 1 SEM). 
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Figure B.3 - Locomotor activity analysis during treatment with RGFA 136 in YG8 rescue 
mice showing vehicle and drug-treated groups (n=20, error bars ± 1 SEM). 
 
  
Figure B.4 - Relative mRNA expression in brain and cerebellum tissues following treatment 
with RGFA 136 in YG8 rescue mice showing vehicle and drug-treated groups (n=4, error 
bars ± 1 SEM). 
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B.2 - DB221 in vivo preliminary short-term study 
  
Figure B.5 - Relative mRNA expression of FXN following treatment with DB221 in YG8 
rescue mice of vehicle and drug-treated mice. The mice were subjected to 3 consecutive 
daily doses of 10mg/kg DB221 sub-cutaneous injections along with a vehicle control 
group. FXN expression was quantified by QRT-PCR and Gapdh was used as an endogenous 
control (n=5, error bars ± 1 SEM). 
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B.3 - Endogenous control test QRT-PCR 
 
Figure B.6 - Gapdh mRNA expression levels. Relative Gapdh mRNA expression as 
determined by QRT-PCR of Vehicle, RGFA 136 (50mg/kg), RGFP 109 (100mg/kg) or RGFP 
109 (150mg/kg)-treated YG8 rescue mice. Vehicle-treated control set at 100%. RER1 used 
as an endogenous control. Error bars represent s.e.m. 
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B.4 - ANOVA associated p-values of RGFA 136 treatment 
Table B.1 - ANOVA associated p-values of time point and treatment effect on manual 
functional measurements during RGFA 136 treatment. 
 
RGFA 136 (50mg/kg) 5-months (WT - n=10, YG8 - n=20) 
Treatment effect on Genotype 
F-ratio values   p-values 
TP TP/TM   TP TP/TM 
Weight 
WT 6.100 0.062   <0.001 0.803 
YG8 6.316 5.014 
 
<0.001 0.026 
Rotarod performance 
WT 1.366 45.425   0.235 <0.001 
YG8 0.932 9.096   0.458 0.002 
Locomotor activity YG8 0.237 17.725   0.946 <0.001 
Abbreviations: TP-Time point, TM-Treatment 
 
Table B.2 - ANOVA associated p-values of time point and genotype effect on manual 
functional measurements during RGFA 136 treatment. 
 
RGFA 136 (50mg/kg) 5-months (WT - n=10, YG8 - n=20) 
Treatment effect on Genotype TM 
F-ratio values   p-values 
TP TP/GT   TP TP/GT 
Weight WT vs YG8 
Vehicle 17.888 2.974 
 
<0.001 0.086 
RGFA 136 8.189 8.980 
 
<0.001 0.003 
Rotarod performance WT vs YG8 
Vehicle 2.105 0.137   0.063 0.711 
RGFA 136 3.618 22.893   0.003 <0.001 
Abbreviations: TM-Treatment, TP-Time point, GT-Genotype 
 
Table B.3 - ANOVA associated p-values of time point and treatment effect on manual 
functional measurements of male and female mice during RGFA 136 treatment. 
 
RGFA 136  5-months (WT - n=5, YG8 - n=10) 
Treatment effect on Genotype Sex 
F-ratio values   p-values 
TP TP/TM   TP TP/TM 
Weight 
WT 
Male 18.443 2.198 
 
<0.001 0.144 
Female 9.574 0.310 
 
<0.001 0.579 
YG8 
Male 10.778 9.381 
 
<0.001 0.002 
Female 8.486 3.864 
 
<0.001 0.051 
Rotarod 
performance 
WT 
Male 0.984 91.187 
 
0.428 <0.001 
Female 1.173 0.002 
 
0.323 0.963 
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YG8 
Male 3.508 25.937 
 
0.004 <0.001 
Female 2.257 0.110 
 
0.048 0.741 
Locomotor activity YG8 
Male 0.324 14.345 
 
0.898 <0.001 
Female 0.289 5.855 
 
0.919 0.016 
Abbreviations: TP-Time point, TM-Treatment 
 
Table B.4 - ANOVA associated p-values of time point and genotype effect on manual 
functional measurements of male and female mice during RGFA 136 treatment. 
 
RGFA 136  5-months (n=5) 
Treatment 
effect on Genotype TM Sex 
F-ratio values   p-values 
TP TP/GT   TP TP/GT 
Weight 
WT vs 
YG8 
Vehicle 
Male 17.326 3.529   <0.001 0.063 
Female 15.960 2.150 
 
<0.001 0.145 
RGFA 136 
Male 31.539 15.895   <0.001 <0.001 
Female 12.106 15.787   <0.001 <0.001 
Rotarod 
performance 
WT vs 
YG8 
Vehicle 
Male 2.038 15.674 
 
0.072 <0.001 
Female 1.753 35.918 
 
0.121 <0.001 
RGFA 136 
Male 15.379 0.160   <0.001 0.689 
Female 0.524 31.567   0.758 <0.001 
Abbreviations: TM-Treatment, TP-Time point 
 
Table B.5 - ANOVA associated p-values of time point and gender effect on manual functional 
measurements of male and female mice during RGFA 136 treatment. 
 
RGFA 136  5-months (WT - n=5, YG8 - n=10) 
Treatment 
effect on Sex Genotype TM 
F-ratio values   p- values 
TP TP/Sex   TP TP/Sex 
Weight 
Male vs 
female 
WT 
Vehicle 16.710 0.179 
 
<0.001 0.674 
Drug 9.229 1.602 
 
<0.001 0.211 
YG8 
Vehicle 8.760 0.023  <0.001 0.879 
Drug 11.328 0.661   <0.001 0.418 
Rotarod 
performance 
Male vs 
female 
WT  
Vehicle 1.881 32.478   0.098 <0.001 
Drug 2.587 9.304 
 
0.026 0.002 
YG8 
Vehicle 1.130 5.824  0.344 0.016 
Drug 3.072 53.978   0.010 <0.001 
Locomotor 
activity 
Male vs 
female 
YG8 
Vehicle 1.479 0.061 
 
0.195 0.805 
Drug 2.265 1.028   0.047 0.311 
Abbreviations: TM-Treatment, TP-Time point 
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Table B.6 - ANOVA associated p-values of time point and treatment effect on beam breaker-
based functional measurements during RGFA 136 treatment. 
 
RGFA 136 (50mg/kg) 5-months (WT - n=10, YG8 - n=20) 
Treatment effect on Genotype 
F-ratio values 
 
p-values 
TP TP/TM 
 
TP TP/TM 
Average velocity 
WT 0.851 2.003 
 
0.515 0.158 
YG8 2.418 28.905 
 
0.035 <0.001 
Ambulatory distance 
WT 4.394 0.341   <0.001 0.560 
YG8 13.929 13.581   <0.001 <0.001 
Vertical counts 
WT 2.672 8.612 
 
0.023 0.004 
YG8 3.494 67.362   0.004 <0.001 
Abbreviations: TP-Time point, TM-Treatment 
 
Table B.7 - ANOVA associated p-values of time point and genotype effect on different beam 
breaker-based functional measurements during RGFA 136 treatment. 
 
RGFA 136 (50mg/kg) 5-months (WT - n=10, YG8 - n=10) 
Treatment effect on Genotype TM 
F-ratio values 
 
p-values 
TP TP/GT 
 
TP TP/GT 
Average velocity WT vs YG8 
Vehicle 1.731 0.401  
0.126 0.527 
RGFA 136 3.358 9.657  
0.005 0.002 
Ambulatory distance WT vs YG8 
Vehicle 11.527 6.021   <0.001 0.014 
RGFA 136 10.330 3.193   <0.001 0.074 
Vertical counts WT vs YG8 
Vehicle 5.410 24.506 
 
<0.001 <0.001 
RGFA 136 2.924 58.956   0.013 <0.001 
Abbreviations: TM-Treatment, TP-Time point 
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Table B.8 - ANOVA associated p-values of time point and treatment effect on beam breaker-
based functional measurements of male and female mice during RGFA 136 treatment. 
 
RGFA 136  5-months (WT - n=5, YG8 - n=10) 
Treatment effect on Genotype Sex 
F-ratio values 
 
p-values 
TP TP/TM 
 
TP TP/TM 
Average velocity 
WT 
Male 0.835 0.264 
 
0.527 0.608 
Female 1.850 2.025 
 
0.109 0.157 
YG8 
Male 2.047 15.011   0.073 <0.001 
Female 1.388 12.711   0.229 <0.001 
Ambulatory distance 
WT 
Male 0.780 0.499   0.779 0.499 
Female 9.360 3.446 
 
<0.001 0.066 
YG8 
Male 3.674 2.417   0.003 0.121 
Female 12.722 15.295   <0.001 <0.001 
Vertical counts 
WT 
Male 0.591 1.344 
 
0.707 0.248 
Female 9.536 13.572 
 
<0.001 <0.001 
YG8 
Male 1.466 22.512   0.202 <0.001 
Female 3.689 50.211   0.003 <0.001 
Abbreviations: TP-Time point, TM-Treatment 
 
Table B.9 - ANOVA associated p-values of time point and genotype effect on beam breaker-
based functional measurements of male and female mice during RGFA 136 treatment. 
 
RGFA 136  5-months (n=5) 
Treatment 
effect on Genotype TM Sex 
F-ratio values 
 
p-values 
TM TM/GT   TM TM/GT 
Average 
velocity 
WT vs YG8 
Vehicle 
Male 1.440 6.528 
 
0.211 0.011 
Female 0.940 2.663 
 
0.455 0.104 
RGFA 136 
Male 1.393 1.469   0.228 0.227 
Female 2.199 9.851   0.055 0.002 
Ambulatory 
distance 
WT vs YG8 
Vehicle 
Male 2.452 3.576   0.035 0.060 
Female 13.279 1.772 
 
<0.001 0.184 
RGFA 136 
Male 2.443 3.741   0.036 0.054 
Female 17.439 31.125   <0.001 <0.001 
Vertical 
counts 
WT vs YG8 
Vehicle 
Male 1.233 12.149 
 
0.295 <0.001 
Female 1.836 15.219 
 
0.106 <0.001 
RGFA 136 
Male 1.305 9.481   0.263 0.002 
Female 5.543 78.287   <0.001 <0.001 
Abbreviations: GT-Genotype, TP-Time point, TM-Treatment 
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Table B.10 - ANOVA associated p-values of time point and gender effect on beam breaker-
based functional measurements of male and female mice during RGFA 136 treatment. 
 
RGFA 136  5-months (WT-n=5, YG8-n=10) 
Treatment 
effect on Sex Genotype TM 
F-ratio values 
 
p-values 
TP TP/Sex   TP TP/Sex 
Average 
velocity 
Male 
vs 
female 
WT 
Vehicle 0.320 2.604 
 
0.899 0.109 
Drug 0.718 0.463 
 
0.611 0.497 
YG8 
Vehicle 1.369 3.411   0.237 0.066 
Drug 2.625 0.784   0.025 0.376 
Ambulatory 
distance 
Male 
vs 
female 
WT 
Vehicle 2.106 4.573   0.070 0.034 
Drug 2.983 24.306 
 
0.014 <0.001 
YG8 
Vehicle 7.073 3.257   <0.001 0.072 
Drug 6.530 0.386   <0.001 0.535 
Vertical 
counts 
Male 
vs 
female 
WT 
Vehicle 0.487 6.403 
 
0.785 0.012 
Drug 8.731 48.239 
 
<0.001 <0.001 
YG8 
Vehicle 7.942 6.079   <0.001 0.014 
Drug 1.856 1.962   0.103 0.162 
Abbreviations: TP-Time point, TM-Treatment 
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B.5 - ANOVA associated p-values of RGFP 109 treatment 
Table B.11 - ANOVA associated p-values of time point and treatment effect on manual 
functional measurements during RGFP 109 treatment. 
 
RGFP 109 5-months (WT - n=10, YG8 - n=20) 
Treatment 
effect on Genotype 
F-ratio values 
 
p-values 
TP TP/TM   TP TP/TM 
Weight 
WT 109 (100mg/kg) 3.515 3.022   0.006 0.080 
YG8 109 (100mg/kg) 5.229 1.287  
<0.001 0.250 
YG8 109 (150mg/kg) 7.475 4.751   <0.001 0.030 
Rotarod 
performance 
WT 109 (100mg/kg) 0.635 8.112  0.673 
0.004 
YG8 109 (100mg/kg) 0.798 13.465  
0.550 <0.001 
YG8 109 (150mg/kg) 2.556 9.869   0.026 0.001 
Abbreviations: TP-Time point, TM-Treatment 
 
Table B.12 - ANOVA associated p-values of time point and genotype effect on manual 
functional measurements during RGFP 109 (100mg/kg only) treatment. 
 
RGFP 109 (100mg/kg)  5-months (n=10) 
Treatment 
effect on Genotype TM 
F-ratio values 
 
p-values 
TP TP/GT   TP TP/GT 
Weight WT vs YG8 
Vehicle 17.888 2.974 
 
<0.001 0.086 
RGFP 109 5.524 0.117   <0.001 0.733 
Rotarod 
performance 
WT vs YG8 
Vehicle 2.105 0.137   0.063 0.711 
RGFP 109 0.955 0.379   0.445 0.539 
Abbreviations: TM-Treatment, TP-Time point, GT-Genotype 
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Table B.13 - ANOVA associated p-values of time point and treatment effect on manual 
functional measurements of male and female mice during RGFP 109 treatment. 
 
RGFP 109  5-months (WT - n=5, YG8 - n=10) 
Treatment 
effect on Genotype Sex 
F-ratio values 
 
p-values 
TP TP/TM   TP TP/TM 
Weight 
WT 109 (100mg/kg) 
Male 9.976 0.035   <0.001 0.851 
Female 16.038 4.896 
 
<0.001 0.033 
YG8 109 (100mg/kg) 
Male 5.289 3.364   <0.001 0.070 
Female 5.776 0.001   <0.001 0.973 
YG8 109 (150mg/kg) 
Male 10.820 6.899 
 
<0.001 0.010 
Female 8.663 3.379   <0.001 0.069 
Rotarod 
performance 
WT 109 (100mg/kg) 
Male 1.727 2.386 
 
0.130 0.124 
Female 2.341 3.344 
 
0.043 0.069 
YG8 109 (100mg/kg) 
Male 0.923 0.651   0.466 0.048 
Female 0.652 20.082   0.660 <0.001 
YG8 109 (150mg/kg) 
Male 0.744 2.517 
 
0.591 0.113 
Female 2.751 8.662   0.018 <0.001 
Abbreviations: TP-Time point, TM-Treatment 
 
Table B.14 - ANOVA associated p-values of time point and genotype effect on manual 
functional measurements of male and female mice during RGFP 109 treatment. 
 
RGFP 109  5-months (n=5) 
Treatment 
effect on Genotype TM Sex 
F-ratio values 
 
p-values 
TP TP/GT   TP TP/GT 
Weight WT vs YG8 
Vehicle 
Male 11.215 4.336   <0.001 0.063 
Female 7.294 2.168 
 
<0.001 0.145 
RGFP 109 
Male 7.633 2.457   <0.001 0.120 
Female 11.281 0.432   <0.001 0.513 
Rotarod 
performance 
WT vs YG8 
Vehicle 
Male 2.038 15.674 
 
0.072 <0.001 
Female 1.753 35.918 
 
0.121 <0.001 
RGFP 109 
Male 1.582 6.468   0.164 0.011 
Female 1.436 2.572   0.210 0.110 
Abbreviations: TM-Treatment, TP-Time point, GT-Genotype 
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Table B.15 - ANOVA associated p-values of time point and gender effect on manual 
functional measurements of male and female mice during RGFP 109 treatment. 
 
RGFP 109  5-months (WT - n=5, YG8 - n=10) 
Treatment 
effect on Sex GT TM 
F-ratio values 
 
p-values 
TP TP/Sex   TP TP/Sex 
Weight 
Male 
vs 
female 
WT 
Placebo 16.710 0.179 
 
<0.001 0.674 
 109 (100mg/kg) 2.101 0.807 
 
<0.001 0.374 
YG8 
Placebo 8.760 0.023   <0.001 0.879 
109 (100mg/kg) 4.865 9.535 
 
<0.001 0.150 
109 (150mg/kg) 13.084 0.081   <0.001 0.770 
Rotarod 
performance 
Male 
vs 
female 
WT 
Placebo 1.881 32.478   0.098 <0.001 
 109 (100mg/kg) 0.246 56.432 
 
0.941 <0.001 
YG8 
Placebo 1.130 5.824   0.344 0.016 
109 (100mg/kg) 0.891 45.918 
 
0.487 <0.001 
109 (150mg/kg) 2.355 0.033   0.040 0.856 
Abbreviations: GT-Genotype, TM-Treatment, TP-Time point 
 
Table B.16 - ANOVA associated p-values of time point and treatment effect on beam 
breaker-based functional measurements during RGFP 109 treatment. 
 
RGFP 109 5-months (WT - n=10, YG8 - n=20) 
Treatment 
effect on Genotype 
F-ratio values 
 
p-values 
TP TP/TM   TP TP/TM 
Average 
velocity 
WT 109 (100mg/kg) 0.943 0.376 
 
0.454 0.541 
YG8 109 (100mg/kg) 1.111 1.464 
 
0.354 0.227 
YG8 109 (150mg/kg) 1.934 4.149 
 
0.087 0.042 
Ambulatory 
distance 
WT 109 (100mg/kg) 2.650 1.924   0.024 0.167 
YG8 109 (100mg/kg) 6.719 22.272 
 
<0.001 <0.001 
YG8 109 (150mg/kg) 12.243 19.801   <0.001 <0.001 
Vertical counts 
WT 109 (100mg/kg) 1.994 2.098 
 
0.082 0.149 
YG8 109 (100mg/kg) 17.99 1.713 
 
<0.001 0.191 
YG8 109 (150mg/kg) 17.186 2.573   <0.001 0.109 
Abbreviations: TP-Time point, TM-Treatment 
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Table B.17 - ANOVA associated p-values of time point and genotype effect on different beam 
breaker-based functional measurements during RGFP 109 treatment. 
 
RGFP 109 (100mg/kg only)  5-months (n=10) 
Treatment 
effect on Genotype TM 
F-ratio values 
 
p-values 
TP TP/GT   TP TP/GT 
Average 
velocity 
WT vs YG8 
Vehicle 1.731 0.401 
 
0.126 0.527 
RGFP 109 1.852 2.047 
 
0.102 0.153 
Ambulatory 
distance 
WT vs YG8 
Vehicle 11.527 6.021   <0.001 0.014 
RGFP 109 3.393 0.685   0.005 0.408 
Vertical 
counts 
WT vs YG8 
Vehicle 5.410 24.506 
 
<0.001 <0.001 
RGFP 109 12.218 2.943   <0.001 0.087 
Abbreviations: TM-Treatment, TP-Time point, GT-Genotype 
 
Table B.18 - ANOVA associated p-values of time point and treatment effect on beam 
breaker-based functional measurements of male and female mice during RGFP 109 
treatment. 
 
RGFP 109  5-months (WT - n=5, YG8 - n=10) 
Treatment 
effect on Genotype Sex 
F-ratio values 
 
p-values 
TP TP/TM   TP TP/TM 
Average 
velocity 
WT 109 (100mg/kg) 
Male 0.747 1.528 
 
0.590 0.219 
Female 0.696 0.065 
 
0.627 0.800 
YG8 109 (100mg/kg) 
Male 1.332 0.876   0.252 0.350 
Female 0.370 1.807   0.868 0.180 
YG8 109 (150mg/kg) 
Male 1.949 0.657 
 
0.087 0.418 
Female 0.340 5.332 
 
0.888 0.021 
Ambulatory 
distance 
WT 109 (100mg/kg) 
Male 0.865 0.141   0.507 0.708 
Female 1.993 3.827 
 
0.087 0.050 
YG8 109 (100mg/kg) 
Male 1.813 6.306   0.112 0.012 
Female 5.137 9.308   <0.001 0.002 
YG8 109 (150mg/kg) 
Male 5.803 0.485 
 
<0.001 0.487 
Female 6.081 26.316   <0.001 <0.001 
Vertical 
counts 
WT 109 (100mg/kg) 
Male 1.136 6.030 
 
0.348 0.016 
Female 2.478 0.106 
 
0.038 0.746 
YG8 109 (100mg/kg) 
Male 3.066 0.486   0.011 0.486 
Female 14.360 0.825   <0.001 0.365 
YG8 109 (150mg/kg) 
Male 5.574 0.479 
 
<0.001 0.489 
Female 14.082 9.195   <0.001 0.002 
Abbreviations: TP-Time point, TM-Treatment 
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Table B.19 - ANOVA associated p-values of time point and genotype effect on beam breaker-
based functional measurements of male and female mice during RGFP 109 treatment. 
 
RGFP 109  5-months (n=5) 
Treatment 
effect on Genotype TM Sex 
F-ratio values 
 
p-values 
TP TP/GT   TP TP/GT 
Average 
velocity 
WT vs YG8 
Vehicle 
Male 1.440 6.528 
 
0.211 0.011 
Female 0.940 2.663 
 
0.455 0.104 
RGFP 109 
Male 1.750 0.002   0.125 0.962 
Female 1.708 1.140   0.135 0.287 
Ambulatory 
distance 
WT vs YG8 
Vehicle 
Male 2.452 3.576   0.035 0.060 
Female 13.279 1.772 
 
<0.001 0.184 
RGFP 109 
Male 1.157 1.686   0.332 0.196 
Female 2.891 0.007   0.015 0.935 
Vertical 
counts 
WT vs YG8 
Vehicle 
Male 1.233 12.149 
 
0.295 <0.001 
Female 1.836 15.219 
 
0.106 <0.001 
RGFP 109 
Male 5.859 0.395   <0.001 0.530 
Female 7.161 3.252   <0.001 0.073 
Abbreviations: TM-Treatment, TP-Time point, GT-Genotype 
 
Table B.20 - ANOVA associated p-values of time point and gender effect on beam breaker-
based functional measurements of male and female mice during RGFP 109 treatment. 
 
RGFP 109  5-months (WT - n=5, YG8 - n=10) 
Treatment 
effect on Sex GT TM 
F-ratio values 
 
p-values 
TP TP/Sex   TP TP/Sex 
Average 
velocity 
Male 
vs 
female 
WT 
Placebo 0.320 2.604 
 
0.899 0.109 
 109 (100mg/kg) 0.726 0.065 
 
0.605 0.799 
YG8 
Placebo 1.369 3.411   0.237 0.066 
109 (100mg/kg) 1.951 0.355 
 
0.088 0.551 
109 (150mg/kg) 2.028 0.172   0.076 0.678 
Ambulator
y distance 
Male 
vs 
female 
WT 
Placebo 2.106 4.573   0.070 0.034 
 109 (100mg/kg) 1.058 0.752 
 
0.389 0.388 
YG8 
Placebo 7.073 3.257   <0.001 0.072 
109 (100mg/kg) 3.402 0.146 
 
0.005 0.703 
109 (150mg/kg) 7.734 3.742   <0.001 0.050 
Vertical 
counts 
Male 
vs 
female 
WT 
Placebo 0.487 6.403 
 
0.785 0.012 
 109 (100mg/kg) 2.801 0.627 
 
0.021 0.430 
YG8 
Placebo 7.942 6.079   <0.001 0.014 
109 (100mg/kg) 7.706 0.009 
 
<0.001 0.923 
109 (150mg/kg) 9.132 0.143   <0.001 0.705 
Abbreviations: GT-Genotype, TM-Treatment, TP-Time point 
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Notes 
 
 
 
 
 
 
 
 
 
 
 
